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Summary 
 
 The research presented in this thesis focuses on the differentiation of medium spiny 
neurons (MSNs) from iPS cells derived from human primary fetal cells with an aim to provide 
genuine DARPP32 positive MSNs for cell transplantation in Huntington’s disease (HD). iPS cell 
lines were generated from various human embryonic tissues, with further neural induction, regional 
specification, and maturation using my modified protocol to directly differentiate the pluripotent 
stem cells (PSCs) towards a neural lineage, specifically lateral ganglionic eminence (LGE) 
precursors and eventually MSNs. Subsequent neuronal differentiation of LGE precursors or early 
post mitotic MSNs was assessed both in vitro and in vivo.  
 Chapter 3 focussed on an alternative approach to that used in chapter 3. Here the 
piggyBac transposon system was used. In this method 5 reprogramming factors were incorporated 
into the plasmid OSKML (Oct4, Sox2, Klf4, c-Myc, Lin28). As a result 5 iPS cell lines were 
successfully established from human embryonic primary whole ganglionic eminence (WGE) and 
fetal fibroblasts. It is noteworthy, that a reprogramming efficiency was 6-14 folds higher when 
using human WGE as a starting material in comparison to cortex tissue and fibroblast. In addition, 
more rapid kinetic in pluripotency conversion was recognised in human WGE which was 7-10 
times faster in human WGE comparing to cortex and fibroblast. Various strategies were applied to 
investigate and characterize the pluripotency of the established iPS cell lines such as 
morphological appearance, in vitro differentiation, teratoma formation and RT-PCR of pluripotent 
gene expression.   
 Chapter 4 looked to take the cell lines generated in chapter 4 and take the cells through 
the process of neural differentiation and subsequent directed differentiation to generate DARPP32 
positive MSNs. In this chapter the human ES cell line (H9) was introduced and used as a control 
for the iPS cell cultures. In the first instance, one iPS cell line (iPS WGE623 C9) was taken 
through neural differentiation, using EBs-based method with the Arber et al protocol (submitted). 
Unfortunately, this iPS cell line was unsuccessful at reaching a state of mature neuronal 
differentiation. As a result it was decided to modify the protocol, and the modified protocol was 
developed and used on the 5 iPS cell lines. In summary, 3 out of 5 iPS cell lines produced MSNs 
like cells confirmed by gene expression profile and immunocytochemistry against a hallmark of 
neural and MSNs markers, especially DARPP32 expression. 1 iPS cell line originating from 
human fibroblasts (iPS HEF 962) was unable to be terminally differentiated to DARPP32 
expressing neurons due to unexpected infection occurring, however, it appeared to be 
differentiating towards a striatal MSNs phenotype as a similar pattern and LGE precursors were 
identified by FoxP1 and FoxP2 markers. Another iPS cell line (iPS WGE623 C9) was unable to 
fully differentiate to MSNs as pluripotent cells expressing Oct4 and Tra-1-60 were persistently 
appearing in culture. This may in fact be related to the method used, the piggyBac transposon 
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system as it would appear there are issues with complete removal of the transposons from the cells 
following reprogramming. Finally, the cells were validated in vivo following transplantation into a 
lesion induced rodent model of HD. iPS cell line WGE 928 and the human ES (H9) cell line were 
used in the transplantation studies. Surviving grafts were identified in 
all animals receiving the iPS derived cell grafts; however, there were 7 out of 20 animals that 
exhibited tumour-like formation at 7 weeks post-surgery. In addition the H9 derived grafts had 
similar findings with 3 out of 6 animals presenting with tumour-like structures. However, when 
this protocol was applied to the H9 cell line using a monolayer based method, there was an absence 
of tumours in all transplanted animals post transplantation at 7 weeks.   
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Chapter 1  Introduction 
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Chapter 1 
Introduction 
 
1.1 Pluripotent Stem Cells 
 
The study of pluripotent stem cells contributes to a broader understanding 
of cell development and differentiation, and presents many opportunities for 
medical science, such as cell transplantation for degenerative diseases, drug 
screening and drug toxicology. 
 
1.1.1 Embryonal Carcinoma cells 
 Embryonal carcinoma (EC) cells were first identified in the 1950s in the 
mouse through the study of teratocarcinoma (Stevens L.C. and Little C.C, 1954). 
This cancer comprises both undifferentiated and differentiated cells of the three 
germ layers: endoderm, mesoderm, and ectoderm (Kleinsmith and Pierce, 1964). 
The pluripotent properties of EC cells and their capacity for (at least theoretically) 
unlimited self-renewal were presented in 1964 (Kleinsmith and Pierce, 1964). In 
the 1970s, mouse EC cell lines were first produced for use in scientific study, such 
as developmental characterisation (Kahan and Ephrussi, 1970). It was reported 
that some EC cells can generate a wide range of somatic cells (Brainster, 1974), 
although in the same year Atkin et al 1974, reported that they have a limited 
developmental potential due to the genetic alterations arising during the 
development of the teratocarcinoma (Atkin et al, 1974). EC cells show some 
similarities of protein and antigen expression with those cells of the inner cell mass 
(ICM) (Gachelin et al., 1977; Solter et al., 1978). A human EC cell line was 
successfully produced in 1977 (Hogan et al, 1977), but these cells had a restricted 
differentiation potential largely due to their aneuploid nature, thus limiting their 
usefulness as an in vitro model of human development. Hence, the usefulness of 
EC cells as a possible cell source for therapeutic application is limited. 
 
 
Chapter 1  Introduction 
2 
 
1.1.2 Embryonic germ cells 
Mouse embryonic germ (EG) cells were first generated from primordial 
germ cells (PGCs) in 1992 (Matsui et al, 1992; Resnick et al, 1992). EG cells 
expressed some of the same markers as ES cells (such as SSEA1 and 3, Oct4) 
and are morphologically indistinguishable from ES cells in culture (Matsui et al., 
1992; Resnick et al., 1992). In addition, chimeras could be generated when EG 
cells were injected into blastocysts (Labosky et al., 1994; Stewart et al., 1994). 
However, EG cells still retain some characteristics of primordial germ cells (PGCs) 
and have genetic alterations which likely reflect the developmental stage at which 
they were originally taken (Labosky et al, 1994; Tada et al, 1997). The derivation 
of human EG cells was first reported in 1998 (Shamblott et al., 1998), but human 
EG cell applications have been restricted by their limited long-term proliferative 
capacity (Turnpenny et al, 2003). To date, no stable EG cell line has been 
reported to generate teratomas with differentiation into all three germ lines 
(reviewed in Yu and Thomson, 2008).  
 
1.1.3 Embryonic stem cells     
 In 1970, Stevens and Solter showed that transferring early mouse embryos 
to the adult mouse kidney or testicular capsule lead to development of 
teratocarcinomas (Stevens L.C., 1970; Solter et al., 1970), demonstrating the 
pluripotent capacity of some cells of the embryo, and thus advancing attempts to 
produce pluripotent cells in vitro. Embryonic stem (ES) cells are generated from 
the ICM of the blastocyst and can give rise to trophectoderm and all three layers of 
the embryo (Evans and Kaufman, 1981; Martin 1981) avoiding the need to 
develop carcinomas as seen with EC cells. ES cells have the ability to proliferate 
extensively whilst maintaining their pluripotency (Martin, 1981). The first mouse 
ES cell line was derived in 1981, using the same culture medium as that used for 
mouse EC cells (Evans and Kaufman, 1981; Martin 1981). ES cells are able to 
differentiate into all cell types of the three germ layers - ectoderm, mesoderm, and 
endoderm in vitro and when transplanted, are capable of germline transmission to 
generate chimeric animals, which is in contrast to EC cells (Bradley et al, 1984). 
Thus, ES cells can be used to generate models of disease and to understand 
developmental pathways by introducing modifications into the mouse germline. 
Initially, a feeder cell layer (mouse embryonic fibroblast, MEFs) was used to 
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culture ES cells, but over time there has been a move away from this method to a 
feeder free system that is more adaptable for clinical application (specifically for 
GMP (good manufacturing practice) manufacture of these cells).  As well as the 
feeder system there have been many modifications to the culture system as a 
whole with, for example, changes to the culture media where this has been 
replaced by medium taken from co-culture with other cells that will nourish the ES 
cells (Smith et al, 1988; Williams et al, 1988). Different ES cell lines are cultured 
optimally under different conditions with adaptations to the feeder layer, substrate, 
and culture medium.     
 
 Human ES cells were first derived in 1998, originally using the previously 
reported mouse ES cell co-culture medium and MEFs (Thomson et al, 1998), and 
were also shown to have the potential to differentiate into cells of all three germ 
layers (Amit et al, 2000). However, the conditions used for optimal culture of 
mouse and human ES cells are different in that human ES cells do not survive in 
leukemia inhibitory factor (LIF)-containing media, a prerequisite for mouse ES cell 
culture (Daheron et al, 2004; Humphrey et al, 2004). In addition, mouse and 
human ES cells require different feeder cells or substrates for culture, and the 
human ES cells are more susceptible to cell death during dissociation procedures 
(Daheron et al, 2004; Humphrey et al, 2004). Human ES cells have been adapted 
over time to feeder free GMP grade cell lines. ES cells offer a potentially unlimited 
supply of cells for use in transplantation, drug screening, and generation of 
disease models. However, use of ES cells is associated with a number of ethical 
and moral issues, and there is also an issue of immune rejection following 
transplantation. These are both important barriers to the use of ES cells as a cell 
source for study and for regenerative medicine applications, and thus it is 
important to continue to explore other cell sources that may circumvent these 
problems (Figure 1.1).  
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Figure 1.1 Schematic of the origin of pluripotent cells from the developing embryo; three 
reprogramming strategies for induced pluripotent cells. (Adapted from Christopher Lengner 
and Rudolf Jaenisch, 2008)  
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1.1.4 Induced pluripotent stem (iPS) cells  
  
One aim of generating pluripotent stem cells from adult somatic cells is to 
produce donor cells for transplantation that have the potential to circumvent the 
supply and demand problems of human fetal cells and the ethical and 
immunological issues associated with both human fetal and human ES cells. Miller 
and co-workers used a cell-cell fusion technique to generate pluripotent cells 
between thymus and EC cells, which resulted in cells that could generate 
teratocarcinomas in syngeneic mice (Miller et al., 1976). Furthermore, the largely 
successful work by Ian Wilmut to clone ‘Dolly the sheep’ in 1997, changed the 
prospect for developmental studies (Wilmut et al., 1997). This experiment ignited 
the idea of using somatic cell nuclear transfer (SCNT) as a method for generation 
of pluripotent stem cells (Wilmut et al., 1997). In addition, however, SCNT and 
cell-cell fusion techniques did not clarify the essential factors needed for somatic 
cell reprogramming (reviewed in Yu and Thomson, 2008).  
 
1.1.4.1 Generation of mouse induced pluripotent stem (iPS) cells  
 Induced pluripotent stem cells were first described in 2006 by Yamanaka’s 
group (Takahashi and Yamanaka, 2006). By introducing four exogenous 
transcription factors in a retrovirus to differentiated cells and nurturing those cells 
in an embryonic environment, they were able to directly reprogram them to 
pluripotent cells. Yamanaka and Takahashi reported that 24 genes are involved in 
reprogramming mouse somatic cells to cells which are similar in appearance to 
mouse ES cells. The potential inducing pluripotent factors were divided into three 
categories. The first division composed of the transcription agents that are highly 
expressed in ES cells such as Oct4, Nanog, UTF1, Sall4, Sox15, Rex1 and Sox2. 
The second category comprised of genes having a key role in ES cells and related 
to tumour generation for example c-Myc, Klf4, -catenin, Grb2, TCL1, ERas and 
Stat3. The final group was the factors particularly expressed in ES cells such as 
ECAT1, Fbx15, ESG1, DNMT3L, ECAT8, ECAT15-1, ECAT15-2, Fthl17, Stella, 
and GDF3; however, the function of the third group of factors remains unclear 
(Takahashi and Yamanaka, 2006). From a series of combinations they concluded 
that the four factors-- Oct4, Sox2, c-Myc, and Klf4, which are present in high levels 
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in ES cells, are sufficient to transform mouse fibroblasts into cells which mimic ES 
cells. (See Figure 1.2). 
 
Figure 1.2 Schematic demonstrates direct reprogramming mouse and human fibroblasts to iPS cells 
with five defined factors Oct4, Sox2, Klf4, c-Myc, and Lin28. After selection, iPS cells are derived. These 
cells could differentiate into all cell types within three germ layers as assayed by teratoma formation and 
developmental contribution. (Adapted from Welstead Grant et al., 2008)  
  
Subsequently, there have been many reports strengthening this finding 
(Maherali et al., 2007; Meissner et al., 2007; Okita et al. 2007; Takahashi et al., 
2007; Wernig et al., 2007; Yu et al., 2007; Wernig et al., 2008; Nakagawa et al., 
2008; Stadfeld et al., 2008; Yamanaka et al., 2008; Brambrink et al., 2008; Woltein 
et al., 2009; Kaji et al., 2009).  
Interestingly, mouse iPS cells derived by the Yamanaka group, in which 
Fbx15 was used as a selection marker, were unable to generate germline cells in 
chimeras, even though they were otherwise found to present the same 
characteristics as mouse ES cells (Takahashi and Yamanaka, 2006). Global gene 
expression was used to distinguish the pattern between the Fbx15-derived iPS 
cells and mouse ES cells; it demonstrated that the promoter areas of Oct4 and 
Nanog still remain methylated in the resulting iPS cells (Takahashi and 
Yamanaka, 2006). Yamanaka and Takahashi mentioned that Oct4 and Sox2 play 
an important role in determining a cells destination, either to a tumour cell or 
resembling an ES cell (Takahashi and Yamanaka, 2006), whereas, c-Myc 
Oct4 
Sox2 
Klf4 
cMyc 
Oct4 
Sox2 
Nanog 
Lin28 
or 
Fibroblast 
Selection 
iPS 
Differentiated cells Teratocarcinoma 
Chimera 
Mesoderm Ectoderm Endoderm 
? 
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facilitates Oct4 and Sox2 by unwinding its chromatin structure (Knoepfler et al., 
2006), thus paving the way for both transcription factors to bind to their target 
gene (Nakatake et al., 2006).             
 Many previous studies, suggested that disturbance of Nanog expression 
leads to loss of pluripotency, thus deriving an endoderm cell line, for example 
Mitsui et al., 2003, and Silva (2006) found that Nanog helps to enhance somatic 
cell reprogramming in the cell-cell fusion method. Thus, much pointed to Nanog as 
a selective marker for the derivation of iPS cells. Selecting iPS cells based upon 
their ability to reactivate Oct4 and Nanog promoters resulted in iPS cells that more 
closely resembled mouse ES cells with respect to epigenetic status and gene 
expression; and the ability to produce all three germ lines in adult chimeric mice 
(Maherali et al., 2007; Okita et al., 2007; Wernig et al., 2007). In addition, 
compared to Fbx15 iPS cells, Nanog iPS cells could maintain stable ES cell 
markers expression for prolonged periods in culture (Okita et al., 2007). Moreover, 
Nanog expressing mouse iPS cells presented the same pattern of gene 
expression as mouse ES cells in response to LIF and retinoic acid compared to 
Fbx15 iPS cells (Okita et al., 2007), which were dissimilar in gene expression 
profile under the same conditions. However, one consideration that needs to be 
made is with respect to the use of c-Myc, as it was reported that iPS cells 
generated under the same conditions as those described above resulted in tumour 
formation in mouse chimeric pups (20% of pups presented with tumours) (Okita, 
2007).  
 Wernig (2007) also generated iPS cells using four defined factors with 
retroviral vector delivery to reprogram MEFs and tail-tip fibroblast (TTFs). Oct4 or 
Nanog were used as selective markers to pick the reprogrammed colonies. The 
Oct4- and Nanog- iPS cells demonstrated similar epigenetic status, and protein 
levels of Oct4, Sox2, and Nanog were the same as ES cells. Moreover, these 
reprogrammed pluripotent stem cells could produce teratocarcinomas as well as 
all three germlines in chimaeras (Wernig et al., 2007). Wernig and colleagues 
reported that the pluripotent property strictly associated with the activity of the 
Oct4 locus, rather than the Nanog- locus. A major hope is that iPS cell technology 
will allow transplantation therapy using patients’ somatic cells as an individual 
resource, to circumvent ethical and immune rejection issues. In an effort to 
overcome this, Sommer and colleagues introduced a lentiviral vector with 
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transduction of 4 defined-reprogramming factors as a transgene set ‘STEMCCA’ 
(Sommer et al., 2009). They claimed that with this transfection method only 1-3 
copies of the viral vector would be integrated into the host genome, compared to 
at least 15 copies with a similar method using a retrovirus reported by Takahashi 
and Wernig in 2007. Sommer suggested that this novel method produced higher 
reprogramming efficiency (0.5%) compared to the relatively low efficiency (0.1%) 
reported in the previous studies as well as avoiding genomic alteration and viral 
reactivation (Sommer et al., 2009; Takahashi et al., 2007; Okita et al., 2007, 
Wernig et al., 2007). (See Table 1.1 for summary of mouse iPS cell generation). 
 
1.1.4.2 Generation of human induced pluripotent stem cells 
  Takahasi et al in 2007 reported the generation of human iPS cells using the 
same cocktail of transcription factors as used in the murine studies (Takahashi et 
al., 2007) and following from this Yu et al also reported successful iPS cell 
generation however, in this instance there was a modification to the transcription 
factor cocktail used with Klf4 and c-Myc being substituted with Nanog and Lin8 
(Yu et al., 2007). Following on from this Park et al reported the successful 
generation of human iPS cells from various origins (differentiated-, neonatal-, 
primary foetal-, and adult- fibroblasts) using retroviral infection method, and 
selecting ES cell like colonies by morphological appearance (Park et al., 2008). 
Oct4 and Sox2 were essential to initiate the reprogramming process; without the 
expression of both transcription factors, iPS colonies were unable to be generated 
(Yu et al., 2007; Park et al., 2008), while either Klf4 or c-Myc elimination led to a 
decrease in the number of ES cell-like colonies as previously presented in mouse 
iPS cell production (Wernig et al., 2008; Nakagawa et al., 2008; Stadtfeld et al., 
2008).  
Therefore, it could be said that three factors are sufficient to reprogram 
somatic cells to pluripotent cells (Park et al., 2008). The iPS cells produced from 
Park’s lab showed pluripotent properties in both in vivo and in vitro studies, for 
example expressing human ES cell surface markers (SSEA3, SSEA4, TRA-1-81, 
and TRA-1-60), showing pluripotent gene expression comparable to human ES 
cells (Oct4, Sox2, Rex1, GDF3), generating teratomas with all three germ lines in 
nude mice, and displaying similar epigenetic pattern as in human ES cells (Park et 
al., 2007). More mature differentiated cells, such as mesenchymal stem cells, 
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neonatal foreskin fibroblasts, and adult fibroblasts, require the addition of more 
factors (hTRAT and SV40 large T) in order to obtain reprogrammed-cell colonies 
(Park et al., 2008). However, Park reported that both hTRAT and SV40 large T 
gene expression were undetectable; therefore his explanation of this event is that 
hTRAT and SV40 large T are nothing to do with reprogramming initiation but help 
to improve the efficiency of iPS cell generation (Park et al., 2008).  
At the same time, Yu also derived CD45+ hematopoietic cells, IMR90 fetal 
fibroblasts, and human foreskin fibroblasts through the application of different 
factors (Oct4, Sox2, Nanog, and LIN28) using lentiviral vectors (Yu et al., 2007). 
The iPS cells obtained from 3 different origins met the pluripotent standard of ES 
cells; for example a morphological appearance similar to ES cells, genes- and 
typical cell surface marker expression comparable to human ES cells, and 
teratoma and Embryoid body (EB) production (Yu et al., 2007). However, foreskin 
iPS cells showed variable teratoma production specifically in terms of the germline 
differentiation within the teratoma with some clones producing more ectoderm 
than others (Yu et al., 2007). Again Oct4 and Sox2 were mentioned as crucial 
factors for reprogramming, while Nanog and Lin28 may help to improve the 
efficiency and frequency of direct reprogramming mechanisms (Yu et al., 2007; 
Park et al., 2007).  
One year later, human iPS cells were successfully reprogrammed with three 
factors in the absence of c-Myc (Nakagawa et al., 2008). As mentioned above c-
myc brought about high rates of tumerogenicity in descendants caused by 
reactivation of this gene (Okita et al., 2007, Yu et al., 2007).  
However, the efficiency of clone generation from human dermal fibroblasts 
was lower with c-Myc omission, at 0.001% (Nakagawa et al., 2008). The iPS cells 
produced in this study showed a similarity with human ES cells in terms of cell 
morphology, specific cell surface markers (SSEA3,4, TRA-1-60,-80, Nanog), gene 
expression (Oct4, Sox2, Nanog, Rex1), teratoma and chimera production 
(Nakagawa et al., 2008). Thus, it was recognized that additional molecules were 
needed in order to improve the efficiency. In the meantime, Lowry performed a 
transduction experiment using 5 reprogramming genes Oct 4, Sox2, Klf4, Lin28 
and Nanog (OSKLN) in a retroviral vector in order to transform human neonatal 
dermal fibroblasts to a pluripotent state (Lowry et al., 2008). The colonies emerged 
around day 14, but gene expression analysis showed them to be partially 
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reprogrammed, and they failed to generate EBs. However, after day 21, ES cell 
like-colonies were identified, that expressed a full range of pluripotent genes, and 
generated cells from all three embryo germ layers (See Table 1.2). 
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Table 1.1 Mouse iPS cells generation.  
Studies Cell source Factors Methods Finding 
Takahashi and 
Yamanaka, 2006 
-Mouse 
Embryonic 
fibroblast 
Oct4, 
Sox2,  
c-Myc, 
Klf4 
- Retrovirus-mediated transfection 
- Fbx15 selection marker 
 
- similar morphology, proliferation as ES cells 
- cannot contribute to adult chimeric mice 
- different DNA methylation pattern and gene expression to ES cells 
Okita et al, 2007 -Mouse 
Embryonic 
fibroblast 
Oct4, 
Sox2,  
c-Myc, 
Klf4 
- Retrovirus-mediated transfection 
- Nanog selection marker 
- mutant c-Myc (T58A) 
- GFP-TRES-PURO cassette  
- similar morphology, proliferation and gene expression as ES cells 
- tumours formation with 3 germ lines 
- efficiency less than 0.1% 
- 20% tumour development in offspring 
Wernig et al, 
2007 
-Mouse 
Embryonic 
fibroblast 
- Tail tip 
fibroblast 
(TTFs) 
Oct4, 
Sox2, 
c-Myc,  
Klf4 
- Moloney-based retroviral vector pLIB 
- Nanog or Oct4 selection marker 
- Oct4-IRES-GFPneo or Nanog-neo 
 
- normal Oct4, Sox2, Nanog RNA and protein levels 
- epigeneticly identical to ES cells 
- able to generate viable chimeras with 3 germ lines  
Meissner et al, 
2007 
-Mouse 
Embryonic 
Fibroblast 
-TTFs 
Oct4, 
Sox2, 
c-Myc,  
Klf4 
- MEFs carried IRES-EGFP at Oct4 loci 
- retrovirus encoded four factors 
- Morphological selection by directly picking 
the colony or whole plate passaging 
- Could generate adult chimeras and teratomas when injected into 
nude mice 
- Efficiency: overall efficiency is about 0.5%   
- Reprogramming is a slow and gradual process 
Okita et al, 2008 -Mouse 
embryonic 
fibroblast 
 
Oct4, 
Sox2,  
c-Myc, 
Klf4  
 
- an adenovirus mediated gene system 
- pcCX-OKS-2A and pCX-cMyc 
  
- generate teratoma with 3 germ layers when transplant to nude mice 
- produce adult chimeric mice 
- similar morphology, proliferation and gene expression as ES cells 
- the efficiency is lower than transduction with viral vector methods 
- Southern blot: no plasmid DNA integration was observed     
Nakagawa et al, 
2008 
-Mouse 
Embryonic 
fibroblast 
-TTFs 
- Human 
fibroblast 
4 factors 
and 3 
factors 
without  
c-Myc 
- GFP-IRES-Puro  
- Nanog selection marker 
- Fbx15 with βgeo 
- DsRed retrovirus 
  
 
 
- day 14 and 21 GFP+ colonies  
- ES cell-like marker genes 
- produce adult chimeric mice  
- significantly reduced tumourigenic risk  
- less efficient, but more specific induction of iPS cells 
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Studies Cell source Factors Methods Finding 
Mikkelsen et al, 
2008 
-Mouse 
embryonic 
fibroblast 
- B lymphocyte  
Oct4, 
Sox2,  
c-Myc, 
Klf4  
 
-inducible lentiviral vectors with Nanog-GFP 
 
 
- similar morphology, proliferation and gene expression as ES cells 
- pluripotentiality of iPS cells line was shown by teratoma formation 
 
 
Brambrink et al, 
2008 
-Mouse 
embryonic 
fibroblast 
Oct4, 
Sox2, 
Klf4, 
c-Myc 
- doxycycline (dox)-inducible lentiviral vector 
 
 
- need at least 12 days to see the iPS cell colonies  
 
Wernig et al, 
2008 
-Mouse 
embryonic 
fibroblast 
4 factors 
and 3 
factors 
without  
c-Myc 
- Retroviral vector 
- Oct4 neo and Nanog neo mice  
- reprogramming process was substantially delayed 
-produce chimeric mice and tumours with 3 germ lines 
- morphologically and functionally the same as 4 factors iPS cells 
Stadtfeld et al, 
2008 
- Oct
IND
 mouse 
TTFs 
- Oct
IND
 
hepatocytes 
- Oct
IND
 fetal 
liver cells 
 
3 factors 
Sox2, Klf4, 
and c-Myc 
- adenovirus transduction 
- using OCT4
IND
 instead of Oct4 viral 
expression
  
 
 
  
- Oct
IND
 fetal liver cells: at 24-30 days 9 iPS cells like colonies 
recognized expressing Sox2, SSEA-1 
- Oct
IND 
TTFs: a single colony 
- Oct
IND
 Hepatocytes: 3 colonies which expressed Oct4, SSEA-1, 
indistinguishable from ES cell markers 
- form teratomas with all three germ layers 
- able to generate adult chimeras  
- efficiency was extremely low: less than 0.0001%-0.001% 
Stadtfeld et al, 
2008 
-Mouse 
embryonic 
fibroblast 
Oct4, 
Sox2, 
Klf4,  
c-Myc  
-inducible vectors 
 
 
- show pluripotent properties and could generate chimeras 
- 0.016% efficiency when introduced to exogenous factors for 8-9 days 
- 0.06% efficiency when exposed to pluripotent transcription factors for 
more than 10 days   
- inducing reprogramming using pluripotent transcription factors is 
gradual processes 
Eminli et al, 2008 -Mouse neural 
progenitor cells 
(NPCs) 
3 factors 
Oct4, Klf4, 
and c-Myc  
- Lentiviral vector - the reprogramming efficiency is about 28% 
- in the human experiment, similar results were obtained  
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Studies Cell source Factors Methods Finding 
Kaji et al, 2009 -Mouse and 
human 
embryonic 
fibroblast 
Oct4, 
Sox2,  
c-Myc, 
Klf4 
- a single multiprotein expression vector 
(pCAG2LMKOSimO)  
- pCAG2LMKOSimO with a piggyBac 
transposon   
- similar morphology, proliferation and gene expression as ES cells  
- tumour development comprising 3 germ layers  
- able to generate adult chimeric mouse   
 
Woltjen et al, 
2009 
- Mouse and 
human 
embryonic 
fibroblast 
Oct4,  
Klf4,  
Sox2,  
c-Myc 
- piggyBac transposon deliver doxycycline 
transcription factors   
- rtTA –MEFs 
 
- contribute to teratoma with 3 embryonic germ layers 
- could generate adult chimeras 
- expressed pluripotent cells markers at a similar level to ES cells 
- PB insertion could be removed from iPS cells by seamless excision 
Sommer et al, 
2009 
-TTFs OSKM as 
‘STEMCCA
’ cassette 
 
-  Lentivirus with 4 definded factors  
- GFP –R26-M2rtTA in Sox2 loci 
- at day 6 (with EFI promoter), morphology similar to ES cells; day 6-8 
(with TetO promoter) no colony in an absences of doxycycline 
- can generate teratoma formation with all germ layears 
- the reprogramming efficiency is 0.5% (10-fold higher than the similar 
method previously reported)  
 
OSKM = Oct4, Sox2, Klf4, c-Myc; OCT4
IND
 = a doxycycline-inducible Oct4 allele driven by a reverse-tetracycline–dependent transactivator (rtTA) present in the ROSA26 locus; 
rtTA= a reverse-tetracycline–dependent transactivator; hES= human ES  
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Table 1.2 Human iPS cells generation. 
Studies Cell source Factors Methods Finding 
Takahashi et al, 
2007 
-Adult human 
dermal fibroblast 
Oct4,  
Sox2,  
c-Myc, 
Klf4 
- Retroviral deliver system -morphology, proliferation, surface antigens, gene expression, 
epigenetic status and telomerase activity similar to human ES cell 
-in vitro and in vivo differentiation to all 3 germ layers  
Yu et al, 2007 - Derived CD45
+
 
hematopoietic cells  
- IMR90 fetal 
fibroblast 
- Human newborn 
foreskin fibroblast 
Oct4,  
Sox2,  
Nanog,  
LIN28 
- Gentamicin selection for  derived 
CD45
+
 hematopoietic cells 
- Morphology selection for  IMR90 fetal 
fibroblasts 
- Lentiviral vectors transduction 
 
 
- all resulting iPS cells from different sources had ES cell 
characteristics,,telomerase re-activation, pluripotent  markers (SSEA3, 
SSEA4, Tra-1-80, Tra-1-60), and epigenetic profile 
- generated teratomas with all three germ layers in adult mice 
- iPS cells differentiated from foreskin showed variations in teratoma 
formations     
Nakagawa et al, 
2008 
- Human dermal 
fibroblast 
3 factors 
Oct4, 
Sox2, 
Klf4 
- Retroviral deliver system 
 
 
- iPS cells were similar to hES cells in terms of cell morphology, cell  
surface markers (SSEA3,4, TRA-1-60,-80, Nanog),   gene expression 
(Oct4, Sox2, Nanog, Rex1), teratomas and chimera production  
 
Huangfu et al, 
2008 
- Primary human 
fibroblast: BJ and 
NHDF 
3 factors 
Oct4, 
Sox2, 
Klf4 and 
VPA 
treatment 
Molony murine leukemia retrovirus 
transduction 
- ES cells like forms selective method 
 
- after 30 days, reprogrammed colonies  
- morphology, gene expression, epigenetic profile, and pluripotent 
properties were comparable to human ES cells  
Kim et al, 2009 - Human fibroblast Oct4, 
Klf4, 
Sox2, 
and c-
Myc 
Cell penetrating peptide (CPP) with 9 
arginine residing amino acid 
 
- protein induced iPS cells with pluripotent, morphology, gene 
expression, pluripotent specific markers.  
- epigenetic status comparable to hES cells 
- Efficiency was low  - 0.001% of input cells 
- slow method 
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Studies Cell source Factors Methods Finding 
Kim JB et al, 
2009 
- Human fetal 
neural stem cells 
1 factor: Oct4 Retroviral transduction  
 
- iPS cells resembled ES cells in terms of morphology, genes 
and pluripotent cell surface marker expression, epigenetic 
patterns 
- generated teratomas and adult chimeras  
- the efficiency is about 0.004% 
Zhou et al, 2009 - Human 
embryonic 
fibroblast (IMR90) 
Oct4, Klf4, 
Sox2,  
and c-Myc 
Adenoviral deliver system 
 
- efficiency very low 0.0002% 
- morphology and pluripotent features similar to ES cells 
- an absence of vector genome detection  
Yu et al, 2009 -  Human foreskin 
fibroblasts 
4 factors: 
Oct4, Sox2, 
Nanog, Lin28 
-6 factors: 
add    c-Myc, 
and Klf4 
-6 factors: 
add  Klf4, 
SV40LT   
Non integrating episomal vectors 
Orip/EBNA1 
- IRES co-expressed with 
reprogramming factors 
-  vectors could be removed using drug 
selection 
 
 
- iPS cells revealed hES cell like  morphological appearance, 
gene expression profiles, epigenetic status, teratomas formation 
with all three germ lines    
- four factors: efficiency 0.1%  
- added c-Myc and Klf4: efficiency 1%   
- free from transgenes and vectors DNA integration 
- reprogramming does not require chromosomal integration or 
continuous expression of exogenous pluripotent factors 
Fusaki et al, 2009 
 
 
- Human 
fibroblasts 
4 factors: 
Oct4, Sox2, 
Klf4, c-Myc  
Sendai virus -  ES like morphology  
- in vivo and in vitro differentiation demonstrated 3 germ layers 
- Oct4 and Nanog promoters were demethylated 
Warren et al, 
2010 
- Human 
epidermal 
keratinocytes and 
murine embryonic 
fibroblasts 
4 factors: 
Oct4, Sox2, 
Klf4, c-Myc;  
-5 factors:  
Oct4, Sox2, 
Klf4, c-Myc, 
Lin28 
In low-oxygen 
condition (5% 
O2) 
Synthetic mRNA modified - ES like morphology  
- in vivo and in vitro differentiation demonstrated 3 germ layers 
- additional of VPA made no different in reprogramming 
efficiency  
- five factors: efficiency 2% 
- five factors in low Oxygen condition: efficiency 4.4% 
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Studies Cell source Factors Methods Finding 
Ban et al, 2011 -Human fibroblasts 
-CD34+-CB cells 
Oct4, Sox2, 
Klf4,  
and c-Myc 
Sendai virus - expression of  human ES marker SSEA4, TRA-1-60, TRA-1-81, 
Nanog, and Oct4 
-  in vitro and in vivo differentiation: EBs and teratomas with all 3 germ 
layers 
- the reprogramming efficiency >0.1%  
- the vectors do not reactivate or are detectable in the established-iPS 
cells at the late passage or after the temperature shifting procedure   
Okita et al, 2011 - Human dermal 
fibroblast 
Different 
combination 
factors of: 
Oct3/4, Sox2, 
Klf4, c-Myc,  
L-Myc, Lin28, 
Nanog,  
p53 shRNA, 
SV40-LT 
Episomal plasmid vector - a cellular morphology similar to human ES colonies 
- Karyotypically normal 
- RT-PCR expressed pluripotent stem cell markers 
- Global gene expression profiles were similar to ES cells 
- DNA methylation levels of CpG sites in promotor region of Nanog 
were low in pla-iPS (plasmid vector derived iPS cells) comparing to 
human dermal fibroblast 
 
Ono et al, 2012 - Human nasal 
epithelial cells 
Oct4, Sox2, 
Klf4,  
and c-Myc 
Sendai virus - reprogramming efficiency 0.075%-0.1% 
- using a temperature-sensitive mutant Sendai virus to shut off 
transgene by temperature shift 
- similar level of endogenous Oct4, Sox2, Klf4, c-Myc to hES cells 
- no expression of vector genome by RT-PCR 
- in vitro and in vivo differentiation: EBs and teratomas 
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1.1.4.3 Efficiency improvement of iPS cell strategies  
Numerous studies have shown integration of transgenes and vector 
DNA into host DNA using retroviral and lentiviral transduction (Yu et al., 2009; 
Zhou et al., 2009). Using the viral transduction method up to 10-20 integration 
sites were reported in the resulting clones (Takahashi et al., 2008; Aoi et al., 
2008;); these alterations in the host genome resulted in; abnormal gene 
transcription (Zhou et al., 2009; Yu et al., 2009), 20% tumour formation found 
in the descendants (Okita et al., 2007), and 18 out of 36 chimeric mice 
generated from iPS cell mosaics were killed by cancer, which has been rarely 
observed from ES cell chimeras (Wernig et al., 2008). Therefore, many 
research groups have attempted to improve the delivery methods required for 
reprogramming, not only to avoid genomic alteration and tumour formation, 
but also to improve the quality and clinical application potential of iPS cells 
(Kim et al., 2009, Ban et al., 2011; Ono et al., 2012).  
In 2009, Yu and co-workers applied internal ribosome entry site 2 
(IRES2) co-expression with four and six reprogramming factors using non 
integrative episomal vectors—Epstein-Barr nuclear antigen-1 (OriP/EBNA1) 
(Yu et al., 2009). Yu claimed that using this delivery system, exogenous 
reprogramming genes and viral vector DNA were undetectable by PCR and 
southern blot analysis of the resulting iPS cell clones (Yu et al., 2009).  The 
pluripotent properties and the developmental direction of the resulting iPS 
cells showed ES cell like features including morphology, pluripotent gene 
profiles, specific human ES cell surface markers, teratomas with all three 
germ layers —ectoderm, mesoderm, and endoderm, and an epigenetic status 
showing highly demethylated Oct4 and Nanog promoters (Yu et al., 2009). 
However, the efficiency was low: just 3-6 ES cell like colonies were identified 
from 1x106 infected fibroblasts (Yu et al., 2009). 
  In the meantime, human fetal fibroblasts were successfully 
dedifferentiated back into pluripotent cells without vector DNA integration by 
adenoviral gene transduction with four factors Oct4, Sox2, Klf4, and c-Myc 
(Zhou et al., 2009). These cells showed human ES cell like characteristics in 
terms of morphology, pluripotent gene expression (SSEA3, SSEA4, TRA-1-
81, TRA-1-60, Oct4, Nanog), comparable ES cell surface markers, and 
generation of teratomas (with 3 germ layers). However, the adenoviral 
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delivery strategy resulted in low efficiency of around 0.0002% (Zhou et al., 
2009). Interestingly from the point of view of this thesis, Zhou claimed 
successful differentiation of dopaminergic neurons from these cells despite 
the low efficiency (Zhou et al., 2009) raising the possibility that MSNs could 
also then be generated following specific directed differentation.   
Cell penetrating protein (CPP) are small peptides rich in positively 
charged amino acids such as arginine or lysine which are able to move across 
the cell membrane (Ziegler et al., 2005; EI-Sayed et al., 2009). Their cell 
penetrating ability was used to deliver four reprogramming factors (Oct4, 
Sox2, Klf4, and c-Myc) in order to induce somatic cells to a pluripotent state 
(Kim et al., 2009). Each defined factor was fused with a 9 arginine peptide 
(9R) and transfected into HEK293 cells to generate the stable HEK cell line 
expressing each reprogramming factor separately (Kim et al., 2009). Human 
fibroblasts cultured in ES cell conditions were subjected to a protein treatment 
with the extracted protein from the four HEK cell lines over a period of 6 days 
for 16 hours each day (Kim et al., 2009). Eight weeks later ES cell like 
colonies were identified with alkaline phosphatase (AP) positive staining and 
morphological selection (Kim et al., 2009). Protein induced iPS cells 
demonstrated pluripotent abilities by formation of teratomas when injected into 
nude mice, and also generated EBs which were able to differentiate into cell 
types from all three germ layers (Kim et al., 2009). Furthermore, the resulting 
iPS cells exhibited similar gene expression profiles (Oct4, Nanog, Sox2, 
Rex1, Gdf3, and hTERT), pluripotent markers (Oct4, Nanog, SSEA3, SSEA4, 
TRA-1-60), and epigenetic profiles (demethylated at Oct4 and Nanog 
promoters) to human ES cells; even though, the derivative efficiency of iPS 
cell production was also reported to be very low, 0.001% of input cells (Kim et 
al., 2009).  
To date there have been many attempts to improve the reprogramming 
efficiency and to generate vector-free iPS cells. One such reprogramming 
technology is the Sendai virus vector (Se V) mediated- iPS cells which was 
introduced by Fusaki and co-workers in 2009 (Fusaki et al., 2009). Se V is an 
enveloped-RNA genome virus vector of the Paramyxovirdae family (reviewed 
in Ban et al, 2011). It was claimed to replicate only in the cytoplasm of 
transfected cells, transfect with high efficiency in a wide range of cell types 
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and species, and more importantly has also been applied as a gene therapy 
in many areas such as AIDS, ischemia, and cystic fibrosis (Fusaki et al., 
2009; Ban et al., 2011; Ono et al., 2012). The major advantage of Se V vector 
is that it is a RNA virus therefore it does not go through a DNA phase nor 
integrate into the host genome. A simple method to remove the vector from 
the genome can be carried out by changing the temperature (Ban et al., 2011; 
Ono et al., 2012) or by applying anti-Se V-HN antibody (Fusaki et al, 2009). 
The reprogramming efficiency was reported to be about 0.75+0.1% (Fusaki et 
al., 2009; Ono et al., 2012). More recently, the temperature-sensitive Sendai 
virus (TS-Se V) vector was innovated as an effective transduction method in 
order to produce iPS cells that are safe enough for clinical usage (0.08-0.1% 
efficiency) (Ban et al., 2011; Ono et al., 2012).  
       Various methods have been developed to improve the efficiency and to 
avoid genetic manipulation. Kaji introduced a single multiprotein expression 
vector which combined four reprogramming factors MKOS (c-Myc, KLF4, 
Oct4, and Sox2) and 2A peptides in order to induce mouse and human 
fibroblasts to a pluripotent like state (Kaji et al., 2009). Kaji claimed that the 
reprogramming efficiency was 2.5%, although the efficiency was calculated 
differently to that used in the viral studies described above (about 0.01-0.1%). 
High expression of c-Myc and Klf4 and similar expression of Oct4 and Sox2 
were found in all 8 iPS cell lines generated from the 12 colonies identified. In 
addition, the protein levels of all four defined factors were comparable to the 
ES cells. Using Cre transfection, Kaji et al claimed to eliminate all four 
exogenous reprogramming factors from the resulting iPS cells. In the same 
period, the piggyBac transposon system was developed to successfully 
deliver doxycycline inducible transcription factors in mouse and human 
somatic cell reprogramming (Woltjen et al., 2009). In this study, piggyBac was 
reported as a simple and effective transduction method, suitable for use in a 
wide range of cell types, along with removable exogenous pluripotent factors.             
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1.1.4.4 Safety concerns about reprogrammed cell generation and usage. 
 The concept of using iPS cells as a donor cell source for 
neurodegenerative diseases is currently hindered by safety concerns. To 
improve the practical quality of iPS cells and avoid tumour development after 
transplantation, Wernig and his team reprogrammed mouse fibroblasts using 
three factors Oct4, Sox2, and Klf4, rather than the previous four defined 
factors (Wernig et al., 2008). The results showed that mouse fibroblasts could 
be reprogrammed in the absence of c-Myc. In the experiment, Oct4 or Nanog 
were used as selection markers both with and without neomycin selection. 
Wernig reported that removal of the drug selection element does not affect the 
rate of reprogramming of somatic cells and as such it remains a slow and 
gradual process (Meissner et al., 2007; Wernig et al., 2007). The conclusion 
was that three factors Oct4, Sox2, and Klf4 are sufficient to completely 
reprogram differentiated cells to pluripotent cells over a prolonged culture 
period. Similarities in morphology and function are reported for three and four 
factor iPS cells derivation, and these iPS cells could produce mature 
chimaeras, and developed three germ line tumours when injected into nude 
mice. However, the number of drug-resistant colonies was dramatically 
reduced in the absence of c- Myc and neomycin-resistant iPS colonies were 
only detected approximately 30-70 days after infection with three factor 
retroviruses (Wernig et al, 2008). Wernig (2008) concluded that c-Myc 
increases the propensity of iPS colonies and speeds up the processes of cell 
reprogramming.    
 At the same time the Nakagawa group published a paper supporting 
the idea of using three key factors, without c-Myc, in both mouse and human 
fibroblasts (Nakagawa et al., 2008). Nakagawa reported that the iPS cells 
maintained good quality with fewer cells of a non-iPS background (Nakagawa 
et al., 2008). As expected, the omission of c-Myc resulted in a significant 
reduction of tumorigenicity in chimeras and their progeny (Nakagawa et al., 
2008). In addition, the results from this study further emphasized that without 
reactivation of c-Myc retroviruses the reprogramming process was delayed 
and fewer iPS colonies were obtained (Nakagawa et al., 2008).                       
In spite of the safety concerns about tumour development after 
transplantation, viral transduction has been considered for clinical application. 
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Meissner et al in 2007 reported a strategy to generate unmodified genetic iPS 
cells based on a morphologically distinctive strategy that did not require the 
use of drug selection (Meissner et al., 2007). This resulted in a 5 fold increase 
in the reprogramming efficiency of MEFs compared to other viral approaches 
(0.1% efficiency). Moreover, Meissner reported that stable iPS cell lines could 
be produced from 5 out of 6 directly selected colonies and also presented 
pluripotent abilities by generating adult chimeras and teratomas when injected 
into nude mice. He also supported the notion that direct reprogramming is a 
slow and gradual method which is also indeterminate and results in biological 
differences in each yield. (See Figure 1.3). 
  
 
Figure 1.3 Two colonies of pluripotent stem cells – one of human ES cells (A) and one of 
human iPS cells, derived from reprogrammed adult cells (B). It is clear from the 
photomicrographs that both cell populations form colonies that share similarities in 
morphology in vitro.  
 
In 2008, Stadtfeld and his colleagues introduced an adenovirus 
transduction system to deliver three defined factors Sox2, Klf4, and c-Myc into 
OctIND mouse TTFs hepatocytes, and fetal liver cells (where the Oct4 has 
been modified using a doxycycline-inducible Oct4 allele present in the 
ROSA26 locus that is driven by a reverse-tetracycline–dependent 
transactivator (rtTA)), instead of using retroviral method therefore avoiding 
DNA integration from viral vectors to the host genomic DNA (Stadtfeld et al., 
2008). 
 However, the efficiency was very low at about 0.0001%-0.001%, 
whereas retroviral usage gave 0.01%-0.1% effectiveness. According to 
southern blot and PCR studies, plasmid DNA integration could not be 
detected in the adeno-iPS colonies and it was not possible to amplify the 
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vector DNA. Okita and coworkers also published a paper in 2008 in which 
mouse iPS cells were produced without viral vectors. In this paper, a pCX-
OKS-2A vector, which identifies the importance of the order in which the 
transcription factors were placed in the vector (Oct4, Klf4, Sox2 respectively), 
and a pCX-c-Myc plasmid were transfected into MEFs. The resulting iPS cells 
not only exhibited morphology indistinguishable from ES cells, but also 
expressed similar levels of pluripotent markers as ES cells. From 
examinations for the unification between host genome and plasmid DNA, 
Okita claimed that the iPS cells generated from plasmid vector appeared to be 
free from the DNA integration. The efficiency of iPS cells generated by the 
Okita group was lower than the viral transfection method, as in Stadtfeld 
group (Stadtfeld et al., 2008; Okita et al., 2008).  
 
1.1.4.5 Molecular changes and mechanisms of reprogramming process.  
 The molecular mechanisms of somatic cell reprogramming are still 
unclear. The variability with which iPS colonies appear in the different 
systems (ranging from 10 days to 8 weeks) makes is more difficult to pinpoint 
these molecular mechanisms and their mode of action. The epigenetic events 
during the reprogramming process and the up-regulation or down-regulation 
of involved pluripotent genes are still a mystery (see Figure 1.4 and 1.5). It is 
not known whether the reprogramming of somatic cells to pluripotent cells is a 
timed sequential process or if it is a random process, but what is important is 
that more studies are needed in order to understand the molecular processes 
before such cells are to be used in any clinical application.  
In 2008, Brambrink and his colleagues attempted to clarify the 
activation pattern of known ES cell markers over the reprogramming period of 
iPS cells. They suggested that AP was activated before SSEA-1, and after the 
cells were completely reprogrammed and Oct4 and Nanog expression were 
exhibited. In addition, in this reprogramming process at least 12 days was 
required after the transduction of the four factor lentivirus before the first iPS 
colonies could be recognised. This finding was emphasized by Stadtfeld’s 
discovery in the same year where it took more than 8 days of inducing 
exogenous transcription factors expression in order to obtain iPS cell colonies 
that were stabilized to maintain their pluripotent status (after day 20) 
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(Stadtfeld et al, 2008). In addition, Thy1 (highly expressed in differentiated 
cells and fibroblasts) was found to be down regulated contrasting with SSEA-
1 (ES cell marker), which increased after this time point. Stadtfeld claimed 
that Thy1 down regulation not only occurred before the expression of SSEA-1, 
but also induced the expression of SSEA-1. Moreover, the results from this 
study supported the previous findings that to be successful in cell 
reprogramming the endogenous pluripotent genes—Oct4, Sox2 and 
telomerase (Stadtfeld et al., 2008) need to be reactivated, whereas the X 
chromosome was kept silent (Maherali et al., 2007; Okita et al., 2007; Wernig 
et al., 2007).  
All these steps were found at the late process of reprogramming as the 
cells became independent from the expression of four defined factors 
(Stadtfeld et al., 2008). However, Stadtfeld pinpointed that the silencing of the 
four exogenous transgenes (Oct4, Sox2, Klf4, and c-Myc) using retroviral 
vectors occurred gradually from the early stage and was complete by the late 
stage of the reprogramming process, corresponding to epigenetic 
modifications and pluripotent gene regulation.  
This finding contrasted with the previous suggestion that incompletely 
reprogrammed cells still displayed imperfect silencing of viral vectors 
(Takahashi and Yamanaka, 2006). Interestingly in his study, he also found 
that Fbx15 was reactivated at the early stage of reprogramming (day 3 after 
exogenous factors transduction) before Nanog and Oct4 genes were 
expressed. Incompletely reprogrammed iPS cells using Fbx15 as a selective 
maker may be explained by this phenomena (Stadtfeld et al., 2008; Mikkelsen 
et al., 2008). In another major study, Mikkelsen and co-workers discovered a 
similar epigenetic profile between Fbx15 iPS cells and 3 lines of partial 
reprogramming cells in his experiments (Mikkelsen et al., 2008). Partial 
reprogramming could be explained by several factors such as activation of 
anti-pluripotent genes triggered by proliferative stress, failing to activate or 
suppress endogenous/exogenous reprogramming factors (Mikkelsen et al., 
2008). He also suggested that to facilitate and improve successful 
reprogramming strategies the application of DNA methyl-transferase inhibitors 
could be considered (Mikkelsen et al., 2008). (Figure 1.4 and1.5). 
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Figure 1.4 Schematic illustrations of direct reprogramming processes to a pluripotent 
cell state. Direct reprogramming as illustrated here comprises 3 steps which are the starting, 
intermediate, and end stages. Pluripotent properties start to be able to recognized by the 
‘intermediate stage’ and further conversion to iPS cells occurs through DNA methylation and 
knock down of lineage-specific genes. Partial reprogramming may stem from transient 
intermediate cells. (Adapted from Hochedlinger and Plath, 2009).            
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Figure 1.5 Schematic showing rewiring of epigenetic regulation to change cell fate with 
two opposing processes – differentiation and direct reprogramming. The transition from one 
cell state to another appears to depending on cellular proliferation, chromatin remodeling, and 
reactivation of pluripotent genes. Therefore, global gene expression pattern will change from 
fibroblast to ES like state. (Adapted from Welstead Grant et al., 2008)    
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1.1.4.6 Therapeutic potential of human induced pluripotent stem cells 
The promise of iPS cells as a novel donor cell source for cell therapy in 
degenerative diseases, their implementation to understand normal development 
and cell lineage differentiation, and their application in disease modeling for 
various human diseases including cancer, have attracted the attention of many 
research groups around the world where multiple attempts have already been 
made to generate human iPS cells.  
In fact nuclear reprogramming in human cells was achieved in 2005 using 
fusion of human somatic cells with human ES cells (Cowan et al., 2005). Cowan 
and colleagues found that there were similarities in morphological structure, 
antigen expression profiles, and genetic profiles such as DNA methylation pattern, 
specific gene expression, reporter gene stimulation between reprogrammed- and 
ES cells. Moreover, Cowan claimed that these hybrid cells also show ES like 
pluripotency by producing EBs in culture and teratomas in nude mice. One year 
later, the capacity of myeloid precursors to be reprogrammed using cell-cell fusion 
model with human ES cells was reported (Yu et al., 2006). Yu highlighted that 
surprisingly the hybrid cells could differentiate back to their original cell type 
(myeloid precursors) with an efficiency similar to ES cells. Yu was also concerned 
about the differences between species and how the reprogramming process may 
differ; the factors that promote self-renewal of human ES cells are distinctively 
different from mouse ES cells. However, the controversy of destroying human 
embryos and immune rejection hinder the use of ES cells for clinical application. 
Thus, iPS cells are an attractive alternative cell source to explore as they 
overcome many of these issues. 
 
1.1.4.7 Safety concerns in human iPS cell usage.     
  Two major hurdles for the clinical application of iPS cells is the efficiency of 
generation, and the involvement of the oncogenes c-Myc and Klf4 which may alter 
the host cells genome (Huangfu et al., 2008). One approach that is working 
towards addressing these issues was reported by Kim et al 2008. In this study 
adult stem cells containing high levels of essential reprogramming factors such as 
Sox2 (in adult neuronal stem cells) were used as the original cell source, and were 
successfully turned to a totipotent state with fewer transcription factors used for 
induction (Oct4 with either Klf4 or c-Myc) (Kim et al., 2008).  
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 The ability to generate iPS cell colonies in the absence of c-Myc identifies a 
move towards the generation of clinically useable cells. In addition, small 
molecules such as histone deacetylase (HDAC) and DNA methyltransferase were 
used as the enhancers to improve the efficiency of somatic cell reprogramming, 
because these molecules do not alter the genomic structure of host cells (Huangfu 
et al 2008). Huangfu reported that two primary human fibroblast lines (BJ and 
NHDF) achieved a pluripotent state after being infected with three transcription 
factors (Oct4, Sox2, and Klf4), and an additional 1-2 weeks of valproic acid (VPA) 
treatment; the efficiency of reprogramming method was claimed on the basis of 
Oct4-GFP positive cell production as 2%, and as 1% based on the number of iPS 
colonies (Huangfu et al., 2008).  
Although, the 3 factor-induced iPS clones met all the criteria to resemble 
human ES cells, infected cells needed to be cultured for up to 30 days in order to 
identify ES cell-like forms (Huangfu et al., 2008). After succeeding in three factor 
reprogramming, Hangfu also induced BJ and NHDF using two core 
reprogramming factors (Oct4 and Sox2) and VPA treatment (Huangfu et al., 
2008). Although, the two factor reprogramming strategy showed a significant 
decrease in efficiency compared to three factors; the iPS cells generated by only 
two factors showed pluripotent characteristics, gene expression profiles, and 
epigenetic patterns comparable not only to iPS cells produced by three factors but 
also comparable to human ES cells (Huangfu et al., 2008). Huangfu concluded 
from his study that Oct4 and Sox2 are the essential factors in direct 
reprogramming method, whereas Klf4 is a non-essential factor, but plays a role as 
the facilitator. Moreover, two factors with small molecule--VPA are sufficient to 
reprogram primary neonatal fibroblasts (that have low levels of reprogramming 
factor expression) (Huangfu et al., 2008). 
  After several attempts to reduce the exogenous transcription factors used in 
reprogramming differentiated cells, in 2009 Kim and his co-workers claimed that 
introduction of Oct4 alone is adequate to induce human foetal neural stem cells to 
a totipotent state (Kim et al., 2009). To obtain the iPS cell colonies, the transfected 
cells were cultured in human ES cell conditions for 10-11 weeks. Single factor 
induced iPS cells shared similarities in morphological appearance and epigenetic 
patterns to human ES cells (Kim et al., 2009). In addition, epigenetic remodelling 
in the resulting iPS cells were confirmed with demethylated Oct4 and Nanog 
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promoters as presented in pluripotent cells (Kim et al., 2009). These iPS cells also 
exhibited the pluripotent characteristics in both in vivo and in vitro examinations 
(Kim et al., 2009). However, the efficiency of using only Oct4 to reprogram somatic 
cells was very low at 0.004%, therefore the finding of novel small molecules to 
improve the efficiency or even replace all the reprogramming factors could be an 
ideal strategy to generate safe and practical iPS cells as a cell source for 
regenerative medicine (Kim et al., 2009).   
 The ultimate goal of iPS cell derivation for degenerative diseases is to 
provide transplantable patient-specific cell sources which overcome ethical and 
immune rejection difficulties as found with other donor cell sources. Hematopoietic 
progenitors (HPs) derived from iPS cells were reported to successfully rescue and 
improve all aspects of pathology in a mouse sickle cell anemia model (Hanna et 
al., 2007). Sickle cell anemia mice were transplanted with iPS cell derived HPs to 
examine “proof of principle” and functional therapeutic potential in the iPS cell 
usage (Hanna et al., 2007).  
 Interestingly, one year later, Wernig reported functional benefit and 
behavioral improvement using iPS cell derived neural stem cells (NSCs) 
transplanted into a Parkinson’s disease (PD) rat model (Wernig et al., 2008). 
Wernig claimed that in vitro NSCs generated from iPS cells were able to 
differentiate into all neural cell types (β-III tubulin (neuronal maker), GFAP (glial 
marker), O4 (oligodendrocyte marker) positive staining) including dopaminergic 
neurons after delivery of patterning factors (FGF8 and sonic hedgehog) (Wernig et 
al., 2008). In addition, migration of NSCs from iPS cells was observed in various 
brain regions such as the striatum, midbrain, and hypothalamus after injection to 
the striatum (Wernig et al., 2008). Furthermore, functional restoration and 
behavioral improvement were confirmed by electrophysiological demonstration of 
action potentials, synaptophysin expression, and bias movement reduction in 
amphetamine induced rotations up to 8 weeks post transplantation (Wernig et al., 
2008). The previously mentioned studies provide evidence that iPS cells have the 
potential to be a donor cell source for cell replacement in regenerative medicine.  
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1.2 Huntington’s disease 
  
Huntington’s disease (HD) was first described by George Huntington who 
detailed the classic features of this neurodegenerative disease in his now well-
known paper of 1872 (Huntington G., 1872). The CAG trinucleotide repeat 
expansion of the huntingtin gene (HTT) encodes mutant protein huntingtin (mHtt) 
which has an abnormally long polyglutamine tract.  This mutation is responsible for 
HD (The Huntington’s disease collaborative research group, 1993). The gain of 
function toxicity caused by mHtt may disturb normal activities (Imariso et al., 
2008). It is clear that the major effects of mHtt are due to toxic gain of function, 
although there is controversy about the extent to which loss of function is 
important in the pathogenesis of HD.  
HD pathology affects increasingly widespread areas of the brain, although 
the predominant pathology in HD is loss of MSNs in the striatum, which results in 
compensatory ventricular enlargement.  Due to the widespread connections of the 
striatum with brain regions subserving many different functions, damage to the 
striatum results in impairment of cognition, motor dysfunction and also leads to 
psychiatric impairments in HD patients. As the disease progresses, more 
widespread areas of brain are affected with shrinkage/degeneration of the cortex 
(Meynert et al., 1877; Jelgersma et al., 1907) (Figure 1.6).  
 
Figure 1.6 Coronal section through normal brain (A) and HD brain (B). The arrow shows 
atrophy of the striatum, due largely to loss of medium spiny neurons. (Picture from 
http://marcora.caltech.edu/science.htm) 
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After the initial discovery of the HTT gene in 1993, understanding HD in 
terms of biology, genetic, and therapeutic potential have gone much further, 
however there is no disease-modifying treatment in clinical usage (Thomson et al., 
2002; Kim SD and Fung VS, 2014; Zielonka et al., 2015) and a clear 
understanding of the mechanism of disease is still unknown. Therapeutic 
treatment in HD is limited compared to some other neurodegenerative diseases 
such as PD (Kelly et al., 2009); most drugs or treatments available at this moment 
are only able to relieve the symptoms rather than cure the disease (Thomson et 
al., 2002). One potential therapy that has shown promise is the transplantation of 
primary fetal striatal tissue in HD, where there is “proof of principle” in both animal 
models (Dunnett et al., 1998; Armstrong et al., 2000), and HD patients (Bachoud-
Levi et al., 2000; Rosser et al., 2002; Bachoud-Levi et al., 2006). However, human 
fetal tissue usage brings controversial ethical issues, limitations in tissue supply, 
accuracy and reliability of dissection following retrieval of tissue, and there is also 
the issue of immune rejection following transplantation (Kelly et al., 2009). 
Therefore, alternative donor cell sources need to be explored and generated. The 
most likely alternatives to replace primary fetal tissue as a donor cell source are 
neurons derived from stem cells.  
 Human pluripotent stem cells such as human ES/iPS cells also hold 
promise as a powerful tool for drug screening, toxicology, developmental studies, 
and study and of neurodegenerative disease mechanisms (Aubry et al., 2008, 
Gaspard and Vanderhaeghen, 2010; Ma et al., 2012; Delli Carri et al., 2013). The 
reason being is that human ES/iPS cells can self-renew and differentiate to almost 
all kinds of desired-cell phenotypes.  
 However, for most of these uses it is important to be able to differentiate 
stem cells towards specific differentiated phenotypes – which for HD is the 
medium spiny neuron.   The extent to which the phenotype needs to be “authentic” 
is not clear for all applications, but for cell replacement therapy in the brain, it is 
clear from animal work that the cells for transplantation must be authentic for full 
functional recovery (Dunnett SB. and Rosser AE., 2011; Rosser, A. E. and 
Svendsen, 2014). There have been a number of attempts to persuade human 
ES/iPS cells toward an MSN phenotype (Aubry et al., 2008; Shin et al., 2011, Ma 
et al., 2012; Delli Carri et al., 2013), described in more detail below.  
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1.2.1 Directed differentiation of pluripotent stem cells (PSCs) towards a 
striatal MSN phenotype 
 The nervous system derives originally from the ectoderm layer. The inner 
cell mass give rises to epiblasts, from which 3 germ layers arise: ectoderm, 
endoderm and mesoderm. The neuroectoderm or neuroepithelium forms the so-
called ‘neural plate’ by the second week of gestation, which then forms a neural 
tube and eventually an entire central nerous system (CNS) (Pankratz et al, 2007). 
Regional specification to forebrain, midbrain, hindbrain and spinal cord is a fine-
tuning process requiring different signals directing the differentiation of distinct 
neural subtypes (Pankratz et al, 2007). Nervous system development consists of 3 
main processes of neural induction, neurulation, and nervous system patterning 
(Rubenstein et al., 1998; Evans et al., 2012). (Figure 1.7) 
 
Figure 1.7 Schematic of how stage specific nervous system development in vivo 
corresponds to distinctive neural cell populations’ in vitro differentiation. ES cells from the 
blastocyst stage or reprogrammed cells such as iPS cells differentiate to early neural epithelial 
cells (NEPs) which give rise to all neural cells similar to the neural plate. Soon after neural 
induction, NEPs display a neural rosette structure (R-NSCs) which mimics neural tube formation in 
development, following which they then differentiate further to human ES/iPS derived neural 
stem/precursor cells (human ES/iPS NSCs). Regional patterning in vitro by exposure to chemical 
combinations in culture can represent antero-posterior (A/P) axis and dorsal-ventral (D/V) 
patterning in vivo. Human ES/iPS NSCs transform to another transitory stem cell type, radial glia 
(RG), which are the majority of the progenitor population in late development and the early post 
natal stages, They then maturate further to neural cells in vitro and in development. (Adapted from 
Casarisa et al., 2013; http://www.intechopen.com/books/neural-stem-cells-new-
perspectives/systems-for-ex-vivo-isolation-and-culturing-of-neural-stem-cells)  
 Initiation of primitive ectoderm occurs when the pluripotent stem cells from 
the inner cell mass (ICM) undergo a series of changes associated with up and 
down regulation of various genes. A decrease in Oct4 expression coupled with 
Chapter 1  Introduction 
32 
 
upregulation of Sox1 and Gbx2 were observed during neural plate configuration. 
Undifferentiated neural progenitors within the neural tube were defined by the 
presence of Sox1, Sox2, Nestin, Mash1, and N-CAM. At the gastrulation stage, 
the neural plate, which lines the anterior axis of the embryo, folds to generate the 
neural tube and finally creates both CNS and peripheral nervous system (PNS). 
The orchestra of genes, molecular signals, and transcription factors such as FGF, 
bone morphogenic protein (BMP), retinoic acid (RA), sonic hedgehog (SHH), and 
Wnts result in development of the designated cellular and molecular identities and 
positional specification (Manel et al., 2010; Evans et al., 2012).   
The positional arrangement of the antero-posterior and dorso-ventral axes 
appear to be triggered by the concentration gradient of Shh and BMP4 from the 
surrounding cells (Reviewed in Lang et al., 2004). SHH has been reported to 
induce the expression of ventral forebrain genes including Nkx2.1, Gsh2, and 
PAX6 (reviewed in Evans et al., 2012).  Retinoic acid (RA) has long been known 
to play a crucial role in neural development and maintenance of a neural 
phenotype (Schwartz H. P. et al., 2008). In addition, RA is also known as a caudal 
restricted inducer, which controls dorsoventral identification in vitro (Zhang SC. 
2006, Schwartz H. P. et al., 2008, Erceg S. Et al, 2008). In contrast to Shh, this 
signalling molecule plays an important role in ventral neural tube patterning of the 
telencephalon and spinal cord via the homeobox gene-Nkx family (Yun K. Et al., 
2000; Schwartz H. P. et al., 2008). (Figure 1.8) 
 
 
 
Chapter 1  Introduction 
33 
 
 
Figure 1.8. An illustration of the molecular gradient between SHH and Wnt signalling within 
the developing cortex accompanied by gene expression resulting from this gradient. 
Progenitors in these domains mainly generate glutamatergic neurons (a), GABAergic projection 
neurons (b), and basal forebrain cholinergic neurons (BFCNs) (c), respectively. (Adapted from Liu et 
al., 2011) SHH= Sonic hedgehog, Wnt= Winless, MGE= medial ganglionic eminence, LGE= lateral ganglionic 
eminence, Nkx2.1= NK2 homeobox 1, Gsx2= glycogen synthase kinase, Pax6= paired box 6.  
  
The pattern of gene expression varied in different regions. Nkx6.1 and Olig2 
indicate the ventral axes whereas the dorsal axis was marked by the appearance 
of by Dbx1, Irx3, and Pax6.  
 The cerebral cortex and basal ganglia develop from the telencephalon 
which is formed by the invagination of the rostral forebrain (Yun K. et al., 2000; 
Schuuemans C. and Guillemot F., 2002). The telencephalon is subdivided into its 
dorsal (pallial) and ventral (subpallial) regions with each region expressing 
different combinations of transcription factors (Yun K. et al., 2000). Glutamatergic 
projection neurons are the main cell population of the pallium compartment. In 
contrast, the subpallium is largely made up of GABAergic neurons (Stoykova et 
al., 1996; Yun K. et al., 2000). The expression of Pax6, Ngn1/2 and Emx1/2 are 
associated with the dorsal telencephalon whilst Gsx1, Gsx2, Gad67, Dlx1, Dlx2 
and Six3 are detectable in the subpallium compartment (Stoykova et al., 1996; 
Yun K. et al., 2000). Thus the development of the telencephalon is tightly 
regulated by various combinations of transcription factors together with small 
molecules such as Shh, Notch and BMP (Schuurmans C. and Guillemol F., 2002, 
Campbell K., 2003). Furthermore there is much evidence to indicate that the 
molecularly defined regional subdivisions and basic organization of the developing 
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telencephalon among vertebrate species has been conserved (Smith-Fernandez 
et al., 1998; Puelles et al., 2000, Yun K. et al., 2000).  
 Arising from the ventral telencephalon is the septum and the MGE and 
LGE, collectively referred to as the whole ganglionic eminence (WGE). The MGE 
and LGE give rise to the adult striatum. The LGE is further divided into 2 
compartments of which the dorsal LGE (dLGE) expresses Pax6, Gsx2 and ER81 
and the larger ventral LGE (vLGE) expresses Gsx1, Gsx2 and Pax6 (Yun K. et al 
2000; Campbell K., 2003). Surrounding the developing telencephalon are two 
proliferative zones the subventricular zone (SVZ) and the ventral zone VZ and it is 
here where the projection neurons and interneurons are born and from where they 
then migrate to populate areas of the adult striatum and the cortex respectively 
(Eisenstat DD. et al., 1999; Campbell et al., 2003; Evans et al., 2012; Campbell et 
al., 1995; Anderson et al., 1997; Olsson et al., 1998; Evans et al., 2012). (Figure 
1.9) 
 
Figure 1.9 A schematic to show the relation between molecular gradients and 
morphological structures in a coronal hemisection of mouse telencephalon at E12.5. The 
ventricular zone (VZ), which is a proliferative area of neuronal progenitors, extends along the D/V 
axis.The subventricular zone (SVZ), which is a special characteristic of telencephalon, also 
contains neuronal precursor cells (presenting by the blue dashed line). Neural progenitors migrate 
from VZ and SVZ to populate particular areas of the brain. The red dashed lines demonstrate the 
approximate boundaries between distinct telencephalon progenitor domains. Abbreviations: 
MGE/LGE= medial/lateral ganglionic eminence; MP= medial pallium, DP= dorsal pallium, LP= 
lateral pallium, VP= ventral pallium. (Adapted from Olsson et al., 1995).  
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1.2.2 Pluripotent stem cells and establishment of neuronal linage 
differentiation in vitro. 
 An ability to differentiate into any type of cell with almost unlimited 
expansion of cells’ progeny make iPS cells an attractive cell source for 
developmental studies, cell therapy, drug screening, and toxicology. Neural 
precursors derived from pluripotent stem cells were reported to share similar 
characteristics to cells differentiating from primary brain tissue with subsequent 
differentiation into neurons and glial cells. There have been many attempts to 
manipulate PSCs cells towards desired phenotypes in order to pave the way for 
therapeutic utilization in regenerative medicine (Figure 1.10). Generally speaking, 
there are several processes involved in neural lineage conversion, for example 
unleashing pluripotentiality, inducing neural lineage identities, and specifying cells’ 
fate restriction. To initiate a neural lineage, different methods are available such as 
aggregation of multicellular EBs, direct differentiation from a monolayer adherent 
system, co-culture with neural inducing cells or membranes and genetically 
engineered-PSC lines (involving the use of nuclease mediated novel gene 
targeting technologies) (reviewed in Schwartz P. H., et al, 2008).(Table 1.3) 
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Figure 1.10. A schematic of in vitro neural induction and conversion of PSC generate NPCs.  A 
distinctive combination of signalling regulators can direct the differentiation of PSCs to positionally restricted 
neural rosette precursors along the developing neural tube (A). Rosette formation in vitro shares similar 
spatial organization of cell junctions and cell polarization with neural tube development in vivo (B).  With 
regional specific commitment, distinct neuronal subtypes were generated (C). (Adapted from Broccoli et al., 
2014) 
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Table 1.3 Pluripotent stem cells and establishment of neuronal linage differentiation. 
Author Cell Method Result 
 Fraichard  
et al. 1995 
Mouse ES cells - EBs for 2 DIV in a presence of 
retinoic acid 1 µM. 
- Aggregated ES cells were re-
plated and cultured in ES 
medium up to 20 DIV. 
- Nestin positive staining at 3-4 DIV. 
- GFAP and O4 positive cells were recognised at 9 DIV. 
- Map2 (a+b), Map5, NF200 positive cells were observed and synaptophysin was also 
identified at 10 DIV. The pattern of expression was similar to primary E16 mouse 
cortex differentiation in vitro.  
- 8 DIV, AchE and GAD were expressed among neuronal-like cells.  
Bain et al. 
1995 
Mouse ES cells - EB formation Day 0-4 without 
RA, and RA supplement 0.5 µM 
on Day 4-8 VS control group no 
RA addition 
- Strong up-regulation of neuronal genes such as MASH1, Wnt-1, NF-M, NF-L. 
- Strongly repressed mesodermal genes such as Brachyury, cardiac actin, zeta-globin. 
Okabe et al. 
1996 
Mouse ES cells - EB formation from day 0-4. 
-Re-plated on coated culture 
disk and incubate with ITSFn 
medium. 
- Highest proliferation of neuronal precursors was found when culturing with 3N3FL 
medium. 
->80% of the NPCs were Nestin+ while 10% of the population was MAP2+. 
-90% of BrdU+ cells were Nestin+ cells.  
Li et al. 1998 Mouse ES cells - EBs with RA supplement. 
- Bifunctional selection system 
of βgeo tagged to Sox2 gene by 
homologous recombination and 
further selective by G418 (200 
µg/ml) application.  
 
 
 
-50% were positively stained for neuronal markers: NF-L, NF-M, MAP2, Tau, β-III 
tubullin while 20% became immunopositive for GFAP. 
-Fresh plated cells were 100% nestin positive and within these cultures were 40-50% 
Sox1 and Sox2 +ve expression.   
-90% β-galactocidase expressing cells were obtained.   
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Author Cell Method Result 
Zhang SC. et 
al. 2001 
hES cells:  H1, 
H9, H9.2 lines 
- 4 DIV as EBs and further 
differentiation as adherent 
aggregated cells in defined 
medium.  
- On FGF2 addition for 5 days 
and start neural induction by 
withdrawal of FGF2.  
-Special selection of neuro 
epithelial cells using Dispase 
and expanding neuronal 
precursors as free floating 
aggregations/neurospheres.   
- By 7 DIV neural rosettes appeared which were immunoreactive for Nestin and 
Mash1. 
- After re-plating as adhered EBs; there was Map2ab and β-III tubulin expression at 7 
to 10 DIV and around 10 to 14 DIV there was NF positivity.  
- No tumour generation in transplantation recipients. The hES derived neural 
precursors could be differentiated into various types of neurons and glia.  
 Perrier L. A. 
et al. 2004 
hES cells: H1, H9, 
HES-3;  
Rhesus monkey 
line: R366; 
Cynomolgus 
parthenogenetic 
line:  Cyno1 
- 28 DIV onto MS5, MS5-Wnt, or 
S2 stroma cells in serum 
replacement medium and N2 
modified medium respectively. 
- Neural rosettes were 
mechanically triturated and re-
plated onto POL/Laminin coated 
plate in N2 medium supplement 
with Shh, FGF8, AA, BDNF for 
7-9 DIV. 
- Withdrawal of Shh and FGF8 
and further differentiate cells in 
N2 medium with BDNF, GDNF, 
dcAMP, TGFβ3, and AA. 
- At 2 weeks, neural rosettes form edon MS5 or MS5-Wnt and expressed neural 
markers, nestin, Pax6, NCAM, and Sox1. 
- Semiquantitative RT-PCR revealed a decrease in gene expression of Oct4 and nanog 
associated with increase in Pax6 and Map2 markers. 
- 3 fold increase in TH positive neurons but no expression of other midbrain 
dopaminergic neuron markers (28 DIV). 
- After P2 (50 DIV) of the 30-50% Tuj1+ expression cells 64-79% expressed TH. 
Astrocytes were observed in long term culture (70 DIV).  
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Author Cell Method Result 
Gerrard et al. 
2005 
hES cells: H1, H7, 
H9 
- Adherent culture system 
- Plate down hES as small 
clump onto matrigel or 
PLL/Laminin coated plate. 
- Using BMP antagonist: noggin/ 
follistatin supplemented in 
N2B27 medium. 
- After 10 DIV, neuro- progenitor like-cells were clearly identified in noggin supplement 
whereas in follistatin they appeared to be fibroblast-like.  
- RT-PCR: down regulation of GATA6 and Id protein.  
- No AFP expression at 6 DIV in both control and noggin supplement conditions. 
- After 13 DIV, AFP positive expression was highly expressed in control groups. 30 DIV 
typical neural rosette formation emerged and expressed nestin, musashi, PSA-NCAM 
(neural progenitor markers). 
- GFAP+ was found from 80 DIV. - 60 DIV: mostly expressed GABA and GAD65 
positive neurons, few TH neurons and no glutamatergic neurons. 
Ueno et al. 
2006 
mES and hES 
cells 
- Amniotic membrane matrix-
based ES cells differentiation 
(AMED) with serum free medium 
system. 
- Mouse ES cells cultured on 
gelatin-coated hAM. 
- hES cells cultured on laminin-
coated hAM. 
- In mouse ES: 7 DIV 90% were nestin+, NCAM+.  
- No gene expression for mesoderm (Brachyury) and endoderm (AFP, SOX17) 
markers. Less proliferation and less efficient (around 60-70%) neural differentiation 
when ES cells were cultured on other matrix such as gelatin, collagen IV, laminin or 
fibronectin. 
- 9 DIV: 62% of TuJ1+ and around 39% TH+ neurons were detected by 13 DIV. In 
hES: 15 DIV >85% nestin+, rosette formation appearance. 30 DIV TuJ+ expressing 
neurons were present, of which ~31% co-expressed with TH+ later on at day40-42.  
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Author Cell Method Result 
Joannides J. 
A. et al. 2007 
hES :H9, HUES9 
(P30-60) 
-hES colonies were cultured on 
MEFs before the ES colonies 
were dissected into small 
fragments and further grown as 
free-floating spheres in human 
neuralizing medium (HNM) to 
generate hES-NSCs. 
-hES-NSCs were terminally 
differentiated by adhering onto 
PDL/laminin-coated plates and 
cultured in DMEM/F12+ 2%B27, 
w/ or w/o FBS for up to 4 weeks 
and were transplanted at 1x10
5
-
2.5x10
5
 cells/µl. 
-D25 immature neuronal markers expressed Nestin+, Masashi1+,Sox1+,Sox2+,Pax6+, 
NCAM+. 
-14 DIV further differentiation in the presence of B27 and FBS neuronal population 
increased but no O4+, or GFAP+ expression. 
-D45 onwards, hES-NSCs exhibited O2+ but not GFAP+ with a high proliferation rate. 
-with terminal differentiation neurons, gila and oligodendrocytes population were 
generated which confirmed the NSC properties. 
Pankratz et 
al. 2007 
- hES: H1, H9 
- Rhesus monkey 
ES: R366.4 
- A chemical defined monolayer 
neural differentiation system. 
- ES cells were grown as EBs 
for 4 days and transferred to 
defined medium for a further 2 
DIV before being attached to 
culture dish.  
- 14-16DIV neuroepithelial cells 
were cultured as aggregates for 
several days before being 
dissociated and re-plated onto 
POL/laminin coated vessel in 
defined medium+ BDNF, GDNF, 
AA, cAMP, laminin.  
- After 8-10 DIV, columnar morphology of neuroectoderm and neural markers with 
anterior regional profile were found.  
- After 6 DIV neuroectodermal markers Sox1, NCAD, Sox3, Zic1, Churchill were 
expressed, whereas Sox1 were present until 15 DIV by RT-PCR analysis which co-
responding to down regulation of pluripotent markers which eventually undetectable 
after10-11 DIV.  
- 54% of PAX6+ expression at 8 DIV - this became 95% by 11 days. At 14-16 DIV 
neural tube-liked rosette structure emerged.  
- PAX6, Lhx2, BF1, Otx2 expression were observed in almost all of columnar cells 
whereas posterior regional markers were not recognized. 
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Author Cell Method Result 
Erceg et al. 
2008 
- hES: H1, H9 - hES cells grow onto human 
foreskin fibroblasts in ES medium.  
- hES cells were transferred onto 
human matrix coated plate and 
cultured in modified TeSR1 for 7 
days. 
- 7-14 DIV culture in GRM medium 
and re-plated the cells at day 14 on 
to POL/laminin coated plate with 
additional GRM/bFGF in culture 
medium.  
- Neural rosette appeared on day 2 after being cultured on plates coated with human collagen IV, 
vitronectin, and fibronectin  
- Neural progenitor marker-nestin was expressed from day 2, whereas PAX6+ was expressed 
within rosette structures from day 5. 
- At 14 DIV cells expressed nestin, PAX6, BLBP, RC2, 
- At 28 DIV cells were positive for Musashi1, A2B5, MAP2. TUJ1 expressing neurons were 
increased from 20% to 62% at 42 DIV (with 46%GABA+, 43% glutamate+, 7% serotonin+, 
14%GFAP+, 23%O4+ in here). RT-PCR showed loss of pluripotent expression and gain of a 
more neuronal profile.  
Li X. et al. 
2008 
hES: H1, H9 (P19-
42) 
-4 DIV as EBs then as adherent 
aggregated cells in defined medium. 
At day 10 RA was added into 
chemical defined medium. neural 
rosettes were collected D14 and 
cultured in free floating manner for 1 
week 
-After 24 DIV BDNF,GDNF, IGF1, 
purmorphamine were supplemented 
to culture condition. 
-Around 45 DIV cells were 
dissociate and re-plated onto 
POL/laminin with a presence of 
BDNF, GDNF, IGF1, B27, RA for 3-
5 day before co-culture with C2C12 
myoblasts.  
-Neuroepithelial cells (NE) emerged at 8-10DIV of differentiation processes which demonstrating 
of primitive anterior NE by positive expression of Otx2 and Pax6. 
-Hoxb4, the start to exibit when supplementing with RA for 1 week.  
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1.2.3 Human PS cell derived GABAergic projection neurons (MSNs). 
In recent years there have been a number of reports of protocols to more 
accurately and more efficiently generate functional GABAergic MSN-like cells from 
PSCs suitable for cell replacement therapy in HD. In comparison to the PD 
literature where there is ample reports generating dopamine neurons from both ES 
and iPS cell lines, the field in relation to HD is relatively in its infancy with only a 
small body of literature reported to date. The initial studies carried out in ES cells 
have shown great potential, however, there is still the need for further 
investigations to be carried out to optimise protocols.  
The first study was carried out by Aubry et al (2008) and using a multistep 
protocol they reported the ability to obtain 56% DARRP32 positive neurons (out of 
a total of 36% GABAergic neurons in the culture) using two human ES cell lines 
H1 and H9. This protocol involved an element of patterning by the addition of 
SHH, DKK-1 (a Wnt signalling inhibitor), and BDNF; and finally, terminal 
differentiation to post mitotic GABAergic MSNs-like cells was achieved by adding 
valproic acid and dbcAMP. However, these human ES derived MSN-like cells 
overgrew post transplantation into the rat quinolinic acid (QA)-lesioned striatum. 
By week 8 post transplantation, the animals exhibited weight loss and disturbance 
of balance and movement. The brains were taken and analysed at 13, 15-16, and 
17 weeks post transplantation. Histological analysis revealed that there was graft 
survival in all brains accompanied by overgrowth and disruption of the striatum, 
even though there was negative staining of the pluripotent marker-Nanog in the 
graft.  
In 2012, Ma and colleagues claimed that with 93% of human ES derived 
(H1 and H9 lines) β-III tubullin positive cells, they could achieve up to 80% 
DARRP-32 expression if they induced human ES cells to a primitive neuro-
epithelial phenotype as suspension EBs for 10-12 days to persuade them to 
ventral neural progenitors. As with Aubry et al (2008) the cells were subjected to 
patterning with the addition of SHH/purmorphamine in order to regionalise the cells 
toward a ventral telencephalon fate. Subsequently neural precursor cells were 
cultured in the presence of BDNF, glial cell derived neurotrophic factor (GDNF), 
insulin-like growth factor (IGF) and cyclic adenosine monophosphate (cAMP) to 
generate mature MSNs. 4 months post transplantation into the QA-lesioned 
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mouse striatum, they found 86% β-III tubulin positive neurons of which 58% were 
DARRP32 positive. In addition, grafted animals showed improvement in locomotor 
deficits on the rotarod and open field tests, as well as on the Treadscan analysis. 
Ma highlighted that the effective production of authentic MSNs needed a defined 
concentration of morphogens during the appropriate time window (Ma et al, 2012). 
Although not specifically reported, the images presented in the manuscript would 
suggest the appearance of overgrowth in these grafted animals.  
More recently, Delli Carri et al reported the generation of so-called 
‘authentic striatal projection neurons’ from iPS- and human ES cells. Dual SMAD 
inhibition - SB431542 and Noggin (from Chambers et al., 2009), was applied to a 
monolayer of human ES/iPS cells to initiate the equivalent to ‘gastrulation stage’ in 
vivo. Again, Shh and DKK-1 were used to pattern the cells thus generating LGE 
specific like cells that were immunopositive for FOXG1 (58%) and GSX2 (64%) in 
vitro, along with RT-PCR analysis indicating DLX5, DLX6, and ISL1 expression. 
Finally, the cells were cultured in a neuronal differentiation environment using N2 
medium supplementing with B27 and BDNF up to 80 DIV that resulted in 20% 
DARPP-32 positive neurons being generated. Subsequent transplantation of 
these cells into the QA lesioned rat brain showed some evidence of functional 
improvement on rotational analysis. However, this was based on a very small 
number of animals and a short period of time post transplantation. Furthermore, 
there was clear evidence of graft overgrowth in these animals. 
In each of these studies, whilst positive data is presented in terms of the 
ability to generate DARPP-32 positive neurons from PSCs, there is clearly further 
work required to modify these protocols so as to address the issues of overgrowth 
in vivo. Also, in each of these studies the in vitro culture period was relatively 
prolonged ranging from 47 to 80 days before MSN like cells were identified. The 
current gold standard marker for mature MSNs is DARPP-32, but other more 
immature markers have been identified that may be important in road mapping the 
progress of these protocols such as FoxP1 and Ctip2 (Tamura et al., 2004; Arlotta 
et al., 2008). (Table 1.4) 
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Figure 1.11. A schematic representing the pathway for generating specific neuronal 
phenotypes from PSCs utilising the information gained through understanding the 
developmental pathways and the gene expression profiles of these cells. ES/iPS cells 
differentiate toward primitive neuroepithelial cells. In the absence of exogenous signalling, 
glutamatergic neurons and GABAergic interneurons are subsequently derived by default from the 
neuroepithelial cells (NE). With the addition of low concentration of SHH, the NE cells differentiate 
to Gsx positive cells/LGE progenitors which later on in culture express DARPP32. In the presence 
of high concentration SHH, MGE progenitors will be generated which produce BFCN and 
GABAergic interneurons. With RA, NE become Olig2 positive progenitors in supplement with SHH 
and later generate motor neurons. Under FGF8 and SHH, NE are specified to ventral midbrain 
progenitors, which then produce midbrain dopaminergic neurons. NE= neruepithelial; Glut. N. = 
glutametegic neurons; GABAergic In. = GABAergic interneurons; MNs= motor neurons; mDA= 
midbrain dopaminergic neurons (Adapted from Liu et al., 2011). 
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Table 1.4 Human PS cell derived GABAergic projection neurons (MSNs). 
Author  Cell lines Methods Results 
Aubry Laetitia 
et al 2008, 
PNAS 
hES (H1 and 
H9) 
- 3 steps: 1. Neural induction by co-
culture with MS5. 
2. Regional commitment by 
mechanically isolated neural rosettes 
and cultured in N2 medium with 
BDNF; ventral telencephalic patterning 
by adding SHH and DKK1. 
3. Neuronal maturation by adding VPA 
and dbcAMP in low density conditions. 
- In vitro: ICC and Q-PCR from 0 -60 DIV; rosette formation appeared around 21-23 
DIV in contrast the Oct4 and Nanog which disappeared.   
- DIV 29-30 Nestin+, PAX6+, and Ki67+; BF1+ expression reached a plateau. 
GSH2 and DLX2 peaked with the addition of BDNF, SHH, and DKK-1.  
- DIV 46-59 to DIV62-72: within the Map2+ population were found ~36% GABA+, 
53% DARRP32+, 10% calbindin+, 55% calretinin, ≤2% TH+, persistent expression 
of Nestin+ and PAX6+; Q-PCR showed increased expression of DARRP32, 
GAD67, and calbindin.  
-Overgrowth of surviving graft.  
Ma et al 
2012, Cell 
hES (H1 and 
H9) 
- 3 steps: 1. Neural induction: hES 
cells were differentiated to NE for 10-
12 days in NI medium.- 
2. Induced ventral progenitors by 
adding SHH 200 ng/ml or 
purmorphamine 0.65 µM from day 12-
26. To generate spinal GABA neurons, 
RA 0.1 µM was added from day 10-23. 
3. Neural differentiation: NPCs were 
dissociated with accutase and re-
plated onto coated coverslips at day 
26 in neurobasal medium 
supplemented with BDNF 20 ng/ml, 
GDNF 10 ng/ml, IGF 10 ng/ml, and 
cAMP 1 µM. 
-In vitro: 32 DIV 93% were neurons based on phase contrast and β-II tubullin+ 
analysis. 90% of these cells were GABA+ of which 89% also express DARRP32. 
- HPLC revealed that the GABA+ neurons responded to high-potassium solution 
(which depolarizes neuron) gave rise to 6 times increasing of GABA- level release. 
-70 DIV whole cell patch-clamp: 16 out of 18 GABA expressing neurons present 
active neuron characteristic firing action potentials  
- Transplantation into QA-lesioned mice: 4 mth after transplantation forebrain 
neurons (FBN) and spinal neurons (SBN) grafts did not overgrow.  62%-80% of the 
FBN and SBN grafts respectively were GABA+ neurons. Only FBN grafts expressed 
Meis2+, Ctip2+ and DARRP32+ (the latter comprising 58.6%+ 3% of total graft 
cells) 
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Author  Cell lines Methods Results 
Delli Carri et 
al. 2013, 
Stem cell 
Rev and Rep 
2013, 
Development 
and Stem 
cells 
  
 hES/iPS 
cells 
3 steps -inhibit the TGF-β/BMP 
pathway for neural induction 
- patterning: SHH and DKK1 for 
ventral telencephalic specification 
 - Human PS cells have been exposed 
to DUAL-SMAD inhibitor Noggin 
(interchangeable with BMP inhibitor--
Dorsomorphin/ Noggin analog-- 
LDN193189) and SB.   
 - Neural induction by Dual-SMAD 
inhibitor and also attain FOXG1+ and 
OTX+. 
- Ventral telencephalon introduction by 
applying SHH with WNT signalling 
modulation pathway- DKK-1. 
- Terminal differentiation uses the 
increasing concentration of BDNF 
from 30 - 50 ng/ml.  
 
ICC- Day15-25: FOXG1+, GSX2+ 
-Day 45: Ctip2+, FoxP1+, FoxP2+ 
-maturation: GABA+,Map2+ 
-Day 80: 20% co-expressing with DARRP32 and Ctip2 (D2 and A2a receptor); 80% 
GABA+ Ctip2+, Calbindin+ 
- Electrophysiological properties: 57% exhibited repetitive firing, 30% elicited a 
single action potential, 13% not respond 
- FOXP1+/FOXP2+/CTIP2+/calbindin+/DARRP32+ MSNs 
- TX cells differentiated to DARRP32+ and restoration of apomorphine-induced 
rotation behaviour in QA lesion rats 
- Within MAP2+ population: contain 78% GABAergic cells, CTIP2+/calbindin+; 20% 
DARPP32 and Ctip2 co-expression. 
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The Project Aim: 
 
 The ultimate aim of this study is to explore an alternative cell source which is 
suitable in term of practical and ethical usage with a potential to be a donor cell 
source for cell therapy in HD.  An iPS cell line has been considered as an attractive 
cell source for degenerative and regenerative medicine after the first recovery in 
2006. Therefore, we aim to generate a clinical safe iPS cell line and explore various 
fetal tissues as a suitable originated cell source. The source material used to 
generate the iPS cells was human fetal derived and two sorts of lines were 
generated: one from human fetal WGE (developing striatum), and one from fetal 
fibroblasts. This has allowed comparisons to be drawn between the two sources in 
terms of their ability to generate iPS cell lines and differentiate into mature MSNs. As 
highlighted above there are a number of options available in terms of protocols to 
generate these cells. Here I explore two of these protocols and highlight the 
advantages of using the piggyBac transposon deliver system over the plasmid DNA 
approach. From an early time point it was clear that the plasmid DNA approach was 
not going to be a viable route and hence the emphasis of this thesis is on the 
piggyBac method. The iPS cells generated using this approach were also compared 
with human ES cells in terms of morphology, pluripotent marker expression, gene 
expression profiles, in vitro and in vivo differentiation. 
 In term of ES/iPS cells derived MSNs, there are only few protocols available 
with the low efficiency to generate functional MSN. I report a novel protocol which 
has been improved to increase the efficiency of MSNs conversion with less time 
expense in vitro differentiation base on previous published papers. I show that these 
ES/iPS cells can differentiate to a desired MSN phenotype with a typical of 
DARPP32 positive expression. In addition, the ES/iPS cells derived MSN can survive 
transplantation, further differentiate, and maturate in a QA-lesioned HD model rat 
brain.  
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Chapter 2 
Materials and Methods 
 
2.1 In vitro Methods. 
 
Mouse and Human Embryonic Fibroblasts (MEFs and HEFs) Maintenance 
methods. 
2.1.1 Derivation of mouse embryonic fibroblasts (MEFs). 
 MF1 pregnant mice were sacrificed by cervical dislocation on embryonic 
day E13.5. The abdomen was cleaned with 70% alcohol and a cut through the 
skin and peritoneum was made to expose the uterine horn. The uterine horn was 
removed and placed onto an untreated bacteriological grade petri dish (Sterilin®, 
Newport, UK) containing Hank's Balanced Salt Solution (HBSS, Life 
Technologies®, Paisley, Scotland, UK). The embryonic sac was cut and the 
embryos were removed from the sac. The embryos were de-capitated and visceral 
organs removed. The remaining carcases were washed in Dulbecco's Modified 
Eagle Medium: Nutrient Mixture F-12 (DMEM/F12, Life Technologies®), placed in 
a clean petri dish, and then minced with a sterile scalpel blade. 0.05% 
Trypsin:EDTA (Life Technologies), 2 ml, was added to the tissue and incubated for 
20 minutes at 37C. DMEM/F12, 5 ml, was added to the petri dish and the tissue 
suspension was transferred to a 15 ml centrifuge tube and centrifuged at 86.64 g 
for 3 minutes. The supernatant was removed; the tissue was manually triturated in 
400 µl DMEM/F12 using a 200 µl pipette until a quasi-single cell suspension was 
obtained. 1ml cell suspension was added to each 140 mm Nunc™ cell culture 
petri-dish (Thermo Scientific™,Bishop Meadow Road, Loughborough) followed by 
19 ml of MEF media (DMEM high glucose (GE Healthcare Life Science, 
Buckinghamshire, UK) 450 ml, 10% Fetal Bovine Serum (FBS, Life 
Technologies®), 1% Penicillin and Streptomycin (PS, Life Technologies®), 1% L-
Glutamine (Life Technologies®) and placed in the incubator at 37C overnight. 
Next day, the spent medium was taken off to remove the floating cellular debris 
and replaced with fresh MEF media. MEFs were allowed to proliferate with a 
change in medium every other day until the MEFs reached 70-90% confluence.  
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Maintenance and Passaging of MEFs. 
MEFs were cultured in MEF medium. Once the MEFs reached 80-90% 
confluency, they were washed once with 1X phosphase buffer saline (PBS) (Life 
Technologies). Trypsin:EDTA, 1 ml, was added to the culture plate and swirled to 
ensure that all the plate was covered. The plate was then incubated 37˚C for 5 
minutes. 10 ml of MEF media was added to the plate to inactivate the 
Trypsin:EDTA reaction and a pipette was used to triturate and dislodge any 
remaining cells. The MEFs suspension was transferred to a 50 ml centrifuge tube 
and centrifuged at 86.64 g for 3 minutes. The supernatant was aspirated off before 
the pellet of cells was dispersed by gently flicking the bottom of the falcon tube. 
The MEFs were split 1:4 with 1 ml of MEF cell suspension added to 19 ml MEF 
medium in a 140 mm cell culture treated petri dish. The MEFs were well 
distributed over the culture plate and incubated in 5%CO2 at 37˚C.  
 
Freezing MEFs 
 The spent culture medium was removed from the culture plate and washed 
once with 5 ml 1XPBS. Trypsin:EDTA, 1 ml, was added to the culture plate and 
incubated at 37C for 5 minutes. Gentle tapping was used to help dislodge the 
MEFs from the dish. DMEM/FBS 9 ml, was loaded onto the plate to wash and 
remove the MEF from the culture dish. The cell suspension was then transferred 
to a 15 ml centrifuge tube and centrifuged at 86.64 g for 3 minutes. The 
supernatant was removed before the cell pellet was dispersed by gently flicking 
the tube. The pellet was re-suspended in 500 µl ice-cold MEF freezing medium 
(10% Dimethyl Sulfoxide (DMSO, Sigma, Gillingham, Dorset, UK) in MEF 
medium) and then transferred to a cryovial (Thermo Scientific™). Cryovials were 
packed into a freezing container and kept in the -80˚C freezer. The cryovials were 
transferred to liquid nitrogen the next day for long term storage.  
 
Thawing MEFs. 
 The cryovial cap was loosened to release the trapped nitrogen after 
removing the cryovial from the liquid nitrogen. The bottom half of the cryovial was 
placed in a water bath at 37°C until a small ice crystal could be observed. The 
cells were gently transferred to 10 ml MEF medium in a 15 ml centrifuge tube and 
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obtain centrifuged at 86.64 g for 3 minutes. The cell pellet was re-suspended in 10 
ml MEF medium before being transferred to a 10 cm culture dish and incubated at 
5% CO2 and 37C.  
 
MEFs Irradiation.  
MEFs were irradiated after 3 passages in culture. MEF media was 
aspirated off from the culture plates, and 10 ml of 1XPBS was flooded onto the 
plate to wash off the old medium. 1 ml 0.05%Trypsin:EDTA was added and 
swirled around the plates after removing the PBS. After 5 minutes or until the cells 
started to separate from the plates, 5 ml MEF media was added to stop the trypsin 
reaction. All media and cells were pipetted into a 50 ml centrifuge tube and 
centrifuged at 86.64 g for 3 minutes. The supernatant was aspirated off; 20 ml 
MEF media was added and a Gilson pipette was used to thoroughly mix the cell 
suspension. 10 µl of suspension was mixed with 10 µl trypan blue (Life 
Technologies®) and then cells were counted using a haemocytometer with 
Countess® Automated Cell Counter (Life Technologies®). Cells were irradiated for 
30 minutes at 216 Rads/minute for total exposure of 6480 Rads. Irradiated cells 
were centrifuged for 3 minutes at 86.64 g, re-suspended with MEF freezing media, 
and aliquoted cells into prepared cryovials (1x106 cells per vial in 1 ml) before 
placing in a cyrobox at room temperature. The vials were placed in the -80˚C for 
24 hours before transfer to liquid nitrogen for long-term storage.   
 
2.1.2 Derivation of human embryonic fibroblasts (HEFs). 
 Human fetal tissue was collected according to Kelly et al., 2011, following 
local research ethics committee approval (02/4446 post mortem human fetal 
tissue for neural transplantation in HD (and PD)) and under the guidelines of the 
Polkinghorne report (Polkinghorne, 1989) and the UK Department of Health 
(Department of Health, 1995), with full ethical consent from the maternal donor, 
under the South Wales initiative for transplantation in HD (SWIFT-HD) program. 
The embryo was washed once with 1XPBS, de-capitated and the visceral organs 
removed into a DMEM/F12 filled-culture dish. The torso was placed onto the 
sterile petri dish and minced with a sterile blade. Human fibroblasts were obtained 
by adding DMEM/F12 to re-suspend the cells before transferring to a 15 ml tube. 
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The tube was centrifuged at 86.64 g for 3 minutes in order to collect the 
fibroblasts’ pellet. The supernatant was aspirated off and the pellet was re-
suspended in 10 ml HEF medium (Minimum Essential Media- GlutaMAX™-I 
(MEMα, Life Technologies®), 20% FBS, 1% PS, 1% MEM Non-Essential Amino 
Acids Solution (Non-essential Amino Acid (NEAA), Life Technologies®)). HEFs 
were transferred to a 10 cm 0.1%gelatin-coated culture plate and were allowed to 
expand at 37C. HEF medium was changed the next day to get rid of debris and 
dead cells.  
 
Maintenance and Passaging of HEFs. 
 HEFs were maintained in HEF medium. At 80-90% confluency, HEFs were 
washed once with 1XPBS, incubated at 37˚C for 5 minutes in 
0.05%Trypsin:EDTA, harvested from the culture dishes following addition of HEF 
medium and centrifuged at 86.64 g for 3 minutes. The supernatant was aspirated 
off and the resulting pellet was re-suspended in 4 ml HEF medium. The cell 
suspension, 1 ml, was re-seeded onto gelatin-treated tissue culture petri-dishes 
filled with 9 ml HEF medium and incubated at 37C.  
 
Freezing HEFs.    
      HEFs were frozen as per the protocol described above for MEFs.  
 
Thawing HEFs. 
 HEFs were thawed as per the protocol described above for MEFs.  
 
Primary Human Fetal Cell Maintenance methods. 
2.1.3 Human Neural Stem Cell.  
 Dissection and preparation of human primary fetal cells.  
Human fetal tissue was collected according to Kelly et al., 2011. WGE, 
cortex and skin tissue were dissected by a member of the brain repair group 
(BRG). Each donor sample is referred to by its SWIFT (South Wales Initiative for 
Fetal Transplantation) number (a unique identifier used for anonymity), however 
clone C9 referred to throughout the text is in fact derived from SWIFT 623, all 
other clones are referred to by their SWIFT number. The cortex and ganglionic 
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eminences were dissected according to Dunnett and Bjorklund (1992) (Figure 2.1 
and 2.2). Dissected tissue pieces were collected using a Pasteur pipette and left 
to descend in 15 ml Hibernate®-E CTS™ medium (Life Technologies®). The 
Hibernate®-E CTS™ medium was removed and 400 µl DMEM/F-12 plus 1% PS 
was added to wash the tissue 2 times. 400 µl 0.1% trypsin (Worthington) was 
added to the tissue and incubated at 37°C for 20 minutes. 0.05% DNAse (Sigma) 
was then added to the tissue. The tissue was again incubated at 37°C for a further 
5 minutes.  
To dilute the enzymes, 10 ml DMEM/F-12 with 1% PS was added to the 
tissue and centrifuged at 86.64 g for 3 minutes. The media was aspirated off; the 
remaining pellet was re-suspended in 400 µl DMEM/F-12 and manually triturated 
using a 200 µl Gilson pipette (10-15 strokes). To assess cell viability, 10 µl cell 
suspension was taken and counted using 0.4% trypan blue exclusion assay and a 
disposable haemocytometer with Countess® Automated Cell Counter (Life 
Technologies®). Cell number was calculated according to the formula (live cells 
counted/1000 (as data is given per ml)/10 x dilution factor = cells/µl cell 
suspension). Total number of cells can be determined based on final volume.  
                  
 
Figure 2.1 the brain removal: The embryo is cut from the front above the eye and the ventral 
mesencephalic flexure. A fine forcep is used to peel off the skin and meninges which covering the 
whole brain (B). The brain is pinched and pulled gently away from the body (C) (Adapted from 
Dunnett and Bjorklund, 1992). 
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Figure 2.2 Dissection of the striatal and cortical eminences: the medial cortex is cut in a 
longitudinal line (A), the striatum is then exposed at the area on the floor of the lateral ventricle (B). 
Iridectomy scissors are used to cut and gently remove the striatum from both hemispheres (C, D). 
(Adapted from Dunnett and Bjorklund, 1992). 
 
Neuronal differentiation culture. 
Sterile 13 mm glass cover slips (Appleton Woods, Birmingham) were 
placed into each well of a 24 well Nunc™ cell-culture treated multidishes (Thermo 
scientific) 500 µl Poly-L-Lysine hydrobromide solutions (PLL) (100 µg/ml, Sigma) 
was added to each well. The plate was left in the fridge at 4°C overnight. PLL was 
aspirated off and the coverslips washed 3 times with sterile water, and then left to 
dry under the UV light for 45 minutes.  
For neuronal differentiation culture, cells were plated at 100,000 cells per 
coverslip in 30 µl of neuronal differentiation medium (DMEM/F12, 1% FBS, 1% 
PS, 2% B-27® Supplements (Life Technologies®)). The cells were allowed to 
settle on the PLL coated coverslips for at least three hours at 37°C, and then 500 
µl neuronal differentiation medium was gently added to each well. Cells were 
incubated at 37°C in humidified 5%, CO2, 95% atmospheric air, and were left to 
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differentiate for 7-14 days. 500µl of fresh differentiation medium was replaced in 
each well every 2-3 days.  
 
 
Proliferation of human primary fetal neural stem cells. 
To culture neural cells (neurospheres), 200 cells per µl were added to T25 
flasks (Thermo Scientific™) with 10 ml proliferation medium (DMEM/F12, 1% PS, 
2% B-27®, 20 ng/ml FGF2 (R&D), 20 ng/ml epidermal growth factor (EGF) (Sigma) 
and were maintained at 37°C. Fresh proliferation medium 5 ml, with 2 times 
concentration of growth factors, replaced 5ml of old medium every 2-3 days.    
                    
Passaging of primary human fetal expanded cells. 
Passaging of neurospheres was undertaken when the spheres increased 2-
3 folds in size with more packed and dense cells inside, approximately 14 days in 
the case of human tissue. Neurospheres and their medium were taken up into a 
15 ml centrifuge tube and centrifuged at 86.64 g for 3 minutes. The medium was 
aspirated off and the pellets were re-suspended by adding 400 µl of trypsin and 
kept in the incubator at 37°C for 20 minutes. 400 µl DNAse was added and the 
pellets were returned to the incubator at 37°C for further 5 minutes. DMEM/F12 10 
ml was added into the centrifuge tube. The tube was centrifuged at 86.64 g for 3 
minutes, the media aspirated off and 400 µl DMEM/F12 plus 1% PS was added to 
the cells that were manually dissociated using a 200 µl Gilson pipette (10-15 
strokes) into a quasi single cell suspension. Trypan blue was used with the 
countess cell counter to assess cell viability as explained above. Cells were plated 
into 24 well plates, as described above, or expanded in 10 ml of proliferation 
medium at the concentration of 2x106 cells per T25 flask.  
 
Pluripotent Stem Cell (PSC) Maintenance and differentiation.  
2.1.4 Human ES and iPS cell Methods. 
Thawing human ES and iPS cell. 
 A vial of human ES/iPS cells was removed from liquid nitrogen and 
immediately placed on ice. The lid was slowly loosened to emit the trapped 
nitrogen. The lower half of the cryovial was then immersed and swirled around in a 
water bath at 37C until the cells’ solution was defrosted. The content was gently 
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transferred to a 15 ml centrifuge tube containing 10 ml of pre-warmed human 
ES/iPS medium in a drop by drop fashion and centrifuged at 21.66 g for 3 
minutes. The supernatant was aspirated; the cell pellet was dispersed by gently 
flicking the tube. 5 ml human ES/iPS (Knock out DMEM/F12 (Life Technologies®), 
20% Knock out serum replacement (KSR, Life Technologies®), 1% L-Glutamine/-
mercaptoethanol solution (Life Technologies®), 1% NEAA, 0.8 ng/µl bFGF (R&D 
systems, Abingdon, Oxfordshire, UK) media was added to the cell pellet and then 
transferred to a MEF feeder plate which had been washed once with 1XPBS. Cells 
were cultured in the CO2 incubator at 37˚C, and fed once every day, by removal of 
old medium and addition of fresh medium.  
 
Maintenance and Passaging of human ES/iPS cell culture. 
 Once human ES/iPS cell reached confluence, 5 ml human ES/iPS cell 
media was replaced with fresh human ES/iPS medium 2-3 hours before passaging 
to nurture the cells. After discarding the culture medium and washing with 5 ml of 
PBS. Collagenase IV medium (1% Collagenase IV (Life Technologies®) in K/O 
DMEM), 2 ml, was added to the cells; the plate was then returned to the incubator 
for 20 minutes until the edges of the human ES/iPS colonies start to curl. The 
collagenase was removed and cells were washed once in 1XPBS before addition 
of 3 ml human ES/iPS media to the cells. The ES/iPS colonies were manually 
picked using a sterile pulled glass pipette to cut around the edges of human 
ES/iPS colonies as well as cut the ES/iPS colonies into smaller pieces. Floating 
colonies were collected in a 15 ml centrifuge tube and centrifuged at 21.66 g for 3 
minutes.  The media was aspirated off and replaced with 5 ml ES/iPS cell medium 
then transferred to a fresh 1xPBS pre-washed plate of MEFs in ES/iPS medium 
and incubated.  
 
Freezing human ES/iPS cell. 
 Three days after passaging, human ES/iPS cells were flooded with fresh 
human ES/iPS medium 2-4 hours before freezing down. The culture medium was 
removed from the culture petri dish and washed once with 1XPBS. PBS was 
removed from the culture petri dish and 2 ml 1%collagenase IV was added to the 
plate. The plate was returned to the incubator at 37C for 20 minutes or until the 
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edges of human ES/iPS colonies started to curl. The collagenase IV medium was 
aspirated off from the culture plate and 5 ml of ES/iPS medium was added to the 
culture plate. The colonies were manually cut around the edges and separated 
from the MEFs using a sterile needle. The ES/iPS cells were transferred to 
cryovial with 200 μl freezing medium (10% DMSO in human ES medium). Cells 
from 1 well of a 6 well plate were distributed to 3 cryovials. The cryovials were 
then placed into a freezing container and kept in -80C. The day after, cryovials 
were moved to liquid nitrogen for the long term storage.  
 
2.1.5 PSC derived neuronal cells.  
Neural induction EB-Based Method (Figure 2.3).  
The human ES/iPS colonies were lifted from feeder cells using collagenase 
type IV medium, manually cut to smaller pieces and picked. Human ES/iPS 
colonies were cultured as free-floating EBs in untreated bacteriological grade petri 
dishes in human ES/iPS medium without bFGF supplement for 2 days. For 
initiation of the neural induction protocol EBs were harvested and transferred into 
KSR medium (K/O DMEM/F12, 10% KSR, 1% L-Glutamine/-mercaptoethanol, 
1% NEAA, 1% PS) with addition of 10 µM SB431542 (Tocris Bioscience, Bristol, 
UK), 200 ng/ml Noggin (R&D systems), 200 nM Dorsomorphin (Tocris), 100 ng/ml 
SHH (R&D systems) and 100 ng/ml Dickkopf-related protein 1 (DKK-1, R&D 
systems). Medium was changed every other day for 5 days. The EBs were 
harvested and transferred to N2B27 medium (1:1 ratio Neurobasal medium to 
Dulbecco's Modified Eagle Medium/Ham's F-12 (Advanced DMEM/F12, 1% N-2 
supplement, 1% B-27®, 0.5% PS, 0.5% Glutamax™ (all from Life Technologies®)) 
with addition of the previously described supplements for further 5 days. At day 
10, EBs were harvested and re-attached onto Corning® Matrigel® Basement 
Membrane Matrix (Matrigel®, USA) in N2B27 medium, which was subsequently 
changed every other day.  
Around day 12-16, neural rosette structures were recognized and these 
were passaged (passage 1) between days 16-22 by incubating with Accutase® 
(Sigma) for 5-7 minutes at 37°C and dissociating as a single cell suspension. 
Then DMEM/F12 10 ml was added and cells were centrifuged at 86.64 g for 3 
minutes. After aspirating off the supernatant, cells were re-suspended in 400 µl 
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N2B27 medium with ROCK inhibitor 10 µM (Y-27632, MERCK Millipore). Cells 
were counted and re-plated onto PLL/POL/Laminin (Poly-L-Ornithine, Sigma; 
laminine, PeproTech) pre-treated coverslips at 100,000 cells/coverslip in 24 well-
plate and 1x106 cells/well of a 6-well tissue culture plate in previous mentioned 
supplement. The media was changed every other day and an additional 25 ng/ml 
recombination human Activin A (PrepoTech) was added to culture medium around 
day 20.  
Cells were subsequently passaged (passage 2) and re-plated onto PLL-POL-
Laminin pre-coated plate/coverslips 9 days later with afore described method and 
culture medium.  
 
 
Figure 2.3 Time line of neural induction from PSC using EBs-Based method which is  
described in section above. (EB= embryoid body, NI medium= neural induction medium, NPC= 
neural precursor cell) 
 
Neural induction Monolayer-Based Method.  
Human ES/iPS cells at 70-80% confluency were passaged as cell clumps 
and distributed from 1 well of a 6 well-plate in 1:3 ratio (~20-25% each well). Cells 
were re-attached onto 9 mg/ml Geltrax® matrix (Life Technologies®) coated 6 well-
plate and cultured in ES/iPS medium. The day after, medium was changed to 
neural induction medium (NI medium, Gibco®, Paisley, Scotland, UK). Full medium 
changing was performed every other day for 7 days until the cells reached 80-90% 
confluence. Cells were passaged (passage 1) as a single cell suspension by 
incubating with 1 ml Accutase® for 5-7 minutes. NI medium 9 ml was added; cells 
were passed through the cell strainer and centrifuged at 86.64 g for 3 minutes. 
Cells were cultured in NI medium and adhered onto Geltrax® coated tissue culture 
dish at 2.5-3.0x105 cells/well of 6-well plate. Between days 10-14, cells were 
dissociated again (passage 2) (using the previously described method). Cells were 
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passaged again (passage 3) between days 16-22, when they were plated onto 
PLL-POL-Laminin pre-treated tissue culture plates/coverslips in neural expansion 
medium (1:1 ration NI medium and Advanced™ DMEM/F12). From this stage cells 
were be able to be expanded and banked as NPCs (Figure 2.4).  
 
 
 
 
Figure 2.4 time line of neural induction from PSCs using Monolayer-based method which 
described in section above.   
 
Neuronal Differentiation. 
 NPCs were maintained in N2B27 medium (1:1 ratio Neurobasal medium to 
Advanced™ DMEM/F12, 1% N-2, 1% B-27®, 0.5% PS, 0.5% Glutamax™) with 
change in the combination of neurotrophic factors, small molecules, and growth 
factors at different days, (Figure 2.5). The differentiation protocol to derive MSN-
like cells is further described in detail in Chapter 5. 
 
Figure 2.5 Time line of PSC differentiation toward MSN liked-phenotype.    
 
Immunocytochemistry and Microscopy. 
2.1.6 Cell Fixation and Immunocytochemistry. 
 After 7-14 days of neuronal differentiation, cells were washed for 3 minutes 
using 1x PBS. Cells were fixed with 4% paraformaldehyde (PFA) for 20 minutes; 
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then washed with PBS three times for three minutes each. Ethanol 100%, was 
added to permeabilise the cells for 2 minutes and then followed by 3 washes in 
PBS for 3 minutes each. Cells were submerged in 300 µl blocking serum (1% 
Bovine Serum Albumin (BSA) (life technologies®) in 1XPBS, 2% appropriate 
normal serum) to prevent non-specific antigen binding for one hour. Blocking 
solution was replaced by primary antibodies (isolated and raised from different 
species to the blocking serum) which were made up in blocking solution at the 
appropriate concentrations (Appendix C). The cells were incubated overnight in 
primary antibody at 4C for double labelling, it is essential that the primary 
antibodies were raised within different species.   
The primary antibody was removed and cells were washed 3X3 minutes 
with PBS. Secondary antibody (Alexa-Fluor fluorescent labels anti mouse 594 
(Red) and anti-rabbit 488 (Green) (Life Technologies®)) was made up in the same 
blocking solution as primary antibody and added at the concentration of 1:200. 
Cells were left in the dark by covering the plate with aluminium foil at room 
temperature for two hours. The secondary antibody was removed and the cells 
were washed 3 times with 1x PBS. 300 µl Hoechst (Sigma) nuclear staining 
solution was added for 5 minutes followed by rinsing 3 X 3 minutes with 1X PBS. 
The coverslips were gently placed onto a glass slide in mountant (PBS: Glycerol, 
1:1) and kept at 4C overnight. The coverslips were sealed with clear nail varnish 
at the edge of each coverslip; all slides were stored in the dark at 4C in order to 
protect from photo bleaching.    
 
2.1.7 Microscopy.                 
 Leica DMRBE Microscope was used to visualize cultured cells under 
different UV fluorescence wave length (red= 594 nm, green= 488 nm, blue= 346 
nm). Photos were taken using Leica image software program. 
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2.2 Molecular methods. 
 
2.2.1 RNA Extraction and Quality check 
The Qiagen RNAeasy mini kit and QiaShredder (both Qiagen, Skelton House 
Lloyd Street North, Manchester) were used to do the RNA extraction following the 
manufacturer’s protocol. The concentration of RNA was determined using 
NanoDrop® ND-1000 Spectrophotometer (Thermo Scientific™) (Appendix E).  
 
2.2.2 cDNA synthesis 
  cDNA synthesis was performed using 1 µg RNA and SuperScript® Reverse 
Transcriptase II (Life Technologies®) following the manufacturer’s protocol from 
Invitrogen (Appendix E). 
   
2.2.3 Polymerase Chain Reaction (PCR) 
The PCR reaction was carried out using a PTC-100TM programmable 
thermal controller (MJ Research, Inc.). The primer sequences used to generate 
reprogramming factors and CPP are shown below, according to Kim et al (2009). 
The optimized RT-PCR programmes are shown in table 2.2. 
 
Table 2.1 Primer sequences for PCR programme for amplification of the reprogramming factors Oct4, 
Sox2, Klf4, cMyc, as well as RFP and CPP. 
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Step 
RFP RFP-9R OCT4 Nanog 
Temp. 
(C) 
Time Temp. 
 (ºC) 
Time Temp. 
 (ºC) 
Time Temp. 
 (ºC) 
Time 
1. Primary denature 98 60 sec 98 60 sec 94 2 min 94 2 min 
2. Cycle denature 98 15 sec 98 15 sec 94 15 sec 94  30 sec 
3. Primer annealing 75 90 sec 72 90 sec 55 20 sec 58 30 sec 
4. Primer elongation 72 5 min 72 5 min 72 1 min  72 30 sec  
5. Go to step 2  
x amount of cycles 
(times) 
75 23  72 19  72 30 72 30 
 
 
Step 
Sox2 Lin28 cMyc Klf4 
Temp. 
(C) 
Time Temp. 
 (ºC) 
Time Temp. 
 (ºC) 
Time Temp. 
 (ºC) 
Time 
1. Primary denature 94 2 min 94 2 min 94 2 min 94 2 min 
2. Cycle denature 94 15 sec 94 30 sec 94 15 sec 94  30 sec 
3. Primer annealing 50 20 sec 58 30 sec 55 20 sec 58 30 sec 
4. Primer elongation 72 1 min 72 30 sec 72 1 min  72 30 sec  
5. Go to step 2  
x amount of cycles 
(times) 
72 34  72 30 72 30 72 30 
 
Table 2.2 Table presenting an optimized RT-PCR programme for amplification of PCR 
product.   
     
 
2.2.4 PCR Product Purification Protocol using Microcentrifuge. 
PCR product was cleaned of any remaining buffers and salt using the PCR 
purification kit (Qiagen). The protocol was carried out as per the manufacturer’s 
guide.  All products were eluted in 30 µl H2O and stored at -20
0C (Appendix E). 
 
Reagents Volume added (µl) 
1. Buffer PBI 1x volume of PCR reaction 
2. Buffer PE 750 
3. Buffer EB or water 30-50 
Typical reaction using the Qiagen PCR clean up kit. 
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2.2.5 DNA Extraction from Agarose gel  
 Linearised vector was purified by running on a 1% agarose gel at 110 volt 
for 1 hour, on confirmation of size, the DNA fragments were excised from the gel 
with a clean sharp scalpel and purified according to gel purification kit (Qiagen). 
DNA was eluted in 30 µl H2O and stored at -20
0. 
 
Reagents Volume added (µl) 
1. Buffer QG 3x volume of gel slice 
2. Isopropanol  1x volume of gel slice 
3. Buffer QG 500 
4. Buffer PE 700 
5. Buffer EB  30-50 
Typical reaction using the Qiagen gel purification kit. 
 
2.2.6 Subcloning pcDNA 3.1 myc-His A with RFP/RFP-9R/Oct4 reprograming 
gene.  
The reactions as described in the table below were prepared on ice at all times.  
Reactions 
Volume added (µl) 
Insert DNA 
(RFP/RFP-9R/Oct4) 
VECTOR 
1. Nuclease free water  6 6 
2. 10X Buffer D  2 2 
3. Insert DNA product  10 (33 ng) - 
4. pcDNA 3.1 myc- His1  - 10(100 ng) 
5. XhoI restriction enzyme  2 2 
6. BSA 0.2 0.2 
Total Volume  20 20 
 
      Reaction of insert DNA product and plasmid vector pre-treated before sub-cloning. 
 
All solutions were added, thoroughly mixed in microcentrifuge tubes, and 
immediately incubated at 37C for 2 hours and then at 65C for a further 15 
minutes in the heat block to denature the restriction enzyme. The tubes were 
centrifuged to collect all DNA solution; the inserted DNA was stored at -20C. 
  The vector was further treated as the following described with shrimp 
alkaline phosphatase (SAP) so as to avoid re-circulisation. 100 ng of plasmid DNA 
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was added to the master mix solution (10x SAP Buffer 5 µl, nuclease free water 
13 µl, SAP 2 µl). The tubes were centrifuged at 18603.52 g for 10-15 seconds and 
then incubated at 650C for 15 minutes.   
 The gene of interest was sub-cloned into plasmid vector as the following 
describes. DNA concentrations of an insert product and vector were determined 
using a NanoDrop® spectrophotometer. The values were inserted into the formula 
below. 
 
 Solutions (µl) Ligation 
reaction 
Vector 
(control) 
Insert 
(control) 
1. Insert DNA  6 - 7 
2. Plasmid DNA 1 7 - 
3. Nuclease free water 1 1 1 
4.10X T4 Buffer 1 1 1 
5.T4 ligase 1 1 1 
Total volume 10 10 10 
                                           Reaction of vector to insert DNA ligation.  
 
2.2.7 Transformation and inoculation of plasmid DNA 
 The ligated plasmids were transformed into chemically competent TOP10 
(Invitrogen) Escherichia. coli (E.coli) by heat shocking the bacteria from ice then 
transferred into sterile bacteriological tubes (Falcon, Becton Dickinson Labware, 
New Jersey, USA) containing pre-warmed SOC media (Invitrogen).  Bacteria were 
incubated in a 4.54 g shaking oven at 37˚C for 1 hour. After cultivation, 50 µl of 
bacteria was plated onto ampicillin (100 µg/ml) LB (Luria-Bertani (DIFCO; Becton 
Dickinson)) selection agar plate. The remaining solution was transferred to 1.5 ml 
microcentrifuge tube and centrifuged at 4650.88 g for 3 minutes. 150 µl of 
supernatant was taken off and discarded; the pellet was re-suspended in the 
remaining medium and plated. The plates were incubated at 37˚C overnight. After 
this step, an individual colony was picked using an inoculation loop, and 
transferred to the tubes containing 5 ml LB medium containing ampicillin. The 
tubes were returned back to the incubator at 37C for 12-16 hours on the shaker 
at 4.54 g (as per the protocol from Invitrogen) (Appendix E).   
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2.2.8 Purification of DNA (Plasmid Mini-prep (Qiagen))  
 The bacteria suspension was centrifuged at 1816.75 g for 3 minutes; the 
supernatant was poured off. DNA was purified using plasmid Mini-prep kit 
(Qiagen) following the manufacturer’s instructions (Appendix E). DNA was eluted 
in 50 µl EB buffer and stored at -200C. 
 
2.2.9 DNA digestion 
 The obtained DNA was digested for an analytical check by incubation with 
restriction enzyme, Xho I, 10x buffer D (Promega, Southampton, UK), and 10X 
BSA. Nuclease free water was added to make up the total volume to 10 µl.  The 
solution was incubated at 37C for 2 hours before heating the tubes at 65C for a 
further 15 minutes. DNA was run for 1 hour at 110 volt on a 1% agarose gel plus 
SafeView nucleic acid stain to check the existence of inserted DNA by visualising 
against undigested DNA and DNA fragments.  
 To confirm the direction of the inserted DNA, the obtained DNA was cut by 
restriction enzyme Age I and AhD I. The reactions as presented in the table below 
were mixed on ice in microcentrifuge tubes. They were incubated at 37˚C for 2 
hours and then a further 15 minutes at 65˚C. To examine the molecular weight of 
interested DNA, an appropriate amount and concentration of loading dye was 
mixed with the DNA, loaded on 1% agarose gel (added with SafeView) and run for 
1 hour at 110 volt. The gel was viewed under UV light comparing 100 bp and 1 kb 
DNA ladder.  
Typical reaction: Age I and AhD I Digest the pcDNA3.1-Myc/His A –RFP checking for the 
orientation of inserted DNA. 
 
Solutions Volume (µl) 
1. DNA  4  
2. Multicore Buffer  1  
3. BSA 0.1  
4. Water 2.9  
5. Age I restriction enzyme 1  
6. AhD I restriction enzyme 1  
Total volume  10  
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2.2.10 Expanding piggyBac transposon (pPB-CAG.OSKML-pu∆tk) and 
transposase (pCyL43/ pCyL50) 
 LB medium, 5 ml, and 150 µg/ml Ampicillin were added into 3 falcon tubes. 
The tubes were incubated at 37˚C for 1 hour before each agarose gel with 
samples were cut into small pieces and put into each falcon tube. The tubes were 
returned to the incubator and further incubated at 37˚C on maximum speed shaker 
for an hour. The medium were poured into each flask which contained 100 ml LB 
medium and 150 µg/ml Ampicillin, 100 µl. The flasks were incubated overnight at 
37˚C on a maximum speed shaker (4.54 g).  
   
2.2.11 Purification of DNA (Plasmid Midi-prep (Qiagen)) 
 The bacterial suspension was harvested into a 50 ml falcon tube. The tube 
was placed into the Centrifuge 5810 R (eppendorf) at 4˚C to spin at 2616.12 g for 
15 minutes. DNA was purified using the plasmid Midi-prep kit (Qiagen) following 
the manufacturer’s instructions (Appendix E). 
 
2.2.12 Transfection of human primary tissues using Lipofectamine®.  
 The day before transfection, human primary tissue or human cell line were 
plated into 6 well-culture plates at 500,000 cells each well. The cells were 
incubated at 37˚C in differentiation medium as mentioned without PS. The 
following day, 1 µg plasmid DNA was gently mixed with 100µl Opti-MEM® I 
reduced serum (life technologies®). Lipofectamine® was used according to 
manufacturer’s instructions. Briefly, Lipofectamine® was prepared with Opti-MEM® 
(using 1:3 ratio of DNA: Lipofectamine®), and then stored at room temperature for 
5 minutes. Both DNA and Lipofectamine® solutions were mixed and allowed to 
stand at room temperature for 30 minutes.   
The differentiation medium was aspirated off cells and 1500 µl of the mixed 
DNA and Lipofectamine® solution was applied. The 6 wells plate were then 
incubated at 37˚C for 6 hours; and then, 1500 µl Opti-MEM® I reduced serum was 
added to each well for 24 hours. 
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2.3 In vivo methods. 
 
2.3.1 Animal care, anaesthesia, and immunosuppression 
 All animal experiments were performed in compliance with local ethical 
guidelines and approved animal care according to the UK Animals (Scientific 
Procedure) Act 1986 and its subsequent amendments. Adult female Sprague-
Dawley rats weighing 200-250 gm (Harlan, UK) were housed in cages of up to 4 
animals in a natural light-dark cycle with access to food and water ad libitum.  
 All surgeries were performed under isoflurane anaesthesia which was 
induced in an induction chamber with 5% isoflurane and 0.8 L/minute oxygen. 
Passive inhalation of isoflurance 1-2 L/minute in a mixture of oxygen 0.8 L/minute 
and nitrous oxide 0.4 L/minute was maintained to keep anaesthesia during 
surgical procedures. Animals were recovered in 38°C recovery chamber and 
received analgesia by subcutaneous injection with 30 µl Metacam and 5 ml of 
0.09% saline glucose. Animals were returned to their cages and monitored for 
weight and health for 3 days after surgery.  
 In xenograft transplantation experiments, animals received intra-peritoneal 
injection (i.p.) with immunosuppressant Cyclosporin A (CsA, Sandimmun, 10 
mg/kg; Novartis, Hampshire, UK) the day before surgery and daily for the duration 
of the experiment.   
 
2.3.2 Quinolinic acid (QA) lesion of the rat striatum 
 QA was dissolved in 0.1 M phosphate-buffer to make a 15 mg/ml (90 mM) 
solution and pH adjusted to 7.4. Animals received a unilateral injection of QA to 
the right striatum. Prior to surgery, animals were injected with 30 µl Metacam into 
the scruff. Then the skull was exposed and small burr holes drilled above the right 
striatum. QA 0.75 µl was injected via a cannula attached to a 10 µl Hamilton 
syringe driven by a mechanical pump at 2 sites for 3 minutes per site and 1.5 
minutes each at 2 heights. The stereotaxic coordinates from bregma were -3.5/-
2.8 mm medial-lateral (ML), -0.4/+1.0 mm AP, and -5.0/4.0 mm DV below dura 
mater. The syringe needle was left in place for 3 minutes at the lesion site 
following the infusion. After withdrawal of the needle, the incision was cleaned and 
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sutured. Animals received a 150 µl intramuscular injection of diazepam for 
sedative effect to prevent post lesion seizure.  
 
2.3.3 Unilateral striatal transplantation 
 For cell transplantation into the adult rat striatum, 500,000 cells in 2 µl of 
neuronal differentiation medium (250,000 cells/µl) were administered at 2 depths 
using a Hamilton syringe with a bore diameter of 0.25 mm. Cells were injected into 
the lesioned right striatum using stereotaxic coordinates +0.7 mm (AP) and -3.1 
mm (ML) from bregma and -4.5 mm and -3.5 mm (DV) for 1 minute at each site 
and the needle was left in situ for a further 3 minutes to minimize reflux of grafts 
along the needle tract. After the needle was withdrawn, the wound was sutured.  
 
2.3.4 Perfusions and tissue sectioning 
 Animals were terminally anaesthetised by intra-peritoneal injection of 
sodium pentobarbital (Euthatal, Merial) and transcardially perfused with a prewash 
solution (PBS at pH 7.3) for 2 minutes followed by 4% PFA solution at pH 7.3 for 5 
minutes. The brains were removed and transferred into 4% PFA overnight shaking 
at room temperature. The following day, the brains were placed into 25% sucrose 
in prewash solution until they sank. Brains were sectioned coronally at 40 µm 
thickness using a freezing-stage microtome. Sections were stored in 48-well 
plates in anti-freezing solution at -20°C.   
 
2.3.5 Haematoxylin and Eosin (H&E) 
 The brain sections (1 in 12 series) were mounted onto glass microscope 
slides (coated with 1% gelatin) and air-dried overnight at 37°C. The sections were 
dehydrated and rehydrated in increasing levels of alcohol before being placed in 
xylene for 1 hour. Sections were then placed in 1% haematoxylin for 20 minutes 
followed by acid alcohol for 3 minutes and 1% eosin for around 20-45 seconds 
before being dehydrated in increasing concentrations of alcohol. The slides were 
placed in xylene before coverslipping with DPX mountant.  
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2.3.6 Immunohistochemistry on free-floating tissue sections with DAB. 
 1 in 12 series of brain sections were washed thoroughly in Tris buffered 
saline (TBS) (pH 7.4) quenched with 10% hydrogen peroxide and 10% methanol 
in distilled water for 5 minutes followed by 3 times washing in TBS for 5 minutes 
each wash. The sections were incubated in blocking solution (3% normal serum in 
0.5% triton X-100 in TBS (Tx-TBS)). After discarding the blocking solution, primary 
antibodies were added at the appropriate concentration in 1% serum in Tx-TBS 
and incubated overnight at 4°C. Sections were washed 3 times for 10 minutes in 
TBS before addition of biotinylated secondary antibodies at 1:200 dilution in 1% 
serum in TBS for 2 hours and followed by another round of 3x10 minutes washes 
in TBS. Primary and secondary antibodies are listed in appendix C. Streptavidin 
ABC (A and B both at 1:200 dilution in 1% serum in TBS which prepared 30 
minutes before use) was added for a further 2 hours. The sections were washed 
3x10 minutes in TBS and rinsed with 0.05 M Tris non saline (TNS) pH 7.4 and 
positive staining was visualized using diaminobenzidine (DAB) staining at 0.5 
mg/ml in fresh TNS with 12 µl hydrogen peroxide (brown). Finally, sections were 
washed twice in TNS before mounting on gelatin coated glass microscope slides. 
Sections were allowed to air dry and then dehydrated in increasing levels of 
alcohol, cleared in xylene and coverslips were mounted using DPX mountant.  
 For double staining with Vector® SG, the SK-4700 kit (Vector, USA) was 
used by mixing 10 ml TNS with 3 drops Chromogen and 3 drops hydrogen 
peroxide. The sections were washed in TNS buffer and incubated in Vector® SG 
solution until the desired level of staining is achieved (5-15 minutes). Sections 
were rinsed with TNS for 1 minute followed by washing in TBS 3 times for 5 
minutes/wash. Free floating sections were mounted on slides and dried overnight 
before dehydration, clearing, and mounting as described above.  
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2.3.7 Immunofluorescence on free-floating tissue sections 
 The brain sections 1 in 12 series were washed with 1X Tx-PBS 0.5% (pH 
7.4) thoroughly for 10 minutes x 3 times. The section were then permeated with 
100% ethanol for 2 minutes and immediately washed with 1X Tx-PBS 0.5% 3 
times for 5 minutes each time. After discarding the Tx-PBS 0.5%, blocking 
medium (1%BSA in Tx-PBS 0.5% and 2% normal serum) was added onto the 
sections and incubated at the room temperature for 1 hour on the shaker. Primary 
antibody was supplemented in the previously described blocking medium and 
added to the brain sections. The sections were then place at 4 C and incubated 
overnight.  
 After overnight incubation, the sections were placed on the shaker for 1 
hour at room temperature. The sections were washed 3 times for 10 minutes in 
PBS before addition of Alexafluor secondary antibodies at 1:200 dilution in 
blocking medium for 2 hours at room temperature followed by another round of 
3x10 minutes washes in PBS. Hoechst (1:10,000 in 1XPBS) was added for 5 
minutes and sections were rinsed twice with 1XPBS for 10 minutes/wash before 
mounting with fluorescence mounting medium (Dako) and coverslipped. 
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Chapter 3 
Generation of iPS cells derived from primary human fetal 
tissue by direct reprogramming using piggyBac transposon. 
3.1 Introduction 
  Several methods for the generation of iPS cells have been reported in the 
literature as outlined in the introduction to this thesis. Using primary fetal neural 
tissue from the developing striatum as the source material for the generation of 
such iPS cells and following on from the failures of the CPP method described in 
chapter 3, we chose to explore an alternative approach, the piggyBac transposon 
method. piggyBac transposon has been introduced as a highly effective gene 
transportation method. The piggyBac transposons take advantage of the fact that 
it can contain a large insertion, up to 10 kb, there is no genomic alteration in the 
host genome and there can be complete excision of the cargo with no footprint 
being left behind, resulting in generation of vector-free iPS cell lines (Kaji et al., 
2009, Yusa et al., 2009; Woltjen et al., 2009). In addition, the piggyBac transposon 
has been reported to be highly active in mammalian and mouse cells (Cary et al., 
1989; Yusa et al, 2009).  
The resulting iPS cell-lines generated from MEFs have been 
indistinguishable from ES cells in terms of their pluripotent properties, proliferation 
and the production of chimeras (Yusa et al., 2009). In addition, the reprogramming 
efficiency was improved overall up to 1%, similar to the viral transfection method 
(Yusa et al., 2009).  
 Similarly, Woltjen et al, 2009 reported the generation iPS cell colonies using 
fibroblast cells as the starting material using the same approach; the piggyBac 
transposon. The resulting iPS cell-lines ticked all the boxes based on 
differentiation evaluations such as teratoma formation, production of chimeras and 
pluripotent marker expression (Woltjen et al., 2009; Yusa et al., 2009).   
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 Here I report on a study carried out using the piggyBac Transposon 
method. iPS cell lines were generated from primary human primary fetal neural 
cells, fetal neurospheres and  skin fibroblasts. The pluripotency of the cell lines 
was verified using a range of methods in vitro and compared to that of human ES 
cells.  
 
3.2 Aims 
 The aim was to propagate a viral-free iPS cell line appropriate for 
transplantation in HD using the piggyBac transposon strategy. Specifically human 
fetal derived tissues were used as the starting material given the local availability 
of this tissue. The hypothesis behind this experiment was based on the notion that 
iPS cells generated from a specific starting material, in this case developing 
striatal tissue may be more readily able to differentiate back to this cells of this 
tissue type during neural induction and differentiation, thereby facilitating the 
process of generating specific neuronal cell types from the iPS cells; i.e. it was 
hoped that the pluripotent cells would retain an “epigenetic memory” that would 
allow this process to be more efficient. Thus, human primary fetal cells derived 
from the developing striatum or cortex, and fetal skin fibroblasts were used; the 
latter two acting as controls for the hypothesis being tested. The iPS cell lines 
generated were rigorously evaluated in terms of morphological appearance, 
pluripotent properties, teratoma formation, cell-specific markers, and gene 
expression profiles. Chapter 5 goes on to investigate the neural differentiation in 
vitro and and following transplantation of these cells. 
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3.3 Experimental design  
To begin with, prior to transfection, the human fetal tissues were prepared 
accordingly; the neural cells were prepared as either primary cell cultures or 
expanded as neurospheres for up to 7 days and both were then dissociated as 
single cells onto PLL and laminin coated tissue culture plates; HEFs were 
dissociated as single cells and re-attached onto gelatin coated tissue culture 
dishes in differentiation medium. The next stage involved a series of steps over a 
number of days. Firstly, the cells were transfected with piggyBac transposon and 
transposase (pPB-CAG.OSKML-pu∆tk and pCLy43) using Lipofectamine® for up 
to 24 hours (Figure 3.1). The transfection solution was then replaced by 
differentiation medium and after 48 hours the transfected cells were separated 
and re-plated on a MEF feeder layer, cultured in differentiation medium for a 
further 24 hours and then ES cell medium was added. The ES medium was fully 
changed every day until iPS cell colonies appeared (Figure 3.2).  
 
Figure 3.1 The schematic of piggyBac Transposon (pPB.CAG.OSKML-puDtk) construction for iPS cell 
generation. The transposon is used as a gene delivery vector system which contains 5’UTR situated between 
the CAG promoter and Oct4 sequences. The reprogramming genes Oct4, Sox2, Klf4, c-Myc, and Lin28 
(OSKML) were linked by 2A peptides. 3’UTR sequence (bpA= bovine growth hormone polyadenylation signal) 
is after Lin28 sequences. A continuous CAG promoter drives the reprogramming transcription with each gene 
linked by 2A peptides, which mediated continuously, transcribe of the five factors OSKML. The PGK promoter 
drived-pu∆tk works as a negative selection marker after removing the transposon from the iPS cells (Adapted 
from Yusa et al, 2009).  
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Figure 3.2 Timeline of transposon mediated-reprogramming of iPS cells. Human neural cells 
(WGE/cortex) and HEFs were plated down and differentiated for 1 day prior to the transposon transfection. 
Day 0, pPB.CAG.OSKML-puDtk and pCyL43 were transfected into the donors in addition with Lipofectamine
®
 
transfection reagent. The transposon was allowed to cooperate with the host genome and alter gene 
expression for 2 days after infection in differentiation medium before the cells were dislodged and re-attached 
onto iMEFs. ES medium with bFGF supplement was added and the media changed daily. The first colony 
emerged around 2-4 days after re-plating and culturing in the ES cell condition. Primary colonies were 
selected and expanded around day 11 as the morphology showed similarities to ES colony.      
 
3.4 Methods 
3.4.1 Reprogramming of human primary fetal neural cells and HEFs using 
transposon vectors. 
 The day before transfection, human primary fetal neural cells and HEFs, 
5x105 cells, were plated down as single cells onto a 6-well plate coated with PLL 
and laminin. The cells were cultured with differentiation medium without antibiotic 
overnight (day -1). The next day (day 0), cells were transfected under various 
conditions as per table (Table 3.1) using Lipofectamine® transfection reagent. 
Lipofectamine® was incubated in Optimem®, 50 µl, at room temperature for 5 
minutes. The piggyBac DNA and transposase were added into Optimem, 50 µl, 
and the solution was mixed with the Lipofectamine® solution. The reprogramming 
cocktail was incubated at room temperature for 25 minutes. 900 µl Optimem® was 
added to the cocktail and gently mixed by pipetting up and down. The 
differentiation medium was aspirated off from each well and then the mixture was 
added onto the cells in each well. 500 µl Optimem® was added to obtain the total 
volume of 1500 µl. The 6-well plate was then incubated at 37˚C for 6 hours before 
1.5 ml of warm, fresh differentiation medium without PS was added to each well 
(total volume 3 ml) and incubated further at 37˚C. 
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Condition 
Ratio 
pPB-CAG.OSKML-pu∆tk  
(1µg = 1µl) 
pCyL43  
(1µg = 1µl) 
Lipofectamine (µl) 
1:3 0.5 0.5 3 
2:6 1.0 1.0 6 
3:9 1.5 1.5 9 
4:12 2.0 2.0 12 
 
Table 3.1 Conditional ratios of vector DNA (piggyBac transposon--pPB-CAG.OSKML-pu∆tk (µg) and 
transposase-- pCyL43 (µg)) with the volume of Lipofectamine® (µl).   
 
3.4.2 Re-plating the transfected human primary fetal neural cells and HEFs 
onto MEFs feeder layer. 
 The day after transfection (day 1), the transfected HEFs and human FNPs 
were dissociated using Accutase®. DMEM/F12 was added to the dissociated cells, 
and the cell suspension was collected in a 15 ml centrifuge tube. The tube was 
spun at 86.64 g for 3 minutes. The supernatant was aspirated off; 200-250 µl of 
differentiation medium was added to the pellet before triturating 25-30 times to 
break up the clump. The MEFs feeder plate was prepared beforehand by washing 
with 1XPBS and culturing with 2 ml fresh and warm differentiation medium. The 
transfected cells were re-plated onto MEFs feeder layer and cultured at 37˚C. 
 
3.4.3 Culturing and passaging the iPS colonies. 
 On day 3, ES cell medium was added to the transfected cells and the 
culture medium was changed every day until iPS cell colonies were identified. 
Each iPS cell colony was separated, picked up, and transferred onto MEFs feeder 
layer in a 24-well plate. The colony was cultured until it was large in size or dense 
enough to passage. Passaging was carried out using collagenase IV solution for 
8-10 minutes until the edge of the colony was lifting off the culture plate and then 
fresh ES cell medium was added. A flame pulled glass pipette was used to cut the 
colony into small pieces, which were collected and transferred to the 15 ml 
centrifuge tube. The plate was then washed again with ES cell medium to collect 
all the colony fragments. The cells were spun at 13.86 g for 3 minutes; then the 
supernatant was aspirated. The cells were re-suspended in the ES cell medium 
and placed onto new MEFs feeder plate for further expansion, maintaining a 
frozen stock for characterization of these cells.     
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3.4.4 Transgene excision by transposase enzyme in reprogrammed iPS cells  
 iPS cells were detached from the feeders as small clumps using 
collagenase IV as described previously. Preparing transposase (pCyL43), 
Lipofectamine® 3 µl was incubated in 50 µl Optimem® for 5 minutes at room 
temperature. The cells were rinsed with warm 1XPBS and centrifuged at 13.86 g 
for 3 minutes before the supernatant was aspirated. The transposase was then 
gently mixed with 1.5 ml Optimem® and applied to the cells in non-attachment 
Sterilin culture dish for 6 hours at 37°C. iPS cells were collected and centrifuged at 
13.86 g for 3 minutes. Supernatant was aspirated and the cell pellet was re-
suspended in ES cell medium before re-plating onto iMEFs. ES cell medium was 
fully replaced every day for additional 2-3 days. 200 ng/ml 1-2'-deoxy-2'-fluoro-ß-
D-arabinofuranosyl-5-iodouracil (FIAU) was supplemented into ES cell medium to 
select the transgene free iPS colonies. Surviving iPS cell colonies were picked 
and further expanded as individual colonies.      
 
3.4.5 Detection of transgene integration within the iPS cell lines         
 Transgene integration and transposon structure can detect by RT-PCR 
using the primers listed below. 
 
Table 3.2 Primers list for exogenous transgene integration. 
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3.4.6 Teratoma formation         
 iPS cell colonies were detached from feeders using collagenase IV. The 
colonies were cut into small clumps using a sterile needle and the cells were 
transferred to a 15 ml centrifuge tube. ES cell medium was added to a total 
volume 10 ml. Cells were centrifuged at 13.86 g for 3 minutes before the 
supernatant was aspirated off. Cell clumps were re-suspended and gently 
triturated in ES cell medium. The cells, approximately 1x106 iPS cells, were mixed 
with Matrigel in a 1:1 ratio to enable them to clump and stay localized following 
injection subcutaneously into dorsal flanks of immune compromised-mice 
recipients. Around 8-10 weeks later, tumours were dissected, processed, and 
analysed by histological applications. The work was done by Dr. Susan Hunter, 
School of Bioscience, Cardiff University.    
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3.5 Results 
The piggyBac Transposon method was applied to a number of samples from 
different maternal donors at various ages in gestation. 
3.5.1 piggyBac Transposon mediated iPS cells originating from human WGE 
(iPS WGE C9).  
 Following transfection of primary human WGE cells with the transposase 
and piggyBac transposon there appeared to be little cell death (Figure 3.3 A). 
After re-plating transfected human primary WGE on a MEF feeder plate the cells 
quickly started to clump (Figure 3.3 B), however at this stage, there were no iPS 
cell like-colonies to be observed. Around days 2-7, a small round patch of forming 
colonies emerged (Figure 3.3 C). The morphology of the gathering cells was 
different from the human WGE cells as previously observed at the earlier stage 
(Figure 3.3 A) with a clear change in the ratio of nucleus to cytoplasm, a 
morphology more in line with what is reported of ES cells.  
Over a number of days most, but not all, of these cells continued to 
proliferate (Figure 3.3 C). The cells that did not proliferate were located around the 
edges of the newly formed clump and were more characteristic in morphology of 
the original starting material (Figure 3.3 C, arrow). The iPS cell colony gradually 
developed with a distinct border from the MEFs and had a rounded dome shape 
like appearance as the cells continued to divide (Figure 3.3 C, insert). Between 
days 7-14, the primary colonies were easily identified, they were larger in size thus 
making them accessible for selection and passaging (roughly 1.5-2.0 mm). iPS 
cell colonies were passaged as described in chapter 2. Interestingly, there were 
several clones that proliferated more vigorously compared to others. These clones 
used up the medium rapidly as evidenced by the yellowish color of the culture 
medium in comparison to other clones. In addition, the morphological appearance 
exhibited different to a typical ES colony. Therefore, the clones that were not 
characteristic of an expectant pluripotent cell colony were not selected to expand 
further as an iPS cell line. 
After several passages, the iPS cells were seen to proliferate in a way that 
is comparable to ES cells and had a morphological appearance similar to a typical 
ES cell colony; rounded shape, distinct border and tightly compacted cells with a 
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nucleus dominant to the cytoplasm (Figure 3.3 D and inset). The iPS cell lines 
were expanded and collected for further analysis and study. This line is referred to 
as iPS WGE623 C9. 
  
 Transformation of the cellular morphologies and a high proliferation 
propensity may suggest that reprogramming has taken place. However, further 
investigation and evaluation of the pluripotent characteristics and gene expression 
pattern compared to human ES cells needs to be carried out before any 
conclusion can be made.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 3                                                                                   iPS cells generation by 
                                                                                      piggyBac transposition method 
79 
 
iPS WGE623 C9 generation. 
 
Figure 3.3 Generation of iPS cells from human primary WGE using piggyBac transposon. Bright-field 
images taken during the derivation of piggyBac transposon–mediated iPS cells. After 12-24 hours of gene 
delivery transduction with piggyBac transposon and transposase (pPB-CAG.OSKML-pu∆tk and pCyL43), 
neural cells appeared healthy with no evidence of cell death (A). Transfected cells started to show signs of 
colony formation after re-plating on iMEFs and culturing in an ES cell environment (B). 2-7 day after re-plating 
they gradually formed ES-like colonies with high degree of proliferation in the middle of the accumulated patch 
of cells (C). Later on, morphological appearances continued to develop by appearing rounded in shape, 
presence of a sharp cell border, and proliferated up like a dome (C, inset). After passaging several times, the 
iPS colony continued to share a morphological appearance that was comparable to a typical ES colony (D) 
composed of nuclear-dominant cell population (insert). (Scale bar=0.01 mm A-B; scale bar=0.1 mm C-D) 
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3.5.2 piggyBac Transposon mediated iPS cells originating from human 
primary WGE, cortex, and HEFs. 
 As mentioned above the procedure was repeated on several samples from 
human fetal striatum (WGE SWIFT number 928, 949, 954), cortex (Ctx SWIFT 
number 962) and skin fibroblasts of different donors (SWIFT number 815 and 
962). One fetal donor derived WGE sample was cultured as neurospheres for 7 
days (SWIFT number 928). The piggyBac transposon- pPB-CAG.OSKML-pu∆tk 
and transposase (pCyL43) were delivered to these cells in the same way as 
described above.  
 There was variability in the timing with which colonies were first observed; 
as early as 2-14 days after transfection in primary WGE, 7-14 days in cortex, and 
14-21 days in skin fibroblasts (Figure 3.4 A, B, C respectively). WGE derived-iPS 
cell colonies continued to appear with time in vitro. Of the resulting colonies only 
48 colonies were collected and expanded from the WGE cultures, 12 colonies 
were obtained from primary cortex and only 2-7 iPS colonies were propagated 
from skin fibroblasts (Table 3.2). Furthermore, subsequent culturing resulted in 
only one of the iPS cell lines derived from the fibroblasts being expanded as the 
other pre-iPS cell colonies did not proliferate or develop any further. The iPS cell 
colonies presented with morphological characteristics similar to a typical ES cell 
colony and had similar self-renewal features (Table 3.2). 
  The iPS cell lines were allowed to freely differentiate in ES/iPS cell medium 
without the addition of bFGF in a bacterial grade petri dish to look at the 
propensity of these cells to form EBs, which are differentiated multicellular 
aggregations of pluripotent cells (Figure 3.4 D).  
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Figure 3.4 Morphological appearances of piggyBac transposon (PB) derived-iPS cells from human 
primary tissues. Developing primary colonies of PB transposon generated iPS cell from human primary 
WGE (SWIFT number 928) were recognized around 2-14 day after infection with piggyBac transposon and 
transposase (pPB-CAG.OSKML-pu∆tk and pCyL43).  The colonyborder was not defined at this stage and 
they needed around 5-7 days to be passaging; scale bar=0.01 mm (A). The colony which failed 
reprogramming to a pluripotent stage was exhibited as a patch of cells without a proliferating area (Figure A, 
upper right corner). The 2
nd
 passage of iPS cell generated from cortex neurospheres demonstrating a more 
clearly defined border; scale bar=0.03 mm (B). A morphological comparison between iPS colonies and their 
original HEFs (C and inset respectively) (SWIFT number 962); iPS colonies propagated from HEFS at around 
passage 4-5 had similar features to typical ES colonies; sacle bar= 0.1 mm (C). The HEF iPS colony 
contained small tightly packed cells, with a proliferating area in the middle of colony, and distinctive 
colonyborder. All established iPS cell lines could generate multicellular aggregates called embryoid bodies 
(EBs) presenting as a ball shapes in ES medium without additional bFGF; scale bar=0.10 mm (D).  
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Table 3.3 The table presents a summary of iPS cells generated using PB transposon based gene 
delivered system in distinct original cell phenotypes and donors as represented by the donor 
collection number (SWIFT number) and the approximate size (CRL) ranged from = 22-49 mm.  
 
In summary, we were able to generate iPS cells from human fetal tissues 
using the piggyBac transposition system with 5 reprogramming factors (OSKLM) 
and transposase pCyL43. However, there appeared to be marked variability in the 
reprogramming efficiency and kinetics between the different donor tissues. 
Specifically, the WGE appeared to generate more clones with rapid kinetics than 
the cortical tissue or the HEF. The first iPS colony generating from human 
embryonic WGE was appeared within 2-7 days after transfection, while using CTX 
or HEF will need at least 14-21 days to obtain the first colony. In addition, the 
conversion efficiency appeared to be 4-5 times higher in WGE as an originated 
cell source in comparison to CTX and HEF respectively. (Table 3.3) 
In the first instance all the cell lines generated were tested using 
immunocytochemistry for pluripotent markers. Due to the high expense and labour 
intensive nature of the work, it was only possible to take the first iPS cell line (iPS 
WGE623 C9) forward for full molecular, in vitro and in vivo validation of 
pluripotency.  
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3.5.3 In vitro Characterization of iPS cell line: iPS WGE623 C9. 
Morphological characterization 
 The iPS cells (WGE623 C9) were similar in morphology to the the H9 
human ES cell line as described above and seen in Fig 3.5.  
 
Figure 3.5 Comparison of the morphological appearance of a human ES colony (H9) (A) and a 
piggyBac Transposon mediated-iPS colony (B). Both ES and iPS colony are similar in terms of the 
morphological appearances—rounded shape, sharp border, tightly packed and nuclear dominant cells. (Scale 
bar = 0.01 mm) 
 
Immunocytochemistry analysis for pluripotent markers. 
 Human ES cells (H9) were used as a positive control in this study.  
Immunofluorescence confirmed pluripotency in human ES cells (H9) and iPS cells 
for stem cell markers such as Oct4, SSEA4, Nanog and Tra-1-60. Fig 3.6 shows 
the positive expression of Tra-1-60 and Oct4 markers in H9 ES cells whilst Fig 3.7 
confirms their expression in the WGE623 C9 iPS cell line and confirms the 
persistence of these markers with time in culture and passaging (passage 26 and 
43) (Figure 3.7). In addition, our established iPS cell lines: iPS WGE 928, iPS 
WGE 949, and iPS HEF962 also expressed hallmark of pluripotent markers such 
as Oct4, Sox2, SSEA4, Nanog, and Tra-1-60 similar to ES cells (Figure 3.8-3.10, 
respectively).  
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Human ES cell (H9) 
 
Figure 3.6 Characterization of human ES cell line H9. Immunofluorescence analysis of Hoechst staining 
(A). Expression of pluripotent markers OCT4 (B), TRA-1-60 (C), triple stained for OCT4, TRA-1-60 and 
Hoechst (D). Scale bar=50 µm.   
 
Human iPS cell from WGE (iPS WGE623 C9) 
     
Figure 3.7 Characterization of iPS WGE623 C9 after continued passage. Immunofluorescence analysis of 
OCT4, Nanog (column 2), SSEA4 and TRA-1-60 (column 3) expression in the piggyBac Transposon 
mediated - iPS cell line C9 at passage 26 and passage 43 which confirm the consistency in pluripotent genes 
expression of this iPS cell line over time (Scale bar=100 µm). Column 4 shows the merged images. 
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Human iPS cells from WGE SWIFT No. 928, 949 (iPS WGE 928 clone 5, 949 
clone 5) 
As mentioned above this process was carried out on a number of lines 
generated. Figure 3.8 and figure 3.9 are representative of two iPS cell lines where 
starting material was fetal WGE from two different maternal donors, showing 
positive expression for stem cell markers. 
 
Figure 3.8 Characterization of iPS cells derived from human fetal WGE (SWIFT No. 928). 
Immunofluorescence analysis of genes expression OCT4 (A), TRA-1-60 (B), SOX2 (D), and SSEA4 (E) in the 
piggyBac Transposon mediated - iPS cell line (iPS WGE 928 clone 5). (C) and (F) show merged images. 
 
 
Figure 3.9 Characterization of iPS cells derivied from human fetal WGE from (SWIFT number 949). 
Immunofluorescence analysis of OCT4 (A), Sox2 (B), SSEA4 (C), and Nanog (D), in the piggyBac 
Transposon mediated - iPS cell line (iPS WGE 949 clone 5). Scale bars, 20 µm.    
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Human iPS cell from HEFs SWIFT No. 962 (iPS HEF 962 clone 2) 
 
The HEF derived iPS cell line was also stained for expression of the 
pluripotency makers Oct4, Nanog, SSEA4, Sox2, and Tra-1-60 (Figure 3.10). 
 
Figure 3.10 Characterization of the piggyBac Transposon mediated iPS cell line derived from HEFs 
(Swift number 962): iPS HEF 962 clone 2. Coexpression of the pluripotent markers OCT4 in the nucleus and 
TRA-1-60 in the cytoplasm (A), Nanog and TRA-1-60 (B), SSEA4 (C), and Sox2 (D). Scale bars, 20 µm.
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Spontaneous In vitro differentiation of iPS WGE623 C9.  
The iPS cell line C9 was allowed to spontaneously differentiate on matrigel 
coated coverslips and cultured in ES medium without the addition of bFGF for 14-
21 days. The results showed the differentiation of these cells into cells of all three 
germ layers: endoderm, mesoderm, and ectoderm (Figure 3.11 B, C, and D 
respectively). Immunocytochemistry was carried out on these cells to define the 
specific differentiated phenotypes. The expression of nestin and β-III tubulin 
represented the ectoderm lineage (Figure 3.12 A, B). The mesoderm phenotype 
was detected by the expression of Desmin, which represents intermediate filament 
in smooth muscle cells as well as expression of Alpha smooth muscle actin (α-
SMA) (Figure 3.12 C, D). The hepatocellular marker Alpha- fetoprotein (AFP) and 
intermediate filament that is derived from mesenchymal cells, vimentin, were 
revealed confirming mesoderm derived cells (Figure 3.12 E, F). The expression of 
the three germ layer markers in these cultures of spontaneous in vitro 
differentiation further confirm the pluripotent properties of this iPS cell line. 
Furthermore, EBs were obtained when dissociated iPS WGE C9 cells were 
incubated with iPS cell medium in the absence of bFGF (Figure 3.11 A).  
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Figure 3.11 Bright field images presenting trigerminal differentiation in vitro. EB formation from the iPS 
cell lines (iPS WGE C9) in iPS medium without the additional of bFGF, cultured for 7 days (A). Morphology of 
endothelial cells (B), muscle cells (C), and neuronal cells (D) were observed following the spontaneous 
differentiation protocol (Scale bar=0.10 mm A-C; scale bar=0.03 mm D). 
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Figure 3.12 Characterisation of In vitro spontaneous differentiation of iPS cells derived from human 
WGE (iPS WGE C9). Immunofluorescence analysis of nestin and β-III Tubullin (A, B) representing  ectoderm 
lineage, Desmin and α-SMA (C, D) representative of a mesoderm lineage, and AFP and Vimentin (E, F) 
showing endoderm lineage. Scale bars, 50 µm.   
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3.5.4 Molecular Analysis of iPS cells.  
Reverse Transcriptase PCR (RT-PCR) analysis  
 Gene expression analysis was carried out on the iPS cell line C9 at various 
passages (P37, 38, 39 and 41) using RT-PCR analysis and pluripotent gene 
expression markers. The results confirmed the consistent expression of essential 
pluripotent transcription factors- Oct4, Sox2, Nanog, Lin28, c-Myc, and Klf4 
(Figure 3.13).  
 
Figure 3.13 RT-PCR analysis of the pluripotent genes expression: Oct4 (573 bp), Nanog (391 
bp) and Klf4 (397 bp), Sox2 (428 bp), Lin28 (323 bp) and c-Myc (328 bp) in the piggyBac 
Transposon –generated iPS cell line at different passages (C9 at P37, 38, 39, 41).  
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3.5.5 In vivo differentiation of iPS cell line (iPS WGE C9).  
Further evidence of established iPS cell pluripotency can be shown 
following injection of these cells subcutaneously into immunodeficient mice (Figure 
3.14 A). Tumour formation emerged within 8-10 weeks after iPS cells were 
injected (N=2) (Figure 3.14 A, B). The tumour was surgically dissected, fixed and 
processed for immuno-histochemistry using H&E staining to distinguish cells’ 
component within the tumour (Figure 3.15). H&E stained sections (Figure 3.15) 
revealed components of all three germ layers thus confirming pluripotency of the 
established iPS cells. 
 
Figure 3.14 In vivo differentiation characterize pluripotency of iPS cells. At week 8, a tumour 
appeared after subcutaneous injection with iPS cells (iPS WGE623 C9) mixed 1:1 with matrigel 
(A). The tumour was 2 cm in size (B) and was surgically dissected from the animals.  
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Figure 3.15 Teratomas generated from piggyBac transposon derived iPS cells showing differentiation 
to all three germ layers. An 8 week teratoma was processed and stained with H&E. The histological sections 
presented trigerminal differentiation of ectodermal cell neural rosette (A and arrow) and pigmented cells (B); 
mesodermal cells such as chondroblasts (C) and smooth muscle fiber  (D and arrow); endodermal such as 
adipose tissue (E) and gland tissue (F). (Scale bar=0.01mm) 
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3.6 Discussion 
 
 The piggyBac transposon strategy provides an effective method to 
reprogramme somatic cells that is comparable in its efficiency to the viral vector 
approaches (Grabundzija et al., 2013). Moreover, different human tissue sources 
such as fibroblast, primary neural tissue, and some cell phenotypes that have 
been reported to be difficult to reprogram, such as T cells (Staerk et al., 2010), can 
be successfully reprogrammed to a pluripotent state using  piggyBac (Yusa et al., 
2009; Woltjen et al., 2009; Grabundzija et al., 2012). This may suggest a high 
efficiency of the piggyBac transposon gene deliver strategy. In this study, we could 
identify more than 48 ES cell-like colonies depending on the starting material used 
with WGE tissue resulting in the greatest number of clones. In addition, we 
observed the continued emergence of ES cell-like colonies in culture with a time 
line similar to that described by Woltjen et al (Woltjen et al., 2009). Whilst there 
was variability in the number of colonies formed depending on the tissue source 
(as few as 2-7 colonies from HEF compared to more than 48 colonies from WGE) 
it is clear that overall the piggyBac transposon method is efficient in generating 
pluripotent cell colonies from these tissue sources. It was not feasible to collect 
every colony that formed and thus up to 48 colonies were picked per condition.  
 Many studies have suggested that a higher number of reprogramming 
factors increased the efficiency of inducing a pluripotent state in differentiated cells 
(Woltjen et al., 2009, Muenthaisong et al., 2013). Woltjen and colleagues (2009) 
suggested a 4 times higher reprogramming efficiency when utilising 5 
reprogramming factors (OSKML) compared to 4 factors (OSKM) (Woltjent et al., 
2009). Recently, a similar trend was revealed by Grabundzija and team where 
using 5 factors (OSKML) not only increased the yield of iPS colonies but also 
shortened the time spent before the first colony was recognized when compared 
to the application of 4 factors (Grabundzija et al., 2013). Aasen and coworkers 
reported a significant conversion efficiency up to 100 folds higher and more rapid 
kinetics up to 2 folds when human keratinocytes were used as the originate cells 
comparing to human fibroblasts (Aasen et al., 2008). This may suggest a plasticity 
and feasibility differences among various cell types in order to generate iPS cell 
lines. In our study, we applied 5 reprogramming factors to various human primary 
tissues with the same gene delivery method piggyBac transposition. As mentioned 
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already the number of colonies generated varied, as did the time taken in vitro to 
observe the first iPS colony, which took 2-3 weeks longer in fibroblasts compared 
to neural tissue. This may associate with the idea that naturally high expression of 
the endogenous pluripotent gene Sox2 in human primary neural tissue may 
accelerate the efficiency of iPS cell generation (Kim JB et al., 2009). Compared to 
previous studies in which fibroblasts have been used and a similar strategy of 
transposon gene transporting system have been applied, we observed iPS cell 
colonies as early as 2-3 days after transfection. Furthermore, the plasticity in the 
different tissue donors may affect the reprogramming capacity as reported by Kim 
et al. (Kim J et al., 2011). In this study, postnatal cortex was unable to be 
reprogrammed to a pluripotent state with the original 4 factors of Oct4, Sox2, Klf-4, 
and c-Myc unless neuronal activation genes and p53 were suppressed (Kim J et 
al., 2011). Thus, this suggests that the human fetal neural tissues used in our 
study may be more plastic, which may then enhance the reprogramming efficiency 
resulting in a richness of iPS colonies without the need to repress the activity of 
neural genes.            
 Muenthaisong et al in 2013 reported the derivation of iPS cells from distinct 
genetic background mice (Muenthaisong et al., 2013). They suggested that the 
differences in genetic background had an effect relating to the efficiency in 
pluripotent state conversion as well as differentiation potential from each 
established iPS cell line. In agreement with these findings, we observed difficulties 
in reprogramming iPS cell from some donors such as HEFs from SWIFT number 
815. Even though many attempts and optimized protocols were applied, iPS cell 
lines could not be propagated from this donor. Interestingly, iPS WGE623 C9, the 
first iPS cell line derived in our hands have struggled to differentiate thoroughly to 
a neural lineage and could not be differentiate into MSNs, in contrast to other 
established iPS lines derived in house (see chapter 4).     
 In the normal human genome it has been reported that there are 18 
integrations sites available for transposons (Wilson et al., 2007). Using the 
piggyBac transposon method in HEK293 cells, it has been found that there are as 
many as 15 integrations in the cells genome (Wilson et al., 2007). Whilst this 
would be of great benefit for gene therapy, in this situation in which we aim to 
generate integration free cell lines, it poses a significant problem. This finding was 
in accordance with other studies such as that reported from Woltjen et al (2009) 
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which claimed to identify an average of 9 transgene integration sites in an iPS 
clone generated using the same system (Woltjen et al., 2009). At the same time, 
Yusa et al (2009) also suggested that a minimum requirement of 3 integration 
sites was needed for efficient reprogramming of differentiated cells (Yusa et al., 
2009).  
The number of integration sites in the cell lines generated here is unknown 
due to technical difficulties with the southern blot technique. However, in an 
attempt to address this we will be able to detect transgene insertions using 
specific reverse primers of as shown in table 3.2 to identify the presence of 
exogenous transgenes remaining in our iPS cells (Woltjen et al., 2009).  
Davis et al (Davis et al 2013) stated that 2-3 integration sites were found in 
their iPS sub clones. Similarly Grabundzija and team (Grabundzija et al 2013), 
revealed at least 2 integration sites in the majority of their established iPS cell 
lines using the Sleeping Beauty (SB) transduction system; even though they 
reduced the DNA concentration of transposon used in the reprogramming process 
(Grabundzija et al., 2013). In addition, Davis and team also tested the method 
multiple times, but found re-insertion of the transgene into other integration sites 
after it was successfully removed from the initial integration site, thus failing to 
produce a transgene free iPS cell line (Davis et al., 2013).  
In terms of taking these cells forward for clinical application, viral gene 
integration or the presence of residual transgenes in the donor cells is unlikely to 
be acceptable. Many reprogramming strategies have been developed; however, 
with non-integration methods the reprogramming efficiency is low. Here our aim 
was to use the piggBac method as a non-viral method to generate iPS cells and 
whilst we successfully generated iPS cell lines as validated by their pluripotency 
and ability to form teratoma’s, these cells continued to express reprogramming 
factors that would inhibit their use clinically. This is a field that is progressing fast 
and it entirely possible that new methods will be identified sooner rather than later 
to overcome these issues.
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 Chapter 4 
Human iPS cell derived GABAergic MSNs-liked cells using 
EBs-Based Method. 
4.1 Introduction 
 Protocols for differentiating human PSCs towards MSNs have been refined 
from generating NPCs, to generating more specific phenotypes using ontological 
recapitulation of brain development (Song et al., 2007; Aubry et al., 2008; Li et al., 
2009; Ma et al., 2012; Delli Carri et al., 2013).  
Neuroepithelial cells have been generated from PSCs by different methods 
such as co-culture with stromal cells (Song et al., 2007; Aubry et al., 2008), multi-
aggregate cells as EBs (Li et al., 2009; Ma et al. 2012), and adherent monolayer 
method (Nasokin et al., 2009; Delli Carri et al., 2013). One disadvantage of neural 
induction by co-culture for applications such as cell implantation is the safety 
concern of exposing the host to the stromal cells such as the murine stromal cell 
lines PA6 (Song et al. 2007) and MS 5 (Aubry et al., 2008). In addition, this is a 
time consuming method as it takes several weeks to initiate and obtain the neuro 
epithelial cells. Therefore, multi-cellular aggregation as differentiated EBs was 
developed, imitating the development of the three germ layers in an embryo. 
However, other non-neural cells differentiating within the EB may interfere with the 
efficiency of neural differentiation by secreting signals to direct cells to lineages 
other than the desired ones and changing the microenvironment of the whole 
culture (Li et al., 2009; Ma et al. 2012). More recently, an adherent monolayer 
based method, which was first introduced by Nasonkin and colleagues in 2009, 
reported success in the generation of ‘authentic DARPP-32 MSNs’ (Delli Carri et 
al., 2013).  
 Ontogeny recapitulation protocols have been considered, improved and 
applied to human PSCs. PSC-derived NPCs were manipulated by either SHH (Ma 
et al., 2012), or a combination of SHH with a Wnt signalling antagonist DKK-1 to 
acquire a ventral telencephalic phenotype before terminal differentiation both in 
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vitro and in vivo (Aubry et al., 2008; Li et al., 2009; Delli Carri et al., 2013). Further 
differentiation of committed ventral telencephalic precursors was assessed 
chronologically by immunocytochemistry, RT-PCR, and Q-PCR for neural 
precursor markers, ventral telencephalic precursors, and post mitotic MSNs 
(Aubry et al., 2008; Li et al., 2009; Ma et al., 2012, Delli Carri et al., 2013). The 
different protocols achieved varying amounts of striatal neurons: Aubry et al. 
reported 53% DARPP32 expression within the 32% of GABA positive cells (Aubry 
et al., 2008); Ma et al. claimed that there was up to 89% DARPP32 positive cells 
within the 90% of GABAergic cells (Ma et al., 2012). Recently, Delli Carri reported 
approximately 20% co-labelling of Ctip2 and DARPP32 as a percentage of all cells 
(Delli Carri et al., 2013).  
Graft overgrowth was recognized in human PSC-derived striatal GABA 
positive grafts in the Aubry’s study, while Ma and Delli Carri claimed an absence 
of teratoma or neuronal overgrowth in their studies. After implanting human PSC-
derived MSNs like cells into the QA-lesioned rodent model of HD, improvements in 
behavioural tests, such as correction of locomotion deficits (Ma et al., 2012), and 
improved apomorphine induced rotations were reported, as well as an action 
potential firing pattern in these neurons (Delli Carri et al., 2013). Taken together, 
these studies show that human PSCs-derived MSNs are capable of providing 
large numbers of donor neurons with a variable proportion of these neurons 
having the sub-phenotype of MSN-like striatal projection neurons, potentially 
suitable for cell implantation therapy in HD.  
However, despite this, the proportions of MSN-like cells is generally lower 
than that developing from primary fetal WGE, and moreover, the behavioural 
improvement following implantation into animal models of HD fails to demonstrate 
the full range of behavioural improvements seen following transplantation of 
primary fetal WGE (reviewed in Reddington et al 2014 Frontiers in cellular 
neuroscience 2014 8, article 398.). One explanation for this is that the 
differentiation protocols used directed cells towards a subtype that displays many 
features of an MSN, but is not a “genuine” MSN.     
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In this chapter, we attempted to produce MSNs from human WGE iPS cells 
using methods based on these studies with further optimisation as described 
further below.  
4.2 Aims 
 In this chapter I hypothesise that (i) human iPS WGE cells can be 
differentiated to an MSN-like phenotype, both in vitro and after neural 
transplantation, and (ii) that epigenetic memory remaining in the iPS WGE cell 
lines may cause the cells to more readily differentiate into MSNs and may in 
addition enhance sub-type specific differentiation.   
The first step was to establish an in vitro differentiation protocol for directing 
iPS cells toward a GABAergic MSN phenotype. The iPS cell lines used were 
derived from WGE (The C9 clone and SWIFT numbers 928, 949, and 954).  We 
take advantage of the fact that the WGE iPS cell lines should already be primed to 
readily differentiate toward our desired MSN phenotype. A HEF line (SWIFT 
number 962), as described in detail previously in chapter 4, and an ES cell line 
(H9) were used for comparison. In addition, human primary fetal WGE was used 
as a source of “genuine” MSNs for comparison. iPS/ES cells underwent neuronal 
conversion protocols which comprised of 3 steps: neuronal induction, regional 
specification, and maturation. A combination of small molecules and morphogens 
were applied to the culture at specific time windows in order to produce projection 
GABAergic MSNs. The iPS derived-neurons were chronologically analysed with 
various methods such as RT-PCR, immunocytochemistry analysis so as to 
demonstrate neuronal markers related to MSNs induction. Finally, cells were 
transplanted into the QA-lesioned rat striatum and immunohistochemistry was 
used to analyse in vivo differentiation.  
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4.3 Experimental design 
 An EB based method was used to achieve striatal MSN differentiation. It 
can be described in 3 stages. First, we generated free floating multicellular 
aggregating cells or EBs from human iPS and ES cells and allowed them to 
proliferate and differentiate freely as described in the schematic in figure 4.1. (1). 
Second, neural induction was started by transferring these EBs into KSR medium 
(days 1-5) and N2/B27 medium (days 5-10) with a combination of selective 
molecules until rosette structures were recognized (2). Third, neuroepithelial cells 
from neural rosettes were subsequently pushed toward a ventral telencephalic 
phenotype generating committed regional specific telencephalic precursors using 
SHH and DKK-1. Following these three steps, these cells were terminally 
differentiated (methods described below) and maturated into striatal MSNs, 
confirmed by an expression of DARPP32 (3). Finally, iPS and ES derived MSN-
like donor cells at 30 days (the early post mitotic stage of mature MSNs confirming 
by positive expression of DARPP32) were implanted into the QA-lesioned rat 
striatum, as an HD model, with the intention to allow them to differentiate in vivo 
for 7 and 20 weeks (although as explained below, both time points had to be 
brought forward) (4). The brains were collected and processed to analyse 
phenotypic characterization using various methodologies (5).  
 
Figure 4.1 The schematic presents the experimental design for producing human iPS and ES derived 
GABAergic projection neurons (MSNs) using an EBs-based method to initiate neural induction in 
culture (1 and 2). A specific phenotype of MSNs-liked cells was generated using a combination of small 
molecules, morphogens, and growth factors supplement within N2/B27 medium (3). The human iPS and ES 
derived MSNs like cells were characterised by various methods (not shown on diagram) before being 
transplantation into a QA lesioned-rat model of HD (4). The surviving grafts were investigated by histology and 
immunohistochemistry (5). 
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4.4 Methods  
4.4.1 Induction and differentiation of ventral telencephalon progenitors and 
GABAergic MSNs from human iPS cells lines  
 Two differentiation methods are described, Protocol 1 is taken directly from 
(Arber et al., submitted) and was used to differentiate the iPS WGE623 C9 line. 
Following the unsuccessful differentiation of this line, I modified the protocol and 
this is termed protocol 2 (currently unpublished). The second protocol was 
eventually also applied to iPS WGE623 C9. 
Protocol 1 
  The whole EBs from iPS WGE623 C9 were re-plated onto a matrigel 
coated tissue culture plate. Neural induction was induced in this culture by 
supplementing KSR medium with dual SMAD inhibitors-SB431542 (10 µM) and  
Noggin (500 ng/ml) (Figure 4.2). From day 6-9, the KSR medium was substituted 
by N2B27 medium. The combination of exogenous signalling regulators (Noggin, 
Dorsomorphin (200 nM), Activin A (25 ng/ml), SHH (200 ng/ml)) was described as 
seen in figure 4.2. Neural progenitors were patterned further to a restricted region 
of ventral telencephalon by exposure to the morphogens SHH from 9 to 26 DIV. At 
9 and 18 DIV, attached-EBs were detached, dissociated as single cell suspension 
using enzymatic digestion reagent Accutase® (1 Unit/ml) in N2B27 medium with 
the addition of ROCK inhibitor (Y-27632) and re-cultured on PLL-POL-Laminin 
treated coverslips. In terminal differentiation and maturation, cells were cultured 
with N2B27 medium supplemented with BDNF (10 µg/ml), GDNF (10 µg/ml), and 
ascorbic acid (200µM). 
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Figure 4.2 Protocol 1: The schematic shows the time line of human ES and iPS cells (iPS WGE C9) 
differentiation toward an MSN specific phenotype in vitro by using a chemical defined medium with 
exogenous signalling regulators as shown in the picture. (Arber et al., submitted) 
 
Protocol 2 
Human iPS cells (line 928, 949, 954, 962, and eventually C9) were 
maintained and expanded on an irradiated MEFs feeder layer as described by 
Thompson et al (Thomson et al., 1998). This protocol was improved and based on 
many previous published papers (Aubry et al., 2008; Chamber et al., 2009; Ma et 
al., 2012; Delli Carri et al., 2013; Arber et al., submitted). Firstly, neuronal 
induction was initiated by manually separating the iPS colonies into small clumps 
using a sterilized glass pipette. The tissues were then harvested and cultured in 
suspension as ‘EBs’ in human iPS medium without addition of bFGF for 2 days. 
From day 3-5, the EBs were transferred to culture in the presence of SB431542 
(10 µM), Noggin (500 µg/ml), Dorsomorphin (200 µM), SHH (100 ng/ml), and 
DKK-1 (100 ng/ml) in KSR medium. At this stage, the iPS cells were allowed to 
differentiate freely as EBs, however, additional dual SMAD inhibitors (SB431542 
and Noggin) were pushed the iPS cells toward ectodermal differentiation by inhibit 
BMP and Lefty/Activin/TGFβ pathways in order to obtain a higher yield of 
ectoderm lineage especially neural cells (Chamber et al., 2009). Moreover, 
dorsomorphin was supplemented in order to further inhibit BMP pathway as triple 
SMAD inhibitors (Arber et al., submitted). Regional differentiation toward ventral 
telencephalon by SHH and DKK-1 supplement were induced as early as in the 
neural induction stage.  
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Then, EBs were again placed in neural induction medium (N2/B27 medium) 
supplemented with the previously mentioned-combinations for up to 10 DIV in 
order to induce neuronal progenitor differentiation (Figure 4.3).  
 For regional patterning toward ventral telencephalon, neuronal precursor 
clusters were produced in 2 different ways. First, EBs were dissociated with 
Accutase® (1 Unit/ml) at 37°C for 5-7 minutes. Second, whole EBs were attached 
on matrigel coated tissue culture plate for several days before being dissociated 
with  Accutase® as mentioned earlier. The cells were further separated into single 
cell suspension and placed onto PLL-POL-Laminin treated coverslips. Then the 
cells were cultured in neural precursors medium with SHH and DKK-1 
supplemented up to 26 DIV. The combination of SHH and DKK-1 gave a 
synergetic effect incomparison to use only one factor of SHH (Delli Carri et al., 
2013). Moreover, the most effective concentration SHH for LGE patterning was 
reported at 200 ng/ml (Ma et al., 2012). Therefore, in this experiment, we decided 
to add 100 ng/ml SHH incombination with 100 ng/ml DKK-1 in order to gain a 
benefit from the synergetic effect with the most effective LGE conversion 
efficiency.  In addition, Activin A (25 ng/ml) was supplemented into the medium 
from day 22-30 so as to encourage neural telencephalic progenitors by promoting 
RA signalling pathway (Cambray et al., 2012). Moreover, Activin A was suggested 
to promote LGE precursor cells via SMAD 2/3 pathway, which further differentiate 
to mature MSNs (Arber et al., submitted).  
 Ventral progenitors were further persuaded to a maturation of GABAergic 
MSN subtype by using a group of trophic factors and small molecules Ascorbic 
acid (200 µg/ml), VPA (10mM/ml), BDNF (100 ng/ml), and GDNF (10 ng/ml). 
BDNF has been reported to get involve in adult neurogenesis, improve activities of 
GABAergic receptors (Waterhouse et al., 2012), and enhance GABAergic 
neuronal maturation, receptors and synapses (Yamada et al., 2002). Moreover, 
GDNF supplement has been suggested to accelerate branching and elongaging of 
neurites in primary cells cuture (Costantini and Isacson, 2000). From day 26-62, 
the cells were allowed to remain in culture in order to enable terminal 
differentiation and maturation (Figure 4.3).  
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 From the previous study, Aubry and co-workers suggested an appropriate 
time window to harvest the cells for transplantation at around 35-45 DIV because 
at this stage, the ES cells derived neurons were situated between a late 
proliferative stage and early post mitotic stage (Aubry et al., 2008). This will 
enhance the graft survival and allow the cells proliferating a little bit further in vivo 
without an overgrowth of high proliferative transplated precursors (Aubry et al., 
2008). In this study, in vivo differentiation within QA-lesioned rat model was 
performed by transplantation of iPS cell derived MSN-like precursors at 30 DIV, 
which DARPP32 positive cells were first recognized.   
 
Figure 4.3 Protocol 2: Schematic of the time line for neural induction from PSC using EBs-
Based method, which is described above. (EB= embryoid body, NI medium= neural induction 
medium, NPC= neural precursor cell)  
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4.4.2 Immunocytochemistry 
 Cells on the coated-coverslips were fixed in 4% PFA for 15 minutes at room 
temperature. Then 100% Ethanol was added to penetrate cells for 2 minutes. 
Blocking solution adding a suitable serum was applied at room temperature for 1 
hour. Following this, the cells were incubated overnight at 4°C with a wide range 
of primary antibodies (for antibody details see table below).  Alexaflour 488 and 
594 appropriated with the primary antibodies were performed at room temperature 
up to 2 hours.  Nuclei were stained with Hoechst for 5 minutes and washed with 
1XPBS prior to coverslip onto glass slides. 
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Primary 
antibody 
 
Isotope Clonal 
Type 
 
Concentration 
 
Supplier Code 
1. Sox2 IgG Rabbit 1:100 abcam ab97959 
2. PAX6 IgG Rabbit  1:500 abcam ab5790 
3. Nestin IgG Rabbit 1:1000 Millipore MAB5922 
4. ZO-1 IgG1 Mouse 1:200-1:500 BD Bioscience BD610966 
5. FoxP1 IgG Rabbit 1:500 abcam ab16645 
6. FoxP2 IgG Rabbit 1:500 abcam ab16046 
7. Ctip2 IgG  Rat 1:200-1:500 abcam ab18465 
8. TTF1 IgG Rabbit 1:200 abcam ab40880 
9. Islet1 IgG Rabbit 1:200 abcam ab20670 
10. GSH2 IgG Rabbit 1:200 abcam  ab26255 
11. β-III tubullin - Rabbit 1:1000 Sigma T2200 
12. MAP2ab IgG1 Mouse 1:200 abcam  ab36447 
13. Dlx1 IgG2a Mouse 1:200-1:500 abcam ab54668 
14. Dlx2 IgG Rabbit 1:200-1:500 abcam ab18188 
15. DARPP32 IgG Rabbit 1:200 Santa Cruz SC11365 
16. hDARPP32 IgG Rabbit 1:1000 abcam ab40802 
17. FoxP1 IgG2a Mouse 1:200-1:500 abcam ab32010 
18. Synaptophysin IgG1 Mouse 1:100 abcam ab8049 
19. PSD95 IgG Rabbit 1:100 abcam ab18258 
20. GFAP IgG2b Mouse 1:1000 abcam ab10062 
21. Otx2 - Rabbit 1:500 Millipore MAB9566 
22. GABA IgG Rabbit 1:200-1:500 abcam ab9446 
23. Ki67 IgG1 Mouse 1:500 Dako M7240 
24. HuNu IgG1 Rabbit 1:500 Millipore MAB1281 
25. β-III tubullin IgG1 Mouse 1:1000 Sigma T9026 
26. GFAP IgG Rabbit 1:1000 Dako ZO334 
 
Table 4.1 Summary table of the primary antibodies used for immunocytochemistry and 
immunohistochemistry analysis both in vitro and in vivo studies.  
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4.4.3 Gene expression analysis 
 The RNA was purified from cultured cells using RNeasy kit from Qiagen the 
protocol as previous described in Chapter 2. cDNA were generate using 
SuperScript III reverse transcriptase and universal primers according to 
manufacturer’s instructions (Invitrogen). RT-PCR of the involved expressing gene 
and primer sequences were described in the table below. 
 
Table 4.2 Summary table of the primer sequences used for RT-PCR analysis of neural differentiation in 
vitro study from human PSCs derived MSN like-cells.  
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4.4.4 Striatal lesion and Transplantation 
 Adult male and female Spague-Dawley rats were used under local ethical 
guidelines and approved animal care according to the UK Animals (Scientific 
procedures) Act 1986. 7 days after unilateral QA-lesions to the right striatum (see 
chapter 2), rats were transplanted with 250,000 cells/µl (500,000 cells in total) of 
human iPS/ES cell derived-neuronal cells, prepared as a single cell suspension in 
DMEM/F12 medium. The transplantation side using stereotaxic coordinates was at 
+0.6 mm AP and -2.8 mm L from bregma, at two heights -5.0 mm and -4.0 mm 
below dura. Immunosuppression- Cyclosporin A was initiated (10 mg/kg) the day 
prior to transplantation and carried on daily until the end of the experiment. Rats 
were perfused at 4 and 7 weeks post transplantation (see Chapter 2 for details). 
Dr.Claire M. Kelly and Dr.Victoria Roberton, BRG, School of Bioscience, Cardiff 
University have done the work.  
 
4.4.5 Immunodetection on brain tissue slices 
 At different time periods post transplantation, animals were sacrificed and 
the brains were processed as follow described. Rats were perfused with cold 4% 
PFA for 5 minutes. Then the brains were dissected and fixed in 4%PFA overnight 
on a shaker. The following day, the brains were incubated with 25% sucrose in 
prewash solution for 48 hours or until they sank. Brains were coronally sectioned 
at 40 µm thickness using a freezing microtome. Sections were stored in anti-
freeze solution and stored at -20 degree. Free-floating immune- and DAB staining 
were as described in Chapter 2.   
 
4.4.6 Microscopy and analysis 
 Cells were visualized under UV fluorescence and images were collected 
using an Axiocam microscope with Axiovision program and a Leica DMRBE 
microscope with LAS V3.8 program.  
 
Chapter 4                                                                                  iPS cells derived GABAergic 
                                                                           MSNs-liked cells using EBs-Based Method. 
 
108 
 
4.4.7 Quantitation of grafts.   
Graft were visualized under the Leitz DRMB light microscope. Digitised 
images were visualized using a Hamamatsu C4752 video camera and NIH 1.55.2 
image analysis software, and the area corresponding to grafted tissue in each 
section was traced around and measured. Graft volume was subsequently 
calculated to be:  
 
Cell number was calculated in all cases by manually counting all cells from a 1:12 
series. 
The Abercrombie correction formula was the applied to calculate the total number 
of cells in the graft: 
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4.5 Results 
In vitro differentiation of human cell lines towards an MSN-like subtype: 
primary fetal WGE, iPS cells, and ES cells   
4.5.1 Human embryonic WGE differentiation in vitro.  
 Human primary WGE was used as the “gold standard” in this study. Human 
primary WGEs (SWIFT number 1006, 1037, 2073) (approximate crown rump 
length (CRL) 22-49 mm.) were dissected, dissociated and plated down for in vitro 
differentiation as single cells onto PLL coated-coverslips in N2B27 medium. 
Cultures were characterised using immunocytochemistry for markers of neurons 
and authentic MSNs at different times post plating (N=2 coverslips/condition). At 
10 DIV, the cells showed neuronal morphology with processes, small cell bodies 
and nuclei on phase contrast microscopy (Figure 4.4 A). The cells were fixed and 
immunocytochemistry was employed at 14 DIV (Figure 4.4 B, D, F, and G) and at 
22 DIV (Figure 4.4 E, H-L).  
Comparison of cultures at 14 DIV and 22 DIV (Figure 4.4 B, C respectively) 
revealed that Ki67 appeared to be less widely expressed by 22 DIV. Ventral 
forebrain markers-Dlx1, FoxP1, Islet1 were present by 14 DIV and persisted and 
expression was still evident at 22 DIV (Figure 4.4 D-I-E). Interestingly, the 
expression of FoxP1 (Figure 4.4 D, E), Dlx1 (Figure 4.4 G, H) and Dlx2 (Figure 4.4 
I) was presented in the cytoplasm at the earlier time point and then translocated to 
the nucleus with prolonged culture to 22 DIV. Expression of the terminally 
differentiated MSN marker, DARRP32, was recognized at 22 DIV co-labelled with 
Ctip2, an earlier marker of less mature MSNs (Figure 4.4 J). To elucidate 
functional neurons, PSD95 and synaptophysin markers involved in synaptic 
activity, were used and found to co-express with the neuronal markers Map2 and 
β-III tubulin at 22 DIV (Figure 4.4 K and L respectively). 
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Figure 4.4 WGE differentiation cultures. Characterisation and phenotypic potential of human primary WGE. 
Representative phase contrast and immunocytochemistry photomicrographs of differentiated human primary 
WGE (CRL= 49 mm.). Neuronal morphology under phase contrast at 14 DIV (Scale bar = 0.01 mm) (A) and 
expression of neuronal marker β-III tubulin (B,C). At 14DIV, human primary WGE demonstrated higher 
expression of proliferative neural cells with Ki67 co-expressed with β-III tubullin (B) compared to 22 DIV (C). 
Region specific characterization of ventral telencephalic markers FoxP1 (D,E), FoxP2 (F), Dlx1 (G,H), and 
Islet1 (H,I).  Expression of Dlx1 appeared in cytoplasm at 14 DIV (G), whereas at 22 DIV, its expression was 
present in the nuclei (H). A similar phenomena was seen for Dlx2 – nuclear staining only shown in I). At 22 
DIV, encoded ventral telencephalic proteins FoxP1 (E) and Dlx1 (H) translocated into nuclei. MSN marker 
DARRP32 co-expressing with Ctip2 (J) and expression of markers suggesting neuronal activity PSD95 (K), 
and synaptophysin (L). Scale bars= 50 µm (B-K) and 20 µm (L). 
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4.5.2 iPS WGE623-derived MSNs: C9 clone (protocol 1). 
  For differentiation of human iPS WGE623 C9 towards striatal MSNs, we 
employed the Arber and Li protocol (submitted), which has successfully generated 
DARPP32 positive cells both in vitro and in vivo. The iPS cell line WGE623 C9, 
the first iPS cell line generated in this thesis as previously mentioned in chapter 4, 
was differentiated toward MSN-like cells following this protocol. The iPS cells were 
allowed to differentiate as EBs for 48 hours before re-plating onto a Matrigel 
coated culture plate. Neural rosette structures are represented by a group of 
radially elongated shaped cells arranged as a flower-like structure (Figure 4.5 A), 
appeared around 6 DIV after subsequently exchanging defined medium with a 
combination of small molecules, growth factors and morphogens.  
Photomicrographs of human iPS WGE623 C9-derived neural cells were 
labelled for the neural progenitor marker nestin (Figure 4.5 B, C), and expression 
of  zonula occludens-1 (ZO-1) a tight junction marker expressed by neuroepithelial 
cells during development of the neural plate, was also seen - figure 4.5 B. With 
time in vitro, ZO-1 expression gradually migrated towards the luminal area 
suggestive of formation of a neural tube-like structure as occurs in development 
(Figure 4.5 C). At 9 and 18 DIV, these cells were passaged and re-attached onto 
culture plates and coverslips with an exchange of N2B27 medium and chemical 
combinations as described in figure 4.3. Neuronal morphological appearances 
were obtained with expression by immuno fluorescence positive for β-III tubulin 
(Figure 4.5 D, E). The ventral telencephalic marker ‘Islet1’ was also identified in 
the culture at 25 DIV fixed cells (Figure 4.5 F). 
 After passage 2, around 20-24 DIV, small islands of ES-like cells emerged 
among the differentiated neural like-cells, later on taking over the whole culture 
(Figure 4.5 G). These aggregations of cells were immunopositive for the 
pluripotent markers Oct4 and SSEA4 (Figure 4.5 H and I). The protocol was then 
optimised to prolong the EB stage and extend time of SMAD inhibition in culture 
and the number of re-plated cells was optimized under different cell densities 
(5x104, 7.5x104, 1x105 cells/coverslips). However, the same situation with 
appearance of ES-like cells took place at similar time point (after passage 2 
around 20-24 DIV). To try to address this, the iPS cell line WGE623 C9 underwent 
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second transfection of transposase enzyme in a further attempt to remove the 
residual transgenes.  
 
Figure 4.5 Photomicrographs presenting expression of neural marker series and pluripotent markers 
from iPS WGE623 C9 derived-MSNs study. Neural rosette formation emerged at around 6 DIV (A). By the 
first passage (9 DIV), the cells demonstrated expression of neural progenitor nestin with the cell adherent 
marker ZO-1 (B). Initially, ZO-1 was expressed at the cell membrane surface (B) but with progression of 
neural rosette rearrangement the expression of ZO-1 became concentrated next to the luminal area (B, C, 
respectively). After passage 1, iPS cell derived-MSNs obtained neuronal morphological appearances as can 
be recognized by phase contrast (D) and demonstrated expression of the more mature neuronal marker β-III 
tubulin (E). Regional specification of the ventral telencephalic marker Islet1 was seen at 25 DIV (F). ES-like 
colonies emerged around 20-24 DIV after passage 2 and the same event kept repeating in other rounds of 
differentiation (G). The ES-like colonies expressed pluripotent markers of Oct4 and SSEA4 (H and I, 
respectively). (Scale bar= 0.10 mm A, D, G; Scale bar= 50 µm B, C, E, F, H, I)   
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EB-Based Method for differentiation of neurons from human iPS and ES 
cells (protocol 2). 
4.5.3 Human iPS and ES derived MSNs-liked cells. 
  Following the problems differentiating the iPS WGE623 C9 clone, 
further iPS cell lines were generated, and the transgene inserts were attempted to 
remove before the iPS cells were differentiated toward neural lineage. In addition, 
I developed a novel neural differentiation protocol based on many previous 
published articles (Aubry et al., 2008; Chamber et al., 2009; Ma et al., 2012; Delli 
Carri et al., 2013; Arber et al., submitted) in order to obtain the desired MSN-like 
projection neurons suitable for cells therapy in HD (Figure 4.2). This was used to 
differentiate the various PSC lines including human ES cells (H9), iPS cell lines 
WGE623 C9, WGE 928, WGE 949, WGE 954, and HEF 962.  All PSCs lines were 
able to form EB structures when detached from MEFs and clumps of PSC 
differentiated as multi-aggregated cells in ES medium without FGF2 supplement 
(figure 4.6 A-F). The generated-EBs did not appear different in their morphology 
when different cell lines were compared in this way. The EBs at 10 DIV were 
allowed to attach on matrigel coated-plates and were further cultured in defined 
chemical medium until neural rosette emerged over the next 2-6 day (Figure 4.6 
G, H). Neural rosette structures were recognized by columnar epithelial cells 
arranged around luminal area in radius direction (Figure 4.6 G). 
Immunofluorescent Hoechst positive nuclei exemplified the structure of neural 
rosettes (Figure 4.6 H).    
Neural rosettes were dissociated and re-attached onto PLL-POL-laminin 
coated culture vessels and coverslips in selective defined medium. The plated cell 
morphology at the earlier stage (12-16 DIV) of differentiation was observed as 
ovoid or elongated shaped cell bodies with short and fine processes comparable 
to neural precursor cells (Figure 4.7 A, C, E, G, I). In contrast to the differentiation 
of the iPS WGE623 C9 clone up to 25-30 DIV, these cells progressively obtained 
neuronal morphological appearances as described by smaller and tighter cells’ 
bodies sending out thick and long neurites (Figure 4.7 B, D, F, H, J).  Different 
human ES and iPS cell lines exhibited a similar pattern of in vitro differentiation 
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from neuroepithelial to neural precursor cell morphology and in becoming 
neuronal like-cells at a later stage.  
 
Figure 4.6 Photomicrographs of EBs formation generated from various human ES and iPS cells lines 
(A-F). Human ES cell (H9) and established iPS cells iPS WGE C9, WGE 928, WGE 949, WGE 954, and HEF 
962 formed EBs after re-suspended in ES medium without bFGF supplement (A-F, respectively). Rosette 
structures appeared like a group of flowers in PSC differentiation, using the EBs based protocol when re-
adhered to the culture plastic (G). A comparison of bright field photomicrograph and immuno-fluorescence of 
nuclei staining (HOECHST) illustrated the rosette structure (H). (Scale bar=0.03 mm (A-G); Scale bar= 10 µm 
H)   
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Figure 4.7 Photomicrographs showing the neuronal morphological appearances of neurally 
differentiated PSCs. An early stage of differentiation after passage 1 is shown in the left hand column (A= 
human ES cell, C= iPS WGE 928, E= iPS WGE 949, G= iPS WGE 954, I= iPS HEF 962). Following 
maturation in vitro, cells gained a morphology close to neuron like cells, with long neurites and small cell 
bodies (B= human ES cell, D= iPS WGE 928, F= iPS WGE 949, H= iPS WGE 954, J= iPS HEF 962) (Scale 
bar= 0.10 mm).  
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Characterisation of iPS cell lines following differentiation towards a striatal 
MSN phenotype.  
 To test our improved MSNs derived-protocol, 5 iPS cell lines (4 derived 
from WGE: 928, 949, 954, and WGE623 C9; and one HEF line: 962) and a 
standard human ES cell line (H9) were compared. Prior to differentiation, all iPS 
cell lines presented typical pluripotent properties by expressing a variety of 
pluripotent markers such as Oct4, Nanog, SSEA4, and Tra-1-60, with no 
differences between lines. In addition, they were indistinguishable in these 
respects from the standard human ES cell (Chapter 3). 
4.5.4 iPS WGE 928 derived MSNs. 
  The iPS WGE 928 cell line was monitored from 0 to 62 DIV using 
immunocytochemistry and RT-PCR. The neural induction step used triple SMAD 
inhibition of SB431542, Noggin, and Dorsomorphin from day 0-22 (Figure 4.2). 
Neural rosettes were recognized as early as 2-6 DIV and progressively more were 
recognized around 6-9 DIV. Immuno-fluorescence staining indicated that at 7 DIV, 
the elongated shape of neuroepithelial cells demonstrated a homogeneity 
expressing neural precursor markers of nestin and Sox2 (Figure 4.8 A, B). After 
passage (passage 1) and re-plating as single cells, the dissociated cells were 
highly proliferative as demonstrated by the expression of Ki67 positive cells 
(Figure 4.8 C). ZO-1 expression was present at the luminal side of rosettes 
confirming generation of neural tube-like structures in vitro (Figure 4.8 A and B). In 
addition, subsequent passages were needed as the neural rosette structures 
continued to emerge up to 60 DIV. A heterogeneous population of immature and 
mature cells was illustrated by the expression of neurons with β-III tubulin 
confirming and neural precursors with nestin positive cells (Figure 4.8 D). At this 
stage, a lot of cell death was observed, probably resulting from the combination of 
defined culture medium, cytokines and morphogens. Cells that failed to 
differentiate along a neural lineage did not survive in this environment and dead 
cells were constantly discarded by exchanging the culture medium.  
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 Regional specific commitment to ventral telencephalon fate was induced by 
SHH and DKK-1 applied into N2B27 medium supplement up to 26 DIV (see 
schematic Figure 5.2). The phenotype of ventral telencephalon identities was 
ensured by the expression of specific markers within this compartment such as 
FoxP2, GSH2, Dlx1, Dlx2, and Islet1 (Figure 4.8 E-H, respectively). Furthermore, 
the post mitotic neuronal marker microtubule-associated protein 2 (MAP2) was 
seen co-expressed with the LGE marker glutathione synthetase (GSH2) (Figure 
4.8 F). In the maturation stage, the committed telencephalic precursors were 
persuaded toward post mitotic neurons with a striatal projection phenotype by 
subsequently separating and re-adhering on PLL-POL-laminin pre-treated tissue 
culture plates. Culture medium was supplemented with Fibronectin, Activin A, and 
VPA around DIV 16 to 26. Next, for terminal differentiation of MSN-like neurons, 
cells were cultured in N2B27 with addition of BDNF, GDNF, and ascorbic acid. 
Ctip2 is exclusively expressed by DARPP32 positive neurons within the striatum, 
was clearly elucidated in high intensity with a nuclear stain of HOECHST around 
25-30 DIV while there was a small number of DARRP32 positive cells at this stage 
(Figure 4.8 I and inset).  
Between 30 DIV and 62 DIV, there was an increase of presumed post 
mitotic MSNs as recognised by DARPP32 expression compared to 30 DIV (Figure 
4.8 J). Moreover, co-expression of Ctip2 with DARPP32 positive cells was seen at 
this time point (Figure 4.8 J and K).  
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Figure 4.8 Phenotypic characterisation of striatal progenitors and MSN-like striatal projection neurons 
derived from iPS WGE 928 line. Typical neural rosette structure demonstrated proliferative properties by 
expressing neural precursor markers nestin and Sox2 with the proliferative marker Ki67 (A-C). Within the 
culture, heterogeneous populations of neural precursors with more mature neurons expressed nestin and β-III 
tubulin (D). Committed ventral telencephalic phenotypes were confirmed with positive immune-reactivity of 
FoxP2, GSH2, Dlx1, Dlx2, and Islet1 (E-H). Ctip2, a marker of post mitotic MSNs, was expressed with high 
intensity (I) concomitant with DARPP32 expression at later time in culture (inset). DARPP32 expression was 
intense in cells’ body area and its expression was increased over time (J). A confocal reconstruction 
confirmed that human iPS cells derived from the WGE co-expressed DARPP32 and Ctip2, typical of a striatal 
projection neuron (MSN-like cells) (K). (Scale bar= 20 µm A-F; Scale bar= 50 µm G-I; Scale bar= 10 µm J,K) 
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Testing the reproducibility of the differentiation protocol in 
differentiating iPS cell lines towards striatal MSNs. 
4.5.5 iPS WGE 949 derived MSNs. 
 To evaluate the efficiency and consistency of the differentiation results, the 
protocol was applied to other PSC lines.  The WGE 949 line, which was produced 
in a similar way to 928 (ie from the induction of early neural spheres) achieved 
similar results to the iPS WGE 928 line. Neuroepithelial cells generated from 
rosette structures were present in a conventional rosette construction with 
expression of stage-matched markers of Sox2 and ZO-1 (Figure 4.9 (A)). 
Chronological expression of neural markers from neural precursors to regional 
ventral telencephalic precursors were revealed over time in in vitro differentiation 
(Figure 4.9). Nestin positive cells were seen promptly after passage 1 (11 DIV) 
(Figure 4.9 B), while later on these cells acquired immune-reactivity against β-III 
tubullin and MAP2 indicating post mitotic neuronal identity (Figure 4.9 C, D). 
Committed ventral telencephalic phenotypes were revealed by Dlx1 which co-
expressed with Otx2 (a rostral regional marker) around 20-25 DIV, while striatal 
precursors were labelled with FoxP2 expressing cells throughout differentiation 
(Figure 4.9 E and G, respectively). At a later time in culture, glia cells emerged 
confirmed by expression of GFAP marker (Figure 4.9 F). The early post mitotic 
MSN precursor marker Ctip2 was abundantly observed in culture, and over time 
cells maturated into terminally differentiated MSNs with an increase in DARPP32 
expression coinciding with Ctip2 (Figure 4.9 H, I and inset).  
 In contrast to the iPS WGE 928 cell line, the iPS WGE 949 cell line seemed 
to have a lower proliferation capacity as observed during in vitro differentiation. 
This cell line could subsequently be passaged several times before acquiring a 
mature neuronal morphology around 30-40 DIV, whereas neural rosette structures 
were persistently recognized and need to be passaged after 60 DIV in iPS WGE 
928.  
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Figure 4.9 Phenotypic identification of in vitro differentiation from the iPS WGE 949 cell line. Sox2 is 
accompanied by ZO-1 at the luminal surface of rosette formation (A). Expression of stage specific markers of 
neural lineage nestin, β-III tubulin, MAP2 (B-D), regional committed ventral telencephalic precursor such as 
Dlx1 and FoxP2 expressed in response to SHH and DKK-1 (E, G). MSNs precursor marker Ctip2 and 
terminally differentiated MSN marker DARPP32 were revealed co-labelling within the nuclei and cytoplasmic 
area respectively (H, I and inset). (Scale bar= 20 µm)  
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4.5.6 iPS WGE 954 derived MSNs. 
 The iPS WGE 954 cell line was generated differently from WGE 928 as the 
original cells were human primary WGE, rather than neural spheres obtained from 
human primary WGE. Again, the improved protocol was applied to this line to test 
the reliability of differentiation into MSN-like cells.  
 The panel of immuno-micrographs revealed stage-specific gene expression 
from the beginning as NPC differentiated to terminal post mitotic DARPP32 
expressing neurons (Figure 4.10). Expression of nestin was seen in almost all 
cells in the culture (Figure 4.10 A). Over time, their appearance changed and they 
gained morphological features similar to neuronal cells with expression of β-III 
tubulin (Figure 4.10 C). Ventral telencephalic fate was demonstrated by the 
presence of Dlx1 and Dlx2 expression (Figure 4.10 B). The regional specific LGE 
marker FoxP2 was also present in a subset of cells expressing β-III tubulin (Figure 
4.10 C). Glial cells emerged around 28-30 DIV with prolonged in vitro 
differentiation. Glial-like cells were seen as a monolayer sheet spread underneath 
extensive neurite processes and neuronal like-cells which expressed β-III tubullin 
(Figure 4.10 D). Expression of Ctip2 gradually increased over time in vitro (Figure 
4.10 E). Around 30 DIV, DARPP32 expressing cells were found predominantly in 
cells bodies and were observed co-labelling with Ctip2 positive cells (Figure 4.10 F 
and inset).  
 Of note, the iPS WGE 954 cell line exhibited a lower proliferation rate in 
comparison to the iPS WGE 928 and 949 cell lines. NPCs propagated from this 
iPS cell line proliferated in a similar ratio to the human ES cell (H9), which is 
further described in 4.5.8. After the second passage, iPS WGE 954 was cultured 
through to terminal differentiation and derived MSN-like cells without subsequent 
passages, similar to human ES cells. This was in contrast to iPS WGE 928 and 
949, which exhibited a sub population of neural progenitor cells and needed many 
subsequent rounds of passaging. Furthermore, only neural phenotypes were 
recognized uniformly in cultures of iPS WGE 954 after subsequent passage. In 
addition, pluripotent cell clusters were not latterly seen in this culture.  
Chapter 4                                                                                  iPS cells derived GABAergic 
                                                                           MSNs-liked cells using EBs-Based Method. 
 
122 
 
 
Figure 4.10 Phenotypic characterization of in vitro differentiation of the iPS WGE 954 cell 
line. A sequential expression of time specific markers from early neuron- nestin expressing cells 
(A), to progressive increase of expression of sub regional ventral telencephalic markers Dlx1, Dlx2, 
and FoxP2 (B-C). With long term culture, gial cells were detected by the presence of GFAP (D). An 
increase in DARPP32 expression was seen coinciding with Ctip2 expression around 30 DIV. 
(Scale bar= 20 µm C-E, Scale bar= 50 µm A,B,F)  
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4.5.7 iPS HEF 962 derived neural cells. 
 In a parallel, a comparison was made with, an iPS cell line generated from 
HEFs using the afore-described differentiation method.  
 Following in vitro differentiation around 13-18 DIV, cells with a distinctive 
appearance similar to fibroblast-like cells were recognizable among the 
population. For neural induction, neural rosettes were formed within EBs in the 
free-floating differentiation process around 5-6 DIV. After re-plating EBs on 
matrigel coated culture plate for 24 hours, definitive neuroepithelial cells were 
indicated by nestin expression. In addition, some cells were characteristic of 
neurons, with extended neurites and positive staining with β-III tubulin (Figure 4.11 
A). It was noticeable that cells expressing more mature differentiation markers (β-
III tubullin in this case) were mostly situated at the periphery of EB formation 
(Figure 4.11 A). After passage 1 (around 16-22 DIV), cells which were re-plated as 
a monolayer acquired a neural phenotype with evidence of immuno fluorescent 
positivity for nestin (Figure 4.11 B). These cells obtained a post mitotic neuronal 
phenotype at a later time point in culture (around 25-28 DIV), confirmed by Map2 
expression (Figure 4.11 C). Moreover, characteristics of early LGE cells and 
ventral telencephalic phenotypes were revealed by expression of FoxP2, Dlx1, 
Dlx2, and Iselt1 (Figure 4.11 D-F).  Unfortunately, the differentiating cultures 
became infected around day 28, therefore iPS cell line HEF962 have not been 
fully characterised because it was not possible to obtain results for DARPP32 
immunohistochemistry.   
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Figure 4.11 Phenotypic verification of in vitro differentiation from the iPS HEF 962 cell line. adherent-
EBs demonstrated Cellular heterogeneity with neural precursors and more mature neuronal phenotypes is 
demonstrated within an adherent EB by the presence of nestin and β-III tubullin respectively (A). Subsequent 
in vitro culture revealed much progress in terms of maturation as indicated by Map2 positive cells (C) and cell 
fate restriction to ventral telencephalic by (Islet1 expression)  (F) with more specific LGE structures (FoxP2, 
Dlx1 and 2 expression) (D-E).  (Scale bar= 50 µm A, B, F; Scale bar= 20 µm C-E)
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4.5.8 Human ES (H9) derived MSNs-liked cells. 
 The H9 human ES cell line was used in this study for comparison with our 
newly generated iPS cell lines. At 20-25 DIV, pluripotent markers of 
undifferentiated stem cells Oct4 and Tra-1-60 were not recognized in culture 
(Figure 4.12 A). Neuroepithelial propagation was again demonstrated via neural 
rosette formation expressing nestin positive cells (Figure 4.12 B). In addition, there 
was expression of proliferative cells expressing the nuclear proliferating marker-
Ki67 and co-labelling with neuronal cells with β-III tubullin expression (Figure 4.12 
C). Expression of Ki67 decreased over time in culture. In contrast, specific brain 
region markers representing ventral telencephalon, particularly the LGE, increased 
in expression under SHH and DKK-1 supplement over time, for example FoxP1, 
FoxP2, Islet1, and Dlx2 (Figure 4.12 D-F). At 30 DIV, a subset of glial cells with 
GFAP positive expression were detected among post mitotic differentiated 
neurons of Map2 (Figure 4.12 G). Striatal projection neurons were seen, as 
indicated by the expression of their precursor marker Ctip2 and DARPP32 (Figure 
4.12 H), and the co-expression of, DARPP32 with the post mitotic neuronal marker 
Map2 were observed (Figure 4.12 I). Notably, DARPP32 positive neurons were 
often recognized as a group rather than standing alone. This was not only 
observed in human ES cells derived-MSNs but the same phenomenon was also 
identified in human WGE primary cell culture and human iPS cells derived MSNs.      
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Figure 4.12 Phenotypic analysis of in vitro differentiation from human ES cell line (H9). No expression 
of the pluripotent genes Oct4 and Tra-1-60 (A). Stage-specific gene expression indicated neural rosette 
structures with expression of the neural precursor marker nestin and cell adherent molecule ZO-1 co-
expressed in a typical rosette appearance (B). Proliferating neuronal cells were still present at 20 DIV as 
indicated by Ki-67, a neuronal proliferation marker, however the expression was reduced over time in 
prolonged culture (C). In the presence of exogenous SHH and DKK-1, a ventral telencephalic phenotype was 
present as evidenced by FoxP1, FoxP2, Islet1, and Dlx2 positive cells (D-F). Around 30 DIV, bona fide MSNs 
with DARPP32 expression were enriched in the culture and co-labelled with Ctip2 (H) and Map2 (I) markers. 
(Scale bar= 50 µm)    
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4.5.9 iPS WGE623 C9 derived MSNs-liked cells: application of modified 
differentiation protocol (protocol 2). 
 Next, I decided to apply the modified EB-based protocol to iPS WGE623 
C9, which was previously unable to generate MSNs-liked cells, in order to probe 
whether the efficiency of the protocol or a general property of the iPS cell line was 
a hurdle for neuronal differentiation. Classical rosette structures were identified 
around 17 DIV after dissociation of adherent EBs and re-plating onto a PLL-POL-
Laminin coated vessel (Figure 4.13 A). Similar to the previous studies in all 
established iPS cell lines, nestin positive cells were abundantly recognized on 
neuroepithelial precursors whereas in contrast ZO-1 was demonstrated at the 
centre point (Figure 4.13 B). These NPCs exhibited Ki-67 expression along with a 
high demand for subsequent passaging (Figure 4.13 D).  
 Once again, pluripotent clusters emerged as in previous observations 
(4.5.2); even though we applied a double round of transgene removal process to 
this iPS cell line. Oct4 and Tra-1-60 positive cells were present after passage 2 
around 20-24 DIV, which corresponded to the previous studies (Figure 4.13 D). 
 
 
 
 
 
 
 
 
 
 
 
Chapter 4                                                                                  iPS cells derived GABAergic 
                                                                           MSNs-liked cells using EBs-Based Method. 
 
128 
 
 
 
Figure 4.13 Phenotypic analysis of in vitro differentiation from iPS WGE623 C9 cell line. Phase contrast 
micrograph presenting neural precursors after replating onto PLL-POL-Laminin coated coverslips in N2B27 at 
17 DIV (A). These cells reorganized and formed rosette structures identified by a typical appearance along 
with immune-reactivity against the neural precursor-nestin and the membrane marker-ZO-1 (B). High levels of 
proliferation were revealed by Ki-67 expressing cells (C). Stem cell-liked colonies subsequently emerged with 
prolonged culture, which can be recognized by their morphology as well as by immune-staining for pluripotent 
gene expression Oct4 and Tra-1-60 (D).(Scale bar= 50 µm)  
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In summary, 3 out of 5 established iPS cell lines and human ES cell line (H9) were 
shown to differentiate into DARPP32 positive cells and expressed the hallmark of 
neural/MSNs markers such as nestin, β-III tubulin, Map2, FoxP1, FoxP2, Dlx1, 
Dlx2, Islet1, GFAP and Ctip2. The iPS HEF 962 line could not be tested for 
DARPP32 expression due to the unexpected infection as outlined above, but 
using the improved protocol there was promising evidence that supported the 
differentiation of this iPS cell line toward a MSN phenotype as indicated by the 
expression of FoxP1, FoxP2, Dlx1, Dlx2, and Islet1. It is noteworthy that iPS 
HEF962 derived MSN experiment was unable to provide a fully diffetentiate 
results, therefore this may not a fair comparison between iPS WGE and iPS HEF 
cell lines derived MSNs in order to clarify benefits of epigenetic memories remain 
in different originated cells will provide an ease for MSN differentiation  
A comparison of neural/MSN marker expression between the PSC lines 
during in vitro differentiation toward MSNs was shown in table 4.3.  
 
 
Table 4.3 Summary table of neural/MSNs markers expression using immunocytochemistry analysis 
from 5 established iPS cell lines and human ES cell line (H9) during in vitro differentiation using  a 
protocol designed to encourage MSN differentiation. (++++ = 75-90% of total Hoechst cells, +++ = 50-
75% of Hoechst cells, ++ = 25-50% of Hoechst cells, + = 1-25% of Hoechst cells, - = no expression, N/A = Not 
available) 
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4.5.10 Expression of neural genes in iPS WGE 928 at the point of 
neural transplantation.   
 Cells need to be transplanted at a slightly earlier stage in their 
differentiation than those matured in vitro for immunocytochemical analysis, as 
described above. iPS WGE 928 cells prepared for neural transplantation were 
assessed by RT-PCR to assess neural conversion. The house keeping gene-
GAPDH was used as a control (Figure 4.14 A).  
The gene expression profile confirmed transformation of neural precursors to 
regional specific progenitors and importantly indicated that the cells carry an LGE-
like identify. By 24 DIV, the early neural genes nestin and Pax6 were seen along 
with GSH2, FoxP1 and FoxP2, the latter appearing to produce a more intense 
band by 35 DIV. Dlx1, known to be related to early LGE generation, was weak at 
24 DIV and stronger by 35 DIV.  DARPP32 was seen by 35 DIV only, (Figure 4.14 
G and H, respectively), corresponding to the emergence of DARPP32 positive 
neurons only after 30 DIV in the immunocytochemical analysis above.  Exogenous 
transgene expression was tracked from 17 to 44 DIV.  
 
Figure 4.14 Gene expression profile observed in neural conversion from iPS WGE 928 cell line. Phase 
contrast micrographs showing gene expression at 24 and 35 DIV using RT PCR. Shown are: GAPDH (A), 
Nestin (B), Pax6 (C), FoxP1 (D), FoxP2 (E), GSH2 (F), Dlx1 (G), DARPP32 (H).   
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Transplantation into the quinolinic acid-lesioned rat striatum 
In order to test the capacity of the iPS cells to differentiate into MSN-like 
cells following transplantation into the adult brain, one of the lines, iPS WGE 928, 
was directed in vitro to an MSN progenitor fate and then transplanted into the 
quinolinic-lesioned rat striatum.  The grafts were compared to H9 cells, similarly 
differentiated, and human primary WGE (the “gold standard”).  
4.5.11 Analysis of iPS WGE 928 grafts.  
 Although the initial intention had been to examine the grafts at 7 and 20 
weeks post transplantation, due to the appearance of ill health in some animals 
that may have been potentially due to graft overgrowth, the animals were 
sacrificed 4 and 7 weeks post transplantation for analysis.    
 Graft survival was demonstrated in all animals at 4 weeks (Figure 4.15 A-D, 
N=4) and 7 weeks (Figure 4.15 E-H, N=16) as revealed by HuNu positive staining.  
Grafted cells were seen to be contained within the lesioned striatum at 4 weeks, 
while by 7 weeks grafts had expanded further and invaded into the adjacent cortex 
(Figure 4.15). Around 6 weeks post-transplantation, we observed an obvious 
tumour emerging at the implantation side in one animal. In addition, the animal 
showed signs of ill health and thus the experiment was terminated at 7 weeks with 
all animals being sacrificed. Within the total number of 20 animals, there were 7 
animals containing invasive tumours, whereas the remaining 13 animals revealed 
good graft survival with no signs of overgrowth. Representative composite images 
of all the grafts at 4 and 7 weeks post transplantation is demonstrated in figure 
4.15 I and J. In addition, the grafted cells appeared to migrate out of the striatum 
into the adjacent cortex. 
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Figure 4.15 A representative 1꞉12 series of DAB staining showing graft morphology post 
transplantation. Surviving grafts were identified by HuNu positive cells which were largely 
restricted to the striatum at 4 weeks post implantation (A-D, N=4), but by 7 weeks had almost 
doubled in size suggesting continued proliferation of the grafted cells (E-H, N=4). Schematic 
comparison of graft borders from all transplanted animals is shown in I for 4 weeks (N=4) and J for 
7 weeks (N=4).      
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At 4 weeks post transplantation, HuNu positive cells were distributed in the 
lesioned striatum along with fine processes of nestin positive cells (Figure 4.16 (A-
D, N=4)). Nestin expression appeared limited to the graft area. At 7 weeks post 
transplantation (Figure 4.16 (E-H), one animal presented with some cells of a 
larger size situated in less dense areas (Figure 4.16 G and inset). The identity of 
these particular cells is currently unclear. 
Overall 7 out of 20 animals had brain tumours after transplantation. Six 
animals had extensive tumours identified in the cortex, while one animal had a 
tumour within the striatum (Figure 4.17 A, C). The brain tumours had defined 
borders, were not well integrated into the host brain, and easily fell out during 
brain dissection. Furthermore, the tumour itself was fragile many not surviving the 
ICC process. Haematoxicillin and Eosin (H&E) staining revealed a heterogenous 
population of cells within the area of overgrowth (Figure 4.17). Neural-rosette like 
structures within the graft were observed as epithelial cells with luminal structures 
(Figure 4.17 B and inset). Immunocytochemistry analysis revealed the tumour to 
contain proliferating graft-derived cells as confirmed by co-expression of HuNu 
and Ki-67 (Figure 4.17 C, D). In addition, there were some DARPP32 expressing 
cells in a subset of the grafted population.  
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Figure 4.16 Panel of representative photomicrographs showing grafts at 4 weeks (N=4) and 7 weeks 
(N=16) post engraftment. The left panel (A-D) demonstrates 4 weeks post transplantation, human grafted 
cells labelled by HuNu in brown together with nestin positive fibers (arrow head) in deep blue which are 
restricted to the grafts area. The right panel (E-H) revealed survival of grafts at 7 weeks post transplantation 
demonstrated by HuNu expressing cells showing that the grafts have breached the striatal borders (E-H). One 
animal presented with a morphology different to the other animals with pockets of larger unidentified cells 
within the graft G and higher power insert representing one of these pockets of cells. (Scale bar= 0.10 mm) 
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Figure 4.17 Characterization of iPS cell derived-tumour formation. The obvious disruption of striatum and 
cortex was revealed by H&E staining (A) scale bar = 0.01 mm. A large proportion of the graft contained 
neuroepithelial cells presented as neural rosette structures as seen in higher magnification; insert (B) scale 
bar = 0.03 mm. The cells within the tumour were positive for HuNu, indicating that they were graft-derived (C). 
MSN-like neurons were indicated by human specific DARPP32 expressing cells in a sub population of grafted 
cells (C (inset)). The proliferating nuclei marker Ki-67 was seen within the grafted region (D). 
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 Grafts were assessed for the expression of general neuronal markers and 
sub-type specific/MSN markers by immuno-histochemical analysis.  
At 7 weeks post transplantation, there was still evidence of proliferating 
cells within the grafts, shown by expression of Ki-67 (Figure 4.18 B). Ventral 
telencephalic precursors were as indicated by immuno-fluorescence reactivity 
against Gsh2 (Figure 4.18 A). In addition, β-III tubulin positive cell bodies and 
processes were seen co-labelled with the striatal MSN precursor marker FoxP1 
(figure 4.18 C). Grafted cells expressed markers characteristic of striatal projection 
neurons including GABA and DARPP32 (Figure 4.18 D and E, F, respectively).  
Human specific DARPP32 positive cells exhibiting typical neuronal 
morphologies were seen in the graft (Figure 4.18 E and F). Moreover, confocal 
analysis confirmed colabelling of DARPP32 with HuNu (Figure 4.19 A to D). 
Confocal microscopy was performed in 4 of the 9 surviving grafts without tumours; 
the other 5 brains were not suitable for high quality analysis as there was 
significant auto fluorescence from these sections.  Fluorescent microscopy 
demonstrated that the DARPP32 cells co-labelled with NeuN.  An additional 
observation was that the DARPP32 expressing cells accumulated as groups 
rather than single dispersed neurons, as previously mentioned in the in vitro study.  
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Figure 4.18 Phenotypic characterization of iPS WGE 928 derived MSNs-liked cells at 7 weeks post 
transplantation. A ventral telencephalic precursor identity was indicated by the presence of GSH2 
expressing cells (A). However, the graft still contained proliferating cells represented by Ki-67 (B). β-III tubullin 
positive neurons were present, co-labelling with FoxP1, indicating an LGE-like patterning of neuronal 
progenitors (C). GABAergic striatal projection neurons were indicated by GABA positive cells co-expressing 
with HuNu (D). DARPP32, a typical post mitotic MSNs marker, was observed co-labelling with NeuN (E) and 
HuNu (F).    
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Figure 4.19 Immuno-photomicrographs using confocal analysis showing expression of DARPP32 and 
HuNu in grafts at 7 weeks post transplantation. The co-labelling of DARPP32 and HuNu was 
demonstrated in the grafts of all animals analysed (N=4) (A-D). DARPP32 positive cells were generally 
identified as a group of cells within graft area rather than as single neurons dispersed throughout the graft.  
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4.5.12 Analysis of Human ES (H9) grafts.  
 Although the initial intention had been to sacrifice the animals at 7 and 20 
weeks post transplantation, we observed 2 out of 3 animals had signs of tumour 
development at 7 weeks. Therefore, the remaining animals were also sacrificed at 
7 weeks before the brains were collected and analysed. Overall, 2 out of 6 animals 
developed tumour at 7 weeks post transplantation with ES cell derived MSN-like 
cells.  
 Graft survival was recognized in all 6 animals. However, in the 2 animals 
that developed tumours, the brains were deformed and the tumour was too fragile 
for processing with immunohistochemistry. Although, the remnant of grafts were 
recognized in the intact brain area. There were differences in grafts size among 
the transplanted animals as exhibited by HuNu positive cells. In addition, all 
surviving grafts were situated in the striatal region and were not distributed 
throughout the cortex (N=4, excluding the 2 animals with tumours) (Figure 4.20).         
 Immunohistochemical analysis revealed DARPP32 expression in all 
surviving grafts (Figure 4.21). Co-expression of human specific DARPP32 with 
HuNu positive cells confirmed the presence of graft derived MSNs (Figure 4.21, 
inset). It is noteworthy that, as mentioned above for the iPS derived grafts, the 
DARPP32 positive cells were identified as an accumulation/group of cells in both 
human primary WGE (Figure 4.21, A) and human ES derived grafts (Figure 4.21, 
B-F).    
 The number of DARPP32 positive cells were assessed at 7 weeks post 
transplantation in both iPS (N=4) and ES (N=3) cells derived MSNs. A significantly 
higher number DARPP32 expressing neurons was obtained from iPS cells derived 
MSNs, p<0.001 (Figure 4.22). This was also reflected in the graft volume with 
there being a significantly higher graft volume from the iPS derived grafts than the 
ES cell derived grafts, p<0.05  (Figure 4.23).     
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Figure 4.20 Panel of representative photomicrographs showing H9-derived grafts at 7 weeks (N=4) 
post engraftment. The left panel (A-D) demonstrates 7 weeks post transplantation N=4 (Scale bar= 0.10 
mm) and the right panel at higher magnification (Scale bar= 0.05 mm), human grafted cells labelled by HuNu 
in brown which are restricted to the striatal area. Schematic comparison of graft borders from all transplanted 
animals is shown in E for human primary WGE transplanted brain as a control (N=1) and F for human ES-
derived MSNs grafts  (N=6; transplanted after 30 DIV) 
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Figure 4.21 Immuno-photomicrographs using confocal analysis showing expression of DARPP32 and 
HuNu in grafts at 7 weeks post transplantation. The co-labelling of DARPP32 and HuNu was 
demonstrated in the grafts of all animals analysed (N=4) (A-D). DARPP32 positive cells were generally 
identified as a cluster of cells within graft area rather than as individual neurons dispersed throughout the 
graft.  
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Figure 4.22 Graph presenting the total Graft volume of both the iPS (N=4) and ES (N=3) cell derived 
grafts at 7 weeks post transplantation. Statistical analysis using a standard t-test showed there to be a 
significant difference between the two graft groups, p<0.05. 
          
Figure 4.23 Graph presenting the total number of DARPP32 positive cells per graft in both the iPS 
(N=4) and ES (N=3) cell derived grafts at 7 weeks post transplantation. Statistical analysis using a 
standard t-test showed there to be a highly significant difference between the iPS and ES derived grafts, 
p<0.001. 
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4.5.13 Comparison of these results with the previous studies. 
 The schematic below summarizes the protocols for the generation of PSC 
derived-MSNs that have been published in the literature to date, Aubry et al. 
(2008), Ma et al. (2012), and Delli Carri et al. (2013) in comparison to the modified 
protocol we used in our study (Figure 4.24). 
 
Figure 4.24 Schematic of different protocols for deriving MSNs from PSCs reported in previous 
studies and this study. 3 different methods have been reported for MSNs differentiation from PSCs: co-
culture with stromal cells (Aubry et al., 2008), EBs method (Ma et al., 2012 and this study), monolayer based 
method (Delli Carri et al., 2013 and this study. Differences in combination of small molecules, growth factors, 
and morphogens presented in separate differentiation time lines.  
 
  As shown in table 4.4, it is demonstrated using our established iPS cell 
lines derived from human primary WGE, that we are able to differentiate these 
cells toward a neural lineage. In addition, sub type specific-MSN like-cells can be 
derived from these iPS cell lines using this modified protocol both in vitro and in 
vivo as confirmed by DARPP32 positive cells.  Furthermore, in our study, the 
differentiation time line from neural induction to neuronal maturation of DARPP32 
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positive cells was shortened compared to previous studies. LGE-like progenitors 
were expressed around 13-17 DIV as indicated by GSX positive cells. In addition, 
cells expressing Ctip2 were identified around 25-28 DIV compared to 45 DIV in 
Delli Carri et al. (2013).  These findings are in accordance with the expression of 
the MSN standard marker-DARPP32, which can be seen around 30 DIV in our 
study, 2 weeks earlier than the 45 DIV reported by Delli Carri et al. (2013).  
  
 
Table 4.4 Table summarises both in vitro and post transplantation results from the previous published 
studies of PSCs conversion to an MSN neuronal subtype. ES/iPS differentiation to striatal MSNs from 
Aubry et al. (2008), Ma et al., (2012), and Delli Carri et al., (2013) and the present study presented in 
categories of markers expression, differentiation efficiency, and evidence of tumour formation post 
transplantation.   
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4.6 Discussion 
4.6.1 Generation of Neural Progenitor cells and Neurons from Transposon-
mediated iPS cell.  
 The methodology for generation of iPS cells has been reported to play an 
important role in the distinctive properties of those iPS cell lines, which may be 
important for downstream application, for example it may influence their 
subsequent neural induction and neuronal differentiation. Ma and collaborators 
demonstrated that by using the same donor somatic cells and generating iPS cells 
using 2 different methods i) a nuclear transfer method and ii) the iPS cells 
generated from over expression of pluripotent transcription factors, that the 
reprogrammed cells had DNA methylation and transcriptome profiles that were 
characteristic of the starting somatic cells, thus suggesting this epigenetic memory 
may be advantageous to subsequent differentiation (Ma et al., 2014).  
In addition, it has been reported that, even though there is an alteration in 
genomic structure during the reprogramming process, this is not powerful enough 
to get rid of all the epigenetic memories (Blelloch et al., 2006; Ng and Gurdon, 
2005 and Ng and Gurdon, 2008). In this study, we hypothesised first, that iPS cells 
derived from fetal WGE could be differentiated to an MSN phenotype, and second 
that epigenetic memory remaining in the iPS cell lines could enhance sub-type 
specific differentiation to the desired MSN-like cells. Interestingly, it was suggested 
that correct functional cardiomyocytes can be better propagated from an iPS cell 
line generated from donor cardiomyocytes, rather than from donor cardiac 
fibroblasts (Rizzi et al., 2012). Therefore, we have generated iPS cell lines from 
human primary fetal WGE, cortex, and fibroblasts, and compared them, with 
respect to neural induction and neuronal differentiation specifically towards striatal 
MSNs.  
Our piggyBac transposon derived-neural progenitor cells produced a high 
number of nestin positive cells in all established iPS cell lines. Indeed, comparable 
expression of nestin positive cells was identified across all lines, 5 iPS cell lines 
(iPS WGE623 C9, iPS WGE 928, iPS WGE 949, iPS WGE 954, iPS HEF962) and 
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1 human ES cell line (H9) (as illustrated in table 5.3). In addition, we were 
successful in repeatedly generating NPCs from the different cell lines, whether 
they were ES or iPS cells, using the defined chemical combination method and 
these cells responded to stimuli using the same pathway. Thus confirming the 
efficiency of our neural induction protocol toward neural lineages.  
This contrasts to a study of ‘The Sleeping Beauty’ transposon mediated iPS 
cells, where the expression of nestin was 16 fold higher in ES-derived neuronal 
precursors (Klincumhom et al., 2012). Therefore, even though we use a similar 
strategy to generate iPS cells, a substantial increase in the proportion of nestin 
expressing cells was seen in our study. A direct comparison with the Sleeping 
Beauty approach would be required for confirmation and to explore this further. 
There are studies suggesting that epigenetic or a remnant of transcriptional 
memories being retained in donor tissue may be responsible for iPS cells showing 
a preference to differentiate down particular lineages (Bar-Nur et al., 2011; Ohi et 
al., 2011). In our study, using iPS HEF 962 cells we observed a recognizable 
amount of fibroblast-like cells upon neural differentiation.  Likewise, when 
differentiating WGE derived iPS cells a similar level of spontaneous differentiation 
was observed in all cell lines tested, thus suggesting that these iPS cells have a 
component of an epigenetic memory remaining, which results in them having a 
tendency to spontaneously differentiate back to the original cell phenotypes.  
 In the Klincumhom study mentioned above, donor mouse fibroblasts were 
used to generate iPS cell lines, whereas in our study, the iPS cells were generated 
from human primary neural tissue (WGE and cortex) thus the high yield of NPCs 
produced in our study may in part be due to the original starting material used to 
create our iPS cell lines. This favourable potential to generate specific lineages 
may offer advantages in sub-phenotypic neural differentiation in our study, which 
will be further described.  
There is increasing evidence of differences in the potential to generate 
NPCs from PSCs. This has recently been reported, not only between distinctive 
PSC lines, but also among different clones from the same cell line (Martinez et al., 
2011, Klincumhom et al., 2012). In addition, more recently, Salewski and team 
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reported a difference in the potential of NPCs derived from ES cells and PB-iPS 
(piggyBac) cells. They pin point an intrinsic distinction within ES versus PB-iPS 
cells in order to generate definitive neural spheres (Salewski et al., 2013). In our 
study, even though MSN-like cells, as determined by DARPP32 positive 
expression, were produced from 3 iPS WGE cell lines (excluding C9) and human 
ES cell line, there were differences with respect to their proliferation capacity, 
neural conversion efficiency, and ease of deriving post mitotic DARPP32 
expressing neurons. 
Out of the iPS WGE lines produced in this study, iPS WGE 954 performed 
most similarly to H9, in terms of the in vitro differentiation time lines and the 
expression of DARPP32. Interestingly, in iPS cell culture, higher proliferation was 
observed in all lines compared to H9 with repeated passaging being required. In 
addition, neural rosette structures were observed at 62 DIV in the iPS WGE 928 
cell line at a time when a more mature phenotype was being observed in the other 
cell lines. This may stem from the reprogramming process which normally requires 
more than 3 copies of pluripotent transgenes to be inserted into the host genome, 
as previously reported in 2009 (Kaji et al., 2009).  
In stark contrast to the lines just described, the iPS WGE623 C9 cell line 
could not be differentiated beyond the NPC stage, expressing Oct4 and Tra-1-60. 
Even though 2 different protocols (Arber et al., and our protocol) were used to 
differentiate this iPS cell line toward neural lineage, the expression of Oct4 and 
Tra-1-60 continually reappeared in the culture. This is in line with a study from 
Rhee et al which suggested that residual or reactivation of exogenous pluripotent 
genes may alter the terminal differentiation of these cells toward certain lineages 
(Rhee YH et al., 2011). In addition, Rhee also claimed that there was no evidence 
of any remaining transgene within their iPS cell lines which were generated using 
the protein based method when compared to reactivation of exogenous pluripotent 
genes that was found in their lentivirus based iPS cells (Rhee YH et al., 2011). 
This may suggest that the remnants of exogenous pluripotent transgenes in our 
cell lines could be a hurdle to complete neural differentiation.  
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In addition, it is well accepted that ES and iPS cells are not identical.  Whilst 
they share the characteristics of pluripotency and self-renewal there are reports of 
variability at the genomic level (Hu et al., 2010, Feng et al., 2010, Narsinh et al., 
2011, Bock et al., 2011). Thus, there is a strong likelihood that a ‘one fits all’ 
approach may not work with these cells, especially in terms of specific protocols 
for their directed differentiation down particular lineages. Therefore, 
reprogramming strategies need to be improved in order to generate single copy 
transgene iPS cells, and also exogenous transgenes need to be removed before 
further application can be performed. Moreover, an important point is to clarify the 
inherent distinction of genetic and epigenetic profiles among PSC lines before 
translation to other applications.   
It is noteworthy, that all our iPS cell lines reported here are capable of 
generating nerosphere-like structures when cultured in neural expansion medium 
with FGF2 supplementation. The neurosphere-like structures can also be 
expanded further (for more than 4 passages). The pattern of proliferation and 
differentiation seen in these iPS-generated NPCs is in accordance with what is 
seen with human primary neural tissue derived neurospheres. Overall, there was a 
considerable level of homogeneity across the cell lines produced here in terms of 
their proliferation and differentiation probably due to the efficiency of the protocol 
itself and this could be directly compared to the primary starting material. 
 
4.6.2 In vitro and in vivo differentiation of human PSCs to a DARPP32 
positive MSN-like phenotype using an EB-Based method.   
Primary human embryonic WGE is considered as the ‘gold standard” donor 
tissue for cell therapy in HD. This donor source was used for the ‘proof of principle’ 
donor source for transplantation in HD patients (Kelly et al., 2009). Development 
of protocols for deriving MSNs from human PSCs have been improved since 2008 
when Aubry and colleagues first reported generating striatal projection 
neurons/MSNs from human ES cells (Aubry et al., 2008). In their study, the neural 
induction stage was performed using murine stromal co-culture, which poses 
safety concerns for clinical translation. In addition, co-culture with stromal cells is a 
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time consuming process as it takes several weeks before neural epithelial 
structures can be identified (Song et al., 2007; Aubry et al., 2008). In 2012, Ma 
introduced a multi-aggregated cell method called ‘EB’ formation that recapitulates 
the 3 germ layer differentiation in embryogenesis (Ma et al., 2012). Nevertheless, 
there are drawbacks to the EB method such as heterogeneity of the cell 
population within and among EBs (Kilncumhom et al., 2012), persistent and higher 
expression of pluripotent genes, and contamination of other cell lineages 
(Salewski et al., 2013). Addition of BMP inhibitors such as Noggin, NOTCH 
signalling molecule such as Delta-like ligand 4  (DLL4), and small molecule 
SB431542 and Dorsomorphin have been reported to improve neural conversion 
from human PSC (Chamber et al., 2009; Sally et al., 2012; Salewski et al., 2013; 
Delli Carri et a., 2013).  
In our study, we applied the EB-based method with Noggin along with small 
molecules SB431542 and Dorsomorphin in order to push the cells down the 
ectoderm lineage, generate neural epithelial cells and improve homogeneity of 
neural precursors (Delli Carri et al., 2013). Here, we succeeded in generating 
neuroepithelial cells as demonstrated by typical rosette formations in vitro, giving 
rise to a high proportion of neural precursors confirmed by gene expression and 
immunopositivity of cells for nestin, PAX6, and Sox2. However, non-neural cell 
types and/or pluripotent cells were still observed in our cultures following the 
neural induction phase.  
In addition, heterogeneous populations, including a mixture of neural 
rosette formation and mature neurons bearing neurites, were observed in several 
lines at a later neuronal differentiation stage (beyond 25 DIV). This raised the 
issue about the accuracy and efficiency of the differentiation protocol. Therefore, 
we looked to enhance neural induction by subjecting our iPS cell lines and human 
ES cell line to a monolayer-based strategy. This is part of ongoing work as the 
time constraints of this thesis didn’t allow completion in time for submission. 
However, the data to date is presented as part of Appendix A. The cell adherent 
method as a monolayer allows fairly even exposure to exogenous signalling 
molecules in defined medium, which results in starting material being at the same 
stage of differentiation and more homogeneity of the cell population as neural 
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precursors in the neural induction stage (Nasonkin et al, 2009; Chamber et al., 
2009; Delli Carri et al., 2013). Overall, human ES cell (H9) with a monolayer-
based method offer a more uniform cell population with no expression of 
pluripotent markers Oct4 and Tra-1-60. In addition, MSN-like cells with DARPP32 
immuno-positive expression has been recognized when supplemented with the 
same combination of chemical defined factors.  
The established iPS cell lines exhibit high proliferation rates, as evidenced 
by Ki67 staining. Therefore, it was necessary to perform more passages of EBs 
and neuroepithelial cells during the neural induction process. However, when 
these cells were transferred to neural progenitor expansion medium with the 
addition of FGF2, neural spheres-liked structures emerged with multipotent 
properties to generate neural progeny over many passages. Subsequent 
passaging of neurospheres with FGF2 supplement improved the quality from 
primitive to definitive neurospheres in a study by Salewski et al. and in addition, 
this method helps to reduce gene expression of pluripotent and contaminating cell 
types (Salewski et al., 2013). Furthermore, a similar strategy was applied to 
monolayer based method to generate ‘long term, self-renewing neuroepithelial 
stem cell population from ‘hESCs’ called ‘It-hESNSCs’ from Koch and colleague in 
2008 (Koch et al., 2008). This provided extensive proliferation of neural precursors 
which could differentiate into any specific sub-phenotypes. 
 In our monolayer-based method, we obtained homogenous and 
proliferative naive NPCs which were able to differentiate further to DARPP32 
positive expressing cells when exposed to distinct combinations of cytokines. 
These cells were able to generate neurons, up to 6-12 fold from the starting NPC 
(Appendix A). 
Regarding sub-phenotypic differentiation, we applied SHH and DKK-1 in 
order to manipulate neuroepithelial cells to cells characteristic of the ventral 
telencephalon sub-region. The combination of SHH and DKK-1 provides a 
synergistic effect and is more effective than when supplementing with SHH alone 
(Aubry et al., 2008, Li et al., 2009; Delli Carri et al., 2013). In 2008, Schwartz and 
colleagues suggested that PSC may maintain low levels of a wide range of 
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transcription factors which can be triggered or repressed by exogenous signalling 
and that this is important for the emergence of differentiated phenotypes 
(Schwartz et al., 2008). Therefore, in contrast to previous studies, combinations of 
developmental factors were applied at the beginning of the neural conversion 
process from day 3 to day 26 (see fig 4.25), even though the appropriate time 
points at which to apply factors to trigger sub-type specific transcription factors has 
not yet been identified. We proposed that our iPS cell lines may be already primed 
to a specific lineage, which are ready to be initiated by the right signals. However, 
SHH and DKK-1 were not provided after 26 DIV as over-expression or prolonged 
presence of SHH supplement can result in cortical or motor neuron phenotypes (Li 
et al., 2009, Danjo et al., 2011; Ma et al., 2012). The observed expression of Dlx1, 
Dlx2, Islet1, FoxP1, FoxP2, and Ctip2 suggest successful to commitment of the 
NPCs to a ventral telencephalic phenotype; in particular the LGE structure.  
These results match the previous studies which characterise the 
progression of developing MSNs and identify the emergence of LGE markers at 
15-25 DIV (Delli Carri et al., 2013), 26 DIV (Ma et al., 2012) and 29-30 DIV (Aubry 
et al., 2008). However, the finding of our current studies do not match the previous 
studies with regard to a time line of LGE markers expression, which emerged as 
early as day 13-17 (see table 4.4) and appeared to increase over time in vitro. It 
seems possible that these results are due to epigenetic memories being retained 
within our founded cell lines, accelerating LGE phenotypic development. In 
accordance with this, human primary WGE exhibit those LGE markers by 7-10 
DIV but expression of the more mature MSN markers Ctip2 and DARPP32 is not 
seen until 18 and 20 DIV respectively.  
 Ctip2 is crucial in the differentiation of striatal MSNs. It has also been 
reported to govern and organize a cellular architecture in the striatum. In addition, 
Ctip2 is expressed in all DARPP32 positive cells and is restricted to projection 
neurons and not interneurons in the striatum. The absence of Ctip2 results in 
drastic reduction of the expression of MSN genes (Arlotta et al., 2008). The results 
of our study indicated high expression of Ctip2 by ICC analysis around 25-28 DIV 
and co-expression with DARPP32 by 30-32 DIV. As shown in table 5.4, this 
finding occurs earlier than the previous study by Delli Carri and team which first 
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identify Ctip2 expression at 45 DIV (Delli Carri et al., 2013). The expression of 
DARPP32 has been reported from 45 (Delli Carri et al., 2013), 47 (Ma et al., 
2012), 60-72 DIV (Aubry et al., 2008). However, in our control study, human 
primary WGE demonstrated abundant Ctip2 positive cells by 18 DIV and co-
labelled with DARPP32 by 20 DIV. This finding is consistent with the ideas of 
Halley-Stott and Gurdon (2013), who suggested that epigenetics governs a 
particular cell’s phenotype pattern and can also be passed on to the progeny. 
Rather than changing the DNA sequences, epigenetic memory control genes 
functions (Halley-Stott & Gurdon, 2013).  
Although epigenetic memory has been reported to be retained in human 
PSCs after multiple passages (Halley-Stott & Gurdon, 2013, Lu et al., 2013), sub-
clonal PSCs shows signs of the emergence of genetic variation over time in 
culture (Hussein et al., 2011; Gore et al., 2011), and exposure to mechanical or 
chemical stimulation can provoke such genomic alterations. Therefore, we limited 
our starting material to much earlier passages in order to avoid the genome 
alteration and minimize unpredictable results. Successful human PSC-derived 
DARPP32 cells expression has been reported from 12-89% among different 
research teams (Aubry et al., 2008; Ma et al., 2012; Delli Carri et al., 2013) as 
illustrated in table 5.4. We observe repetitive enriched Ctip2 and DARPP32 
expression in our in vitro studies.  
Immuno-fluorescence expression over time from neural precursors to MSN-
like cells and RT-PCR of gene expression profiles suggest successful derivation of 
striatal projection neurons from our established cell line as compared to that 
recently reported by Delli Carri and co-worker in 2013 (Delli Carri et al., 2013). The 
results illustrate the efficiency of our differentiation protocol to differentiate cells 
from a distinct background toward striatal MSNs.  
Following characterisation of in vitro differentiation, in vivo differentiation 
was performed following transplantation into the QA lesioned rat striatum to 
compare our iPS WGE 928 derived MSNs and human ES cell (H9) derived MSNs 
using the same EBs-based differentiation method. These cells had been 
previously differentiated for approximately 30 DIV, and expressed LGE markers 
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and Ctip2. In our study, 7 animals generated tumours post transplantation with iPS 
derived MSNs, compared to, 3 out of 6 animals transplanted with human ES (H9) 
derived MSNs after 7 weeks post transplantation. Our results agree with the 
findings of Aubry et al. (2008) which reported overgrowth of human ES derived 
striatal progenitors at 8 weeks post transplantation in the QA lesion HD model 
(Aubry et al., 2008).  
In addition, Aubry characterised tumour compartments, which generated 
from transplanted cells differentiated for 21-23 DIV (neural precursors stage), 29-
30 DIV, 37-40 DIV, and 45-59 DIV (striatal progenitors stage). Aubry suggested 
that the content within the grafts depended on DIV of transplanted cells. 
Teratroma-like regions and neural rosette structures were observed when 
transplanting with neural precursor cells whereas transplantation with more mature 
neurons generated fully committed neural lineage grafts with absence of teratoma 
like areas (Aubry et al., 2008). In our study at 7 weeks H&E staining revealed 
rosette structures of neural epithelial like cells with an absence of other cell 
phenotypes. However, pluripotent markers such as Oct4 and Tra-1-60 needed to 
be performed to identify undifferentiated cells within the grafts. This may be due to 
the heterogenous population of transplanted LGE precursors along with the 
remnants of neural precursor cells in our differentiation culture. Mixed populations 
of neural precursors and more mature neurons may give rise to distinct 
combination among our grafts (N=20, brain with tumour formation=7).  
Interestingly, the tumours generated from our iPS derived-MSNs behaved 
differently from those in Aubry et al. (2008). We observed the migration of 
transplanted cells from striatal area to cortex with independent tumours 
compressing the striatum and ventricle (5 out of 6 animals with tumour formation) 
which have not been reported in previous studies. This finding is a rather different 
pattern to that seen in Aubry et al where the overgrown cells remained in the area 
of the striatum and compressed the lateral ventricle. In addition, the tumour 
separated from the intact brain, thus making it impossible to perform further 
analysis of the cells component within our tumours.  
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 Another reason for graft overgrowth in our study may be the relatively large 
number of transplanted cells (5x105 cells per animal) in comparison to Aubry et al. 
(5x104 – 2x105 cells) and Ma et al. (5x104 cells) (Aubry et al., 2008; Ma et al., 
2012). Therefore, if we reduce the number of transplanted cells to 5x104 cells per 
animal, tumours may not develop. Furthermore, we explored a monolayer based 
method of deriving MSNs using the same chemical defined factors and medium as 
the EBs-based method reported earlier (results in Appendix A). Interestingly, 7 
weeks after transplanting with 5x105 human ES derived-LGE precursor cells 
(prepared at 30 DIV) no tumour formation was identified in any transplanted 
animals (N=7). There was also 100% graft survival, confirmed by HuNu positive 
cells (data not shown). This corresponds to the work of Delli Carri et al. (2013) 
which claimed an absence of graft overgrowth or tumour formation using the same 
cell numbers and the same methodology of monolayer differentiation method (Delli 
Carri et al., 2013). However, the images presented in the manuscript of Delli Carri 
would suggest the likelihood of overgrowth and it must be highlighted that only 3 
animals were used in that study. Thus, differentiation methods may affect 
differentiation efficiency and the ability of cells to terminally differentiate to the 
desired phenotypes. We hypothesise that using monolayer-based method, where 
there is no bias of cells within the population being exposed to exogenous 
signalling, leads to homogeneity in the cell population and more complete 
differentiation toward the desired lineages.  
It is noteworthy, that we observed other features corresponding to previous 
reports from Aubry et al. First, DARPP32 positive cells were identified as 
groups/clusters of cells rather than standing alone both in vitro and in vivo. This 
may support the idea that cell-cell interactions are essential for a maturation of 
striatal projection neurons/MSNs. This idea was also supported by Fraichard et al. 
(1995) who suggested that striatal MSNs need to associate as groups of cells in 
order to mature, which is different to the maturation requirements of dopaminergic 
neurons (Fraichard et al. 1995). In addition, similar to Aubry’s study, bipolar 
neuronal morphology with medium sized cell bodies were identified after 7 weeks 
in the grafts, both for human ES and our established iPS cell donors.  Second, 
despite the obvious overgrowth we observed no migration of neuronal cells 
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beyond the graft border in our EBs-based experiment (N=7), whereas in 
monolayer-based method, albeit in only one animal, we identified grafted cells 
starting to migrate into across the graft host border. Interestingly, a control group 
of grafted human primary WGE cells migrated and distributed evenly in the host 
striatal area at the similar time point (7 weeks post transplantation). This may 
suggest that PSC derived-neuronal cells need longer time in vivo to integrate into 
the host genome and reconstruct the neuronal circuit.  
 It will be important to clarify the cell components within our tumour, as this 
may affect the solution. For example, if undifferentiated cells were identified 
efficient transgene removal strategies could be implemented, whereas if graft 
overgrowth is due to high proliferation of more mature neural precursors, longer 
periods of in vitro differentiation may be required, or even reduced numbers of 
transplanted cells. Once the tumour issue is overcome other assessments such as 
electrophysiology and behavioural studies will be more meaningful.  
Finally, assessment of DARPP-32 expression in grafts revealed a 
significantly higher number of DARPP32 expressing cells from iPS WGE derived-
MSNs compared to human ES cell (H9). Furthermore, the graft volume was also 
significantly greater in the iPS derived grafts than in the ES cell grafts at this time 
point. At this stage this is a preliminary result as the numbers of grafted animals 
assessed was small (iPS group N= 4; ES group N= 3) and thus more extensive 
quantitative assessments will be necessary.  However, despite being preliminary, 
this result supports the notion that it may be possible to take advantage of 
epigenetic memory to generate cell sources with a propensity to differentiate into 
specific desired cellular phenotypes. 
Chapter 5                                                                                      General Discussion. 
 
 
156 
 
Chapter 5 
General Discussion 
5.1 The challenges of iPS cell line generation 
 The discovery of methodology to generate iPS cells has paved the way to 
produce unlimited numbers of almost any kind of cells with many potential 
applications, including disease modeling, drug screening and regenerative 
medicine.  There are some distinct advantages of using iPS cells in regenerative 
medicine in terms of avoiding some of the ethical issues associated with primary 
fetal tissue and ES cells and avoiding some of the problems of immune rejection. 
Since 2006, when Yamanaka and team first reported the generation of iPS cells, 
there have been many attempts to generate them from various types of cells such 
as fibroblast, adipose tissue, urine and menstrual tissue (Meissner et al., 2007, 
Chen MJ 2014, Xue Y et al., 2013, Li Y et al., 2013), and technological 
advancements are continuing to improve and simplify the method of production. 
However, iPS cells are not free of all ethical concerns as they raise some novel 
concerns related to human cloning (Lo B et al., 2010) and furthermore there is no 
international committee or restriction agreement between countries. In addition, 
there is still controversy about what iPS cells are: what the biological processes 
are underlying the reprogramming; whether they are really indistinguishable from 
ES cells; and concerns about their safety, with some scientists having referred to 
iPS cells as ‘man made cancer stem cells’ and thus questioning their suitability for 
clinical usage (Liu et al., 2008, Sipp D., 2010).  
Despite these ongoing concerns, we cannot deny the potential of iPS cells 
to provide insight into the developmental, pathological, and toxicological studies, 
and the possibilities they present for regenerative medicine. However, it is 
important to bear in mind that even though iPS and ES cells share many 
similarities, they cannot necessarily be considered as identical, and many of the 
hidden mysteries of these cells need to be better understood before jumping on 
the iPS bandwagon. Furthermore, with regard to clinical translation, extensive and 
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vigorous in vitro and in vivo experiments will need to be performed to ensure the 
safety of these cells before pursuing their application in cell replacement therapy.  
 In this thesis, I am ultimately interested in producing striatal MSNs for cell 
replacement therapy and have attempted to generate iPS cells from tissue 
containing MSN progenitors in the hope that iPS cells from this source will be 
more easily differentiated back to an MSN phenotype due to retention of an 
‘epigenetic memory’. There have been previous attempts to directly proliferate 
such progenitors in vitro as neurospheres and as monolayers, but it proved 
impossible to cause them to proliferate beyond one passage without losing their 
capacity to differentiate back to MSNs (Anderson et al., 2007; Zietlow et al., 2012).  
There have been many reports related to the epigenetic memories retained in iPS 
cells, which is sometimes seen as a disadvantage, but may also make iPS cells 
more attractive in terms of their accurate differentiation to specific phenotypes 
such as the MSNs (Shtrichman R et al., 2013, Sullivan GJ et al.,  2010, Kim K et 
al., 2010). For example it has been shown that iPS cells derived directly from 
blood cells more readily formed haematopoietic colonies in culture when directly 
compared to iPS cells derived from fibroblasts in the mouse (Kim et al 2010). 
Furthermore it was highlighted that neural derived iPS cells have the propensity to 
retain residual methylation sites that may be important when directing the 
differentiation of these cells. Therefore, considering generating iPS cells from the 
target cell type may offer advantages. However, it is likely that other pluripotent 
properties should equate closely to the standard ES cell in order to propagate a 
stable and faithful iPS cell line.  
 In this study, I started by attempting to generate a viral-free iPS cell line 
using CPP methodologies as described in Chapter 3. However, it became evident 
that this approach was not a viable means to generating iPS cells due to the 
technical difficulties in getting the plasmid into the cells along with the 
reprogramming factors. Despite many attempts to overcome these difficulties I 
was unsuccessful in generating an iPS cell line. Thus it was decided to explore a 
different method that had at the time just been published, the piggyBac method. 
Chapter 4 describes how this approach was utilized to generate iPS cell lines from 
human fetal striatal tissues. Whilst iPS cell lines were successfully generated it 
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was not without issues. The piggyBac method suggests that the reprogramming 
transgenes can be removed from the established iPS cells, thus making an 
integration free cell line. Despite exposing the cell lines generated in this thesis to 
the protocols for removing the transgene it was found that complete removal was 
not achievable with variability seen in the level of residual transgene expression 
between different iPS cell lines. Even though the piggyBac transposon is an 
efficient method, however, our downstream application is for cell replacement 
therapy; therefore pluripotent transgenes must be removed. Chapter 4 looked to 
direct the differentiation of the established iPS cell lines generated in chapter 3 
specifically into MSNs using previously described protocols as well as a new 
protocol devised in house. Subsequently the cells were transplanted into an 
animal model of HD as this was the ultimate goal to generate a cell line for cell 
replacement therapy in HD. I successfully generated DARPP32 positive neurons 
from iPS cell lines and the efficiency of this method was considerable with a large 
proportion of positive cells identified both in vitro and in vivo.  
  Since the start of this thesis, integration free methods of re-programming 
have been improved and include strategies such as miRNA, synthetic modified 
mRNA, and Sendai virus (Fusaki et al., 2009; Warren et al., 2010; Anokye-Danso 
et al., 2011). The reprogramming efficiency using viral free methods has been 
improved from a general figure of around 0.001 up to 10% and so the possibility of 
incorporating these protocols along with the understanding that neural tissues 
contain a high level of endogenous Sox2 may be a way forward when generating 
iPS cells from fetal neural tissue specifically WGE or Cortex. The drive to optimize 
the production protocol for generating integration viral free methods for 
reprogramming has resulted in a significant amount of experimental data and 
literature being published. However, at the time of writing the most promising 
approach would appear to be the Sendai virus method. This approach has been 
used on human cells and works to a high degree of efficiency (Fusaki N 2009). 
However, as is the case with all methods described to date it has not been 
possible to completely remove the vector from the iPS cells generated using this 
approach. Thus moving forward the aim would be to develop a protocol that would 
allow complete removal of the reprogramming factors before these cells could be 
considered for clinical application. However, the cell lines generated using the 
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current methods are important as they can be used for preclinical experimental 
analysis.     
 Producing cell systems for clinical application, however, requires 
consideration of aspects beyond the efficiency and safety concerns associated 
with iPS cell production as described above. For example, it may not sufficient to 
select the primary clones by their morphological similarity to ES cells. Therefore, it 
will be important to consider using live AP or Tra-1-80 pluripotent markers in cell 
culture to facilitate selecting the right iPS colonies. This strategy is likely to 
increase the chance of obtaining a reliable cell line. Moreover, the epigenetic and 
genomic profiles should have been observed and monitored from the starting 
material to the established iPS cell line and also the later subsequent progeny of 
the iPS cells in comparison to human ES cells.  
Another consideration is the system used for iPS cell propagation. We 
considered transferring our iPS cells to a feeder free and animal free culture 
system because of the eventual aim of designing such cells for clinical application. 
These refinements would get rid of the problem of contaminating feeder cells and 
facilitate the selection of more uniform populations of cells for further passaging 
(Amit et al., 2006). As described in Chapter 5 it was found that using the EB 
method for directed differentiation of the iPS cells and ES cells, there was the 
propensity of these cells to form tumours following neural transplantation. Thus an 
alternative method was explored and I have also been successful in deriving 
MSNs form human ES cells using monolayer neural differentiation protocol (see 
appendix A), whilst using the same exogenous signaling molecules as were used 
in the EBs-based method. As mentioned in the literature reviews, the neural 
induction stage and regional patterning are separate stages, therefore subjecting 
the cells to a monolayer-based method should not affect the competence of 
subtype specification from our chemical defined combination (Delli Carri et al., 
2013). In addition, monolayer-based methods allow the exogenous signaling 
molecules easier and more equal access to the cells, ultimately leading to more 
cell homogeneity in terms of differentiation. This may lead to improvements in the 
differentiation of cells within a graft and may help to reduce tumour formation as 
we would have more control over the lineage specification of the transplanted 
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cells. Preliminary results have shown this method to produce a homogenous 
neural population, an ease to manipulate into neural lineages and an absence of 
pluripotent cells or tumour formation in vitro and in vivo following directed 
differentiation. Therefore, the monolayer differentiation strategy may enhance the 
quality and quantity of our MSNs-like cells. However, this data is part of ongoing 
work and at the time of completion of this thesis there were still animals alive that 
had received transplants and were awaiting analysis. Following on from the 
positive outcomes with human ES cells, iPS cells will be exposed to this 
monolayer protocol and transplanted for in vivo analysis.  
 
5.2 In vitro study of human iPS/ ES derived-MSNs. 
 In cell differentiation experiments such as those reported in this thesis, it is 
crucial to perform close and careful observation, tracking the cells from the 
pluripotent stage through to terminally differentiated cells. In our study, the specific 
time points for collection of samples for ICC and RT-PCR were taken from the 
obvious changes in the differentiation phases, such as the neural rosette stage, 
neural precursor stage, the appearance of LGE progenitors, and terminal neuronal 
differentiation. However, there are gaps between each time point where we may 
miss out on important information. In addition, although RT-PCR provides useful 
information about the presence or absence of the expression of genes of interest, 
it is limited in that it does not produce accurate information about levels of 
expression. It would have been useful to have been able to use Q-PCR to observe 
up- and down- regulation of the expression of genes of interest, from the 
pluripotent stages through to the differentiated MSN phenotype. This would set a 
solid framework and would allow cross reference to other characterization 
strategies such as ICC, electrophysiology, and cross comparison of in vitro to in 
vivo differentiation.  
We were fortunate in these studies to have access to human fetal WGE, 
which provided a supply of “genuine’ MSN progenitors.  It would have been useful 
to apply Q-PCR to assess their gene expression profile too as this would have 
provided a standard profile of neural differentiation with which to compare the iPS 
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cells. This would likely help to accelerate improvement of the neural conversion 
protocol by addition or withdrawal of the supporter/repressor signaling in a more 
accurate time frame as seen in the gene expression patters of primary WGE 
differentiation.   
As discussed in this thesis, to date only a small number of protocols to 
differentiate MSNs from human PSCs have been reported and there is still much 
work ongoing to improve such protocols. Of the reports to date, there are huge 
differences between studies in terms of their efficiency in producing DARPP32 
positive neurons, ranging from only 20% up to 89% (although direct comparison is 
complicated by the fact that the studies use different methods of estimating the 
efficiency). Thus, specific, reliable, and stable conditions need to be improved to 
optimize and standardize the differentiation protocol. In Chapter 4, we reported a 
failure to achieve stable neural conversion in our iPS cell line WGE623 C9; even 
though, we used a protocol which has been reported to successfully generate 
MSNs from human ES cells (Arber et al submitted to Development). There are a 
number of reasons why this might have occurred, and one that was discussed in 
chapter 4 was the possibility that the transposons had been inadequately 
removed.  However, it is also possible that the differences between PSC lines is 
such that translation of a protocol from one line to another is not straight forward. 
Further careful controlled observations are needed to probe and characterize the 
differences between various cell lines. Indeed as highlighted in Chapter 4 it was 
possible using our newly devised protocol to silence the expression of the 
endogenous transgenes in some cell lines and this is something that may be of 
great importance if methods can’t be identified to generate completely transgene 
free iPS cells albeit with variability across cell lines. The detailed mechanisms 
whereby the silencing occurred have not been investigated here and why it 
worked for some cell lines and not others is unknown but raises important 
questions for further investigation.  
In our studies, we were able to convert several iPS cell lines and a human 
ES line to MSN-like cells, as indicated by their gene expression and antibody 
staining for specific markers. However, there is a room for improvement in our 
studies in which we could further test our hypothesis and enhance the current 
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protocols reported here. As described in Chapter 4 and above, an EBs-based 
protocol was used to derive MSN-like cells, but this presented some problems 
including disorganized aggregation, heterogeneity of the differentiated population, 
persistence of pluripotent cells and possibly also for the differentiation of non-
neural lineages within EBs. And as said above, we are exploring the monolayer 
approach and this is the subject of ongoing work. As aforementioned, in our 
studies we have chronologically observed the specific stages of differentiation 
using gene expression markers such as ICC and RT-PCR. However, this passive 
characterization may not be sufficiently effective to detect small errors within the 
experiment, such as subset of pluripotent cells amongst the differentiated cells. 
One way to overcome this could be the integration of reporter genes to allow the 
identification of expression of key genes. As an active characterization strategy, 
the expression of reporter genes may act to confirm the cells characteristic in vitro, 
thus allowing the grafting of cells at specific stages of differentiation and allowing 
purification of cells using technologies such as FACS sorting. The importance of 
grafting cells at specific stages of differentiation has been previously noted and 
related to tumour formation or hyper proliferation of the grafted cells (Aubry et al., 
2008; Ma et al., 2009; Seminatore et al., 2011). The best estimate to date of the 
most suitable stage for grafting has been reported to be around the proneuronal 
stage up to the early post mitotic stage; therefore the reporter genes for our MSN-
like cells should be expressed within this time window (Fricker-Gates RA et al., 
2004).    
Cell transplantation in HD aims to reconstruct the damaged neuronal 
circuits of the striatum. Thus, being able to demonstrate appropriate function of 
PSC derived MSNs after transplantation into the striatum in animal models of HD 
is an important step. Furthermore, this is the ultimate test that the PSC derived 
MSNs are fully functional. As discussed in Chapter 5, there is limited improvement 
in the behavioral outcomes reported in the previous studies in which human PSC-
derived MSNs are transplanted into HD animal models (Aubrey et al., 2008; Ma et 
al., 2012; Delli Carri et al., 2013), despite the fact that such cells appeared to 
possess the markers expected of MSNs in the in vitro studies.  This raises two 
issues: first, are there better in vitro culture systems for assessing the 
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differentiation of PSCs; and secondly, why is it that the PSC-derived MSNs so far 
reported in the literature appear to function less well than their WGE counterparts?  
  To first consider the suitability of the culture system: a two dimensional 
culture system is not ideal when compared to the natural environment of neural 
cells, and this may be one of the reasons why neurons produced within culture do 
not show full function post transplantation. A 3D culture system may be preferable, 
in which cells can differentiate, migrate, and connect in a manner that is closer to 
what they would do in the brain (Ortinau et al., 2010), and this in itself may 
promote differentiation and accelerate phenotypic maturation (Thonhoff et al., 
2008; Holmes et al., 2000; Taraballi et al., 2010; Ortinau et al., 2010).  
In tissue engineering, biomaterial scaffolds have been introduced and used 
to aid differentiation of various cell types for regenerative medicine, such as spinal 
cord injury (Ortinau et al., 2010; Li et al., 2012; Binan et al., 2014). Ortinau et al. 
(2010) reported a higher survival rate of human neural progenitor cells and fewer 
dead cells over time when cells were cultured in a 3D, rather than a 2D culture 
system (Ortinau et al., 2010). In addition, this correlated to the number of β-III 
tubulin expressing neurons which is higher in 3D culture. However, it would be 
necessary to optimize any biomatrix in terms of composition, concentration, and 
functionalization if such a 3D system were to be applied in our study.   
It is not only the spatial dimension that is different between in vitro and in 
vivo differentiation; the cellular microenvironment within those two conditions are 
also distinct. In the natural CNS environment, there are many signaling pathways, 
both stimulators and inhibitors, coming from every direction. In addition, other 
neural cell types, such as surrounding, astrocytes, oligodendrocytes, and 
interneurons, which may secrete various factors, such as neurotrophic factors, that 
may influence the developing neural cells in a variety of ways (Ruiz et al., 2012; 
Perucho et al., 2013). Therefore, co-culture with gial cells derived from human 
WGE, or their conditioned media, may increase phenotypic differentiation, improve 
postmitotic maturation, and enhance the appropriate function of MSN-like cells 
produced from our iPS cells.  
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From our data it can be seen that the expression of DARPP32 was 
confirmed much earlier than in other reported protocols. This is suggestive of the 
role of the importance of the ‘epigenetic memory’ in affecting the differentiation 
potential of our iPS cells. Whilst we can’t say this for certain as further 
investigations are required to confirm this there is strong evidence to suggest its 
significance. Further work would require epigenetic screening of both the 
DARPP32 positive cells from the iPS cells and the donor derived tissues. 
Interestingly the expression of DARPP32 was also seen at this earlier time point in 
ES derived neural cells using the same protocol, albeit at a lower level. At this 
point detailed quantification has not been carried out to be able to directly 
compare between the two cell types but initial analysis would suggest that there 
are differences between the two cell types in vitro and in vivo.  
  
5.3 In vivo study of human iPS/ES derived-MSNs. 
 As discussed in Chapter 5, tumour formation was reported at 6-7 weeks 
post transplantation in a proportion of animals having received iPS cell derived 
neural grafts and also human ES cell derived neural grafts, although they were 
less common in the latter. The tumours appeared to contain areas of 
hyperproliferation activity of neural epithelial cells and/or neural precursors. Similar 
structures were observed and reported in 2008 by Aubry and team (Aubry et al., 
2008).  H&E staining of the grafts where significant overgrowth was seen would 
suggest that the tumour like structure in the graft area is the result of neural 
precursor overgrowth rather than teratoma formation based on the absence of 
mesoderm and endoderm type cells based on morphology alone. This is an 
important finding as it validates the neural induction protocol used but highlights 
the need for some refinements to prevent future overgrowths occurring. 
Interestingly, graft overgrowth in primary cells transplanted into the rat striatum 
has been reported from time to time (Geny et al., 1994).  
There are a number of ways to overcome this issue including, as mentioned 
above, looking at transplanting the cells at different stages in the differentiation 
protocol. Another way to overcome this obstacle is to apply DAPT 4-5 days in vitro 
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culture prior to harvesting the cells for transplantation. As previous study from 
Kirkeby and colleague (2012) suggested that DAPT, which is Notch signaling 
pathway inhibitor and γ-secretase inhibitor, accelerates neural cells commitment 
and decreases the proliferation property (Kirk et al., 2011; Kirkeby et al., 2012). In 
addition, good graft survival without tumour formation was obtained when 
transplanted with DAPT treated human PSC-derived neuronal cells (Kirkeby et al., 
2012). FACS sorting is another option to select particular cells types within a 
population. This method offers the opportunity to pick up stage-specific cells, and 
avoid transplanting pluripotent or highly proliferative cells. However, the viability of 
sorted cells may decrease due to various disturbing processes associated with the 
procedure itself. Therefore, we could consider re-plating the FACS sorted cells 
and transplanting the cells after a recovery period. Which method will be employed 
will be determined based on further understanding of the nature of the tumour 
itself.  
An additional problem related to the final distribution of the grafted cells in 
the brain is that some grafted cells were observed within the needle tract 
suggesting backflow of cells up the needle during surgery. This may have 
contributed to the grafted cells reaching the cortex. One potential method to 
address this would be to implant the cells within a hydrogel matrix.  Hydrogels 
have been suggested to promote cell viability, reduce scar formation, and improve 
grafted cell implantation in stroke models (Chai et al., 2007; Potter et al., 2008; 
Zhong et al., 2010). Many gels contain hyaluronan, which is an extracellular matrix 
component, and the viscoelastic and mechanical characters of this hydrogel is 
similar to the extracellular matrix of the brain (Zhong et al., 2010). These 
properties appear to encourage cell differentiation and allow neurite extension 
without encouraging scar formation and may help to maintain transplanted cells 
within the graft region. Furthermore, neurotrophic factors can be incorporated into 
the hydrogel to support the grafted neurons. Thus, I would be interested in 
transplanting our iPS/ES-derived MSNs within a hydrogel composing of 
hyaluronan+heparin+collagen with BDNF, GDNF, and Rock inhibitor supplement 
(Zhong et al., 2010).  
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In this study, we transplanted iPS cells derived MSN-like cells into the QA-
lesioned rat model using a xenograft paradigm (human-to-rat) cross-comparing to 
human ES derived MSN-like cells and human primary WGE. This model allows us 
to investigate graft survival, grafted cells differentiation and integration into host 
tissue, reconstruction of neural circuits, and eventually, correction of symptom 
deficits via behavioral studies. However, immune suppression is needed in 
xenograft transplantation; as a result the transplanted animal will inevitably 
become sick and will need to be scarified around 20 weeks post implantation. 
Therefore, this model may not permit us to validate terminally differentiated grafted 
cells in vivo which is essential in preclinical PSC transplantation studies. As 
extensive in vivo differentiation is needed, desensitization of the host animal with 
the xenogeneic donor tissue at neonatal stage is an alternative choice to escape 
immune reactivity problems (Kelly et al., 2009). This strategy would allow the 
transplanted cells to terminally differentiate longer term post transplantation. In 
addition, repeated behavioral studies can be performed to investigate the 
beneficial effect from grafting cells at alleviating deficits in the diseased model. 
Furthermore, extensive long-term differentiation is important for more 
comprehensive recognition of tumour formation at later time in the study because 
tumour production can take time to emerge.  
The hypothesis behind the work carried out in this thesis was that the iPS 
cells generated from fetal derived WGE would have an epigenetic memory of their 
origin thus facilitating their differentiation into mature MSNs in vitro. The data 
presented here, whilst not confirming this, suggest the possibility that this may be 
the case. Due to time constraints it was not possible to carry out a detailed 
epigenetic screen of our iPS cells and to compare this to our starting material 
however, future work would look to prioritize this experiment. Moreover, we would 
not only compare the WGE derived iPS cells to WGE primary tissue but would 
also include ES derived MSNs as well as cortex and fibroblast derived iPS cells in 
the analysis.  
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 5.4 Functional characterization of iPS/ES derived-MSNs 
 As aforementioned, the ultimate aim of the work described in this study is to 
produce cells that are suitable to reconstruct the neural network in the damaged 
striatum. Therefore, it is crucial to ensure appropriate functional properties from 
these MSN like-cells before and after implanting into the host brain. First of all in 
vitro studies were performed measuring: the expression of markers such as 
synaptophysin, demonstrating synaptic transmission activities; GAD65/67 
identifying GABA synthesizing enzymes which provide an indicator that the cells 
may be functional neurons; and PSD95 presenting post synaptic protein with 
varying expression seen between ES and iPS derived neurons. Expression of 
these markers also needs to be analysed in graft sections. Neuro-
electrophysiology should be performed in culture at chronological time point so as 
to monitor the functional maturation and their firing pattern over time in vitro. In 
addition, the same strategy should be applied on to human primary WGE at a 
similar time window for comparison with ‘natural’ MSN development. Moreover, 
neuro-electrophysiological on brain slices would allow us to record the action 
potential of the grafted neurons and monitor their function in the normal brain 
environment.  
The ultimate test of whether the iPS and ES derived MSNs are functional is 
to transplant them into animal models of HD to see whether they are capable of 
repairing the damaged neural circuitry.  Our initial studies looking at this have 
found that both the iPS and ES derived neurons had the ability to differentiate into 
mature MSN-like cells expressing DARPP32 in vivo 7 weeks post transplantation. 
However, the presence of tumours in these animals is a major concern and will 
need to be rectified before further in vivo experiments can be carried out. Future 
studies would first look to incorporate anterograde and retrograde labelling to 
allow us to examine neuronal connectivity between grafted-host tissues (reviewed 
in Sanberg et al., 1989) and to further understand the potential of these cells to 
reform connections in the brain. In addition detailed behavioral characterization at 
a motor and cognitive level should be investigated. Various tasks can be assessed 
such as spontaneous/amphetamine induce hyperactivities, haloperidol induced 
catalepsy, asymmetry rotation on a motor level, whilst cognitive deficits can be 
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assessed using conditioned behavior such as delay alteration tasks (Nakao and 
Itakura, 1999). However, the HD rodent model may not be the most effective 
model to assess such aspects of the disease as the psychiatric component, and it 
may eventually be necessary to consider using non-human primate models 
(Nakao and Itakura, 1999).   
Concluding remarks     
 iPS cells technology provides us with a powerful tool to understand 
biological development from its origin and can be applied in various branches of 
knowledge including cell replacement therapy. However, all PSC derived donors 
must be vigorously tested in every aspect in order to ensure safety when 
considering using such cells in patients. Absolute requirements for neural cell 
replacement therapy  are that the desired specific subtypes can be efficiently and 
effectively produced, that they are functional, that non-target cell types are kept to 
an acceptable minimum, and that cells with significant proliferative properties (in 
particular, pluripotent cells) are eliminated. The efficient and reliable generation of 
sufficient numbers of genuine functional MSNs for cell therapy in HD is 
challenging, and there are many issues to take into consideration, such as genetic 
and epigenetic alteration, teratoma formation, and immuno-reactivity. 
In this thesis some challenges of iPS cell generation are highlighted and 
iPS cells generated using piggyBac technology are characterized and found to be 
capable of differentiating into MSNs, although the issue of tumour formation 
remains problematic. It appears that our modifications of pre-existing 
differentiation protocols may be more efficient at generating MSNs and that MSNs 
generated from human WGE may be more ready to differentiate into MSNs than 
cells from other sources, although further work will be needed to confirm this. 
Ultimately, quantitative assessment, and an array of characterization and 
behavioral studies need to be undertaken in order to complete this work.   The 
drive to establish an efficient protocol for the generation of iPS cells is ongoing 
and it is important that we keep abreast of this literature as more efficient methods 
may become available for generating these cells thus overcoming some of the 
issues highlighted with the current protocol. 
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Appendix A 
Human ES cell (H9) derived MSN-like cells 
mono-layer based method. 
 
Neural induction Monolayer-Based Method.  
(this is ongoing work that was incomplete at the time of submission of this thesis but is 
relevant for consideration and discussion) 
 
Human ES/iPS cells at 70-80% confluency were passaged as cell clumps 
and redistributed from 1 well of a 6 well-plate in 1:3 ratio (~20-25% each well) into 
Geltrax® matrix (Life Technologies®) coated 6 well-plate and cultured in ES/iPS 
medium. The day after, medium was changed to neural induction medium (NI 
medium, Gibco®, Paisley, Scotland, UK). Full medium changes were performed 
every other day for 7 days until the cells reached 80-90% confluence. Cells were 
passaged (passage 1) as a single cell suspension by incubating with 1 ml 
Accutase® for 5-7 minutes. NI medium 9 ml was added; cells were passed through 
the cell strainer and centrifuged at 86.64 g for 3 minutes. Cells were cultured in NI 
medium and adhered onto Geltrax® coated tissue culture dish at 2.5-3.0x105 
cells/well of 6-well plate. Between days 10-14, cells were dissociated again 
(passage 2) (using the previously described method). Cells were passaged again 
(passage 3) between days 16-22, when they were plated onto PLL-POL-Laminin 
pre-treated tissue culture plates/coverslips in neural expansion medium (1:1 ration 
NI medium and Advanced™ DMEM/F12). From this stage cells were be able to be 
expanded and banked as NPCs. (Figure 1)  
Neural induction was as per shown in Figure 1 below (lower panel). The 
cells were exposed to SB431542, dorsomorphin and noggin from days 16-22 DIV 
as well as SHH, DKK1 and Activin A from day 16 to 26 DIV. From day 28 as well 
as Activin A, GDNF, BDNF, ascorbic acid and VPA were also added to the culture 
for maturation of the neural precurosor population.  
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Figure 1. Schematic of the time line for neural induction and neuronal differentiation from 
PSCs using Monolayer-Based method (as described above).  
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In vitro differentiation to MSN-like cells. 
 7 days after passage 2, neural induction medium was changed to N2B27 
medium with supplementation with the chemical combinations as described 
above. Cells started to form 2D rosette structures (Figure 1 A). Later on in culture, 
cells transformed to neural like morphology with short and fine processes (Figure 
1 B). Cells progressively obtained a neuronal morphology with small and tight cell 
bodies, thickening and long neurites (day 28, Figure 1 C). Gial cells were identified 
in prolonged culture around day 28 as a carpet underlying the neuronal layer 
(Figure 1 D). There was an absence of other non-neural cell phenotypes or 
pluripotent like cells.  
 
Figure 2. Phase contrast micrographs of human ES (H9) derived MSN like cells using monolayer-
based method. Neural rosette structures were identified 3 day after changing to N2B27 medium (A). After 
passage 3, cultured with N2B27 and a combination of small molecules, morphogens, and growth factors 
designed to encourage differentiation to an LGE progenitor phenotype, cells gradually changed their 
morphology to resemble neuronal cells with short and fine processes (B). The cells’ maturated appearance 
was similar to neurons with small and tight cell bodies; thick and long connecting neurites were identified (C). 
Glia cells emerged later, forming a carpet underneath the neuronal cells (D). Scale bar = 0.10 mm.  
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In vitro Analysis of H9 derived MSN-like cells. 
 Immunocytochemistry was performed at different time point during in vitro 
differentiation followed the previous study in Chapter 5. Neural precursors were 
identified with Nestin (Figure 3 A) around day 7 after passage 2 (Figure 1). At a 
later time in culture, cells with long processes were identified by more the neuronal 
marker of β-III tubulin and post mitotic neuronal marker, Map2 (Figure 3 B and C). 
LGE progenitors were identified by the hall mark markers such as FoxP1 and 
FoxP2, co-expressed with the less mature MSNs marker Ctip2 (Figure 3 D and E). 
GFAP positive glial cells emerged at later time in culture (Figure 3 F). Around 28-
32 DIV, DARPP32 positive cells were recognized as groups of cells co-localizing 
with Ctip2 (Figure 3 G and insert, H). The postsynaptic NMDA receptor PSD-95 
was also recognized from around day 30 onwards (Figure 3 I).  
Figure 3. Immunocytofluorescence micrographs of the phenotypic characterization of striatal progenitors and 
neurons generated from human ES (H9) cells using a monolayer-based method. Neural maturation is indicated by the 
neural progenitor marker, Nestin (A) through to a more mature neuron marker, β-III Tubullin (B), and post mitotic neurons 
Map2 (C). FoxP1 and FoxP2 were present throughout differentiation (D, E), whereas Ctip 2 appeared around day 20-25 
with increasing expression over time in culture (D, E, G). From 30 DIV, DARPP32 with Ctip2 co-labelling were identified (G 
and insert, H). GFAP, representing glia cells, was identified in a prolonged culture at later time in differentiation (F). A 
synaptic marker PSD-95 was also recognized in this study (I).    
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In vivo differentiation to MSN-like cells. 
 
 Cells at 30 DIV were transplanted into the QA-lesioned rat striatum (HD 
model) at 5x105 cells per animal. At 7 and 20 weeks post-surgery, animals were 
sacrificed and their brains were collected for immunohistochemistry analysis as 
described in Chapter 2. Graft survival was identified in all animals with expression 
of HuNu positive cells. No tumour formation/graft overgrowth were found in any 
transplanted animals (N=7). Migration of transplanted cells across the graft host 
border within the striatum showed integration of the grafted cells in 1 out of 7 
animals (data not shown). The surviving grafts (N=7) were situated in the striatal 
area and are illustrated in a schematic in figure 4, A. Immunohistochemistry was 
performed, DARPP32 expressing cells with HuNu co-labelling confirmed in vivo 
differentiation of human ES (H9) derived MSNs (Figure 4, B).  
 
 
 
 
Figure 4. Schematic of surviving grafts of human ES (H9) derived MSN like-cells post transplantation 7 
weeks (N=7)  (A). Surviving grafts were recognized by HuNu positive cells in the striatal area with absences 
of tumour formation or neural epithelial overgrowth. Immunofluorescence was performed on the brain 
sections, DARPP32 expressing cells revealed the presence of human ES (H9) derived MSNs in vivo (B). 
HuNu positive  cells co-labelled with DARPP32-expressing cells indicated graft-derived MSNs.  
 
 In summary, we demonstrate that human ES (H9) cells can be 
differentiated towards MSNs phenotype using our revised protocol. This revised 
protocol was the one used (the same chemical combinations) in EBs-based 
differentiation presented in chapter 5. This suggested an efficient protocol which 
could be applied to various PSC lines in adapted culture conditions. Importantly, 
no tumour formation was identified at this stage (7 weeks) post transplantation. 
However, this is only a preliminary study, due to time constraints, and is ongoing 
with more animals waiting to be sacrificed and analyzed.  
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Appendix B 
Materials and Suppliers 
 
Materials Suppliers Location 
Accutase PAA Labs Farnborough, Hampshire, 
UK 
Activin A R&D  
Advanced DMEM/F12 Gibco Paisley, Scotland, UK 
Agarose electrophoresis 
grade 
Invitrogen Paisley, USA 
 Age I Promega  
AhD I NEB  
Ampicillin DIFCO  
Ascorbic acid   
B27 Gibco Paisley, Scotland 
BDNF Peprotech  
bFGF  invitrogen  
Biotin-High Prime Roche  
B-mercaptoethanol Sigma Poole, Dorset, UK 
BSA Sigma  
Cyclopamine Calbiochem Hull, UK 
DifcoTM LB AGAR BD Claix, France 
DifcoTM LB BROTH BD  
Dispase Solution STEMCELL 
technologies 
 
DKK1 R&D Systems Abingdon, Oxfordshire, 
UK 
DMEM/F12 Gibco  
DMSO Sigma Poole, Dorset, UK 
DNase Sigma Poole, Dorset, UK 
Dorsomorphin Tocris  
EGF Sigma Poole, Dorset, UK 
FCS Gibco Paisley, Scotland 
FGF2 R&D Systems  
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Materials Suppliers Location 
FIAU TCI Tokyo, Japan 
Fibronectin Sigma  
Fugene®6 Transfection 
Ragent 
Promega 
 
GDNF Tocris  
Gelatin Chemicon Chandlers Ford, 
Southampton, UK 
HBSS-- Solution Gibco Paisley, Scotland 
Hoechst Fisher Loughborough, 
Leicestershire, UK 
HyClone® Thermo Scientific USA 
IMDM Gibco  
Insulin Sigma  
KSR Gibco  
Laminin Sigma  
L-Glutamine Gibco Paisley, Scotland 
Lipid concentrate Gibco  
Lipofectamine Invitrogen Paisley, USA 
LookOut® Mycoplasma PCR 
detection kit 
Sigma Poole, Dorset, UK 
Matrigel BD  
MyTaq™ Bioline  
Neon™ transfection system Invitrogen Paisley, USA 
Neurobasal Gibco  
NGS Dako Glostrup, Denmark 
Noggin R&D  
Non-essential amino acids 
(MEM) 
Gibco 
 
Nuclease free water Ambion  
Opti-MEM® I reduce serum Invitrogen  
Paraformaldehyde Fisher Scientific  
PBS Gibco  
pcDNA3.1(+)/myc-HisA Invitrogen  
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Materials Suppliers Location 
PD0325901 Sigma  
pDsRed-Express-N1 Clonetech  
Penicillin Streptomycin Gibco Paisley, Scotland 
Plasmid Mini-prep Qiagen  
PLL Sigma Poole, Dorset, UK 
Primate ES Cell medium ReproCELL Japan 
Proteinase K Gibco  
PSF Gibco  
Purmorphamine Calbiochem  
QIAquick Gel Extraction Kit Qiagen  
QIAquick PCR Purification 
Kit 
Qiagen 
 
QIAprep Spin Miniprep Kit Qiagen  
RA Sigma  
SafeView Biolabs  
SB431542 Tocris  
SHH R&D  
SK-4700 Kit Vector® SG  
SOC media Invitrogen Paisley, USA 
SuperScript™ II Reverse 
Transcriptase 
invitrogen  
SYBR Green Bioline  
TOP10 Invitrogen Paisley, USA 
Transferrin Sigma  
Tryphan blue Sigma  
Trypsin 
Worthington 
Biochemical 
Corporation 
Freehold, New Jersey, 
USA 
Trypsin/EDTA Gibco  
Trypsin inhibitor Sigma  
-mercaptoethanol Sigma Gillingham, Dorset, UK 
1 kb DNA Ladder Biolabs  
10X BSA Promega  
100 bp DNA Ladder Biolabs  
 
  Appendix 
 
 
197 
 
Appendix C 
Antibodies for immunofluorescence  
Primary 
antibody 
 
Isotope Clonal 
Type 
 
Concentration 
 
Supplier Code 
1. Sox2 IgG Rabbit 1:100 abcam ab97959 
2. PAX6 IgG Rabbit  1:500 abcam ab5790 
3. Nestin IgG Rabbit 1:1000 Millipore MAB5922 
4. ZO-1 IgG1 Mouse 1:200-1:500 BD Bioscience BD610966 
5. FoxP1 IgG Rabbit 1:500 abcam ab16645 
6. FoxP2 IgG Rabbit 1:500 abcam ab16046 
7. Ctip2 IgG  Rat 1:200-1:500 abcam ab18465 
8. TTF1 IgG Rabbit 1:200 abcam ab40880 
9. Islet1 IgG Rabbit 1:200 abcam ab20670 
10. GSH2 IgG Rabbit 1:200 abcam  ab26255 
11. β-III tubullin - Rabbit 1:1000 Sigma T2200 
12. MAP2ab IgG1 Mouse 1:200 abcam  ab36447 
13. Dlx1 IgG2a Mouse 1:200-1:500 abcam ab54668 
14. Dlx2 IgG Rabbit 1:200-1:500 abcam ab18188 
15. DARPP32 IgG Rabbit 1:200 Santa Cruz SC11365 
16. hDARPP32 IgG Rabbit 1:1000 abcam ab40802 
17. FoxP1 IgG2a Mouse 1:200-1:500 abcam ab32010 
18. Synaptophysin IgG1 Mouse 1:100 abcam ab8049 
19. PSD95 IgG Rabbit 1:100 abcam ab18258 
20. GFAP IgG2b Mouse 1:1000 abcam ab10062 
21. Otx2 - Rabbit 1:500 Millipore MAB9566 
22. GABA IgG Rabbit 1:200-1:500 abcam ab9446 
23. Ki67 IgG1 Mouse 1:500 Dako M7240 
24. HuNu IgG1 Rabbit 1:500 Millipore MAB1281 
25. β-III tubullin IgG1 Mouse 1:1000 Sigma T9026 
26. GFAP IgG Rabbit 1:1000 Dako ZO334 
27. Oct4 IgG Rabbit 1:1000 abcam ab18976 
28. Tra-1-60 IgM Rabbit 1:1000 abcam ab16288 
29. Nanog IgG Rabbit 1:500-1:1000 abcam ab80892 
30. SSEA4 IgG3 Mouse 1:500-1:1000 abcam ab16287 
31. AFP IgG1 Mouse 1:500-1:1000 Santa Cruz SC166335 
32. SMA IgG2a Mouse 1:500-1:1000 abcam ab7817 
33. Vimentin IgG2a Mouse 1:500-1:1000 DAKO M7020 
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Appendix D 
Solutions 
1. Culture Media: 
- Dulbecco’s modified eagle medium (Standard Medium) 500 ml 
- 1% PSF (Penicillin, Streptomycin, and Fungizone) 5 ml 
 
2. Neural Differentiation Media: 
- DMEM/F12 
- 1% PS 50 ml 
- 1% Fetal Calf Serum (FCS) 500 µl 
- 2% B27 1 ml 
 
3. MEF Media: expansion (4C) 
- DMEM 450 ml 
- FBS(Fetal Bovine Serum) 50 ml 
- Penicillin or Streptomycin 5 ml 
- L-Glutamine 5 ml 
Mix thoroughly, expiry date within one month from formulation 
 
4. MEF Media: derivation (4C) 
- DMEM 450 ml 
- FBS(Fetal Bovine Serum) 50 ml 
-  Antibiotic, Antimycotic or MYKOKILL 5 ml 
-  L-Glutamine 5 ml 
Mix thoroughly, expiry date within one month from formulation 
 
5. MEF Freezing Media (4C) 
- MEF media (expansion) 45 ml 
- DMSO 5 ml 
Mix thoroughly, expiry date within one month from formulation 
 
6. Trypsin solution: 
- 0.1% Trypsin 
- 0.05% DNase 
- HBSS 
 
7. DNase solution: 
- 0.05% DNase 
- Dissection medium 
 
8. Phosphate Buffered Saline (PBS): 
- Sodium Chloride (NaCl2) 8.5 gm 
- Dihydrogen Sodium Phosphate 0.4 gm 
- Disodium Hydrogen Phosphate 1 gm 
- Distilled water up to 1,000 ml 
The pH 7.4, was adjusted using Hydrochloric acid 
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9. TRIS-BORATE EDTA (5XTBE): 
- Tris Base 54 gm 
- Boric acid 27.5 gm 
-    EDTA (0.5M) 20 ml 
- Distilled water up to 1,000 ml 
Working concentration 0.5XTBE: 5XTBE 100 ml add distilled water  
up to 1,000 ml 
 
10.  1% Agarose Gel (for 400 ml) 
- Agarose powder 4 gm 
- 0.5X TBE add up to 400 ml 
- Put on microwave for 2 min and shake well until dissolved, keep in the oven  
 
11.  Formalin 4% (for 50 ml) 
- 38%(V/W)  40% Formalin 5 ml 
-  1X PBS add up to 50 ml 
 
12.  Poly-L-Lysine (PLL)  
- Aliquot Poly-L-Lysine 5 ml 
- Add distilled water 45 ml  
 
13.  Proliferation Media 
- DMEM/F12  
- 1% PS 50 ml 
- 2% B27 1 ml 
Growth factor:  
- FGE-2 20 ng/ml 
- EGF 20 ng/ml 
 
14.  LB AGAR  
- Difco LB AGAR 16 gm 
- Add distilled water up to 400 ml 
- Before use add Ampicillin 1:1,000 (400 µl), IPTG 1:1,000 (400 µl), and 
XGAL (Stock concentration 20 mg/ml, Working concentration 40 µg/ml)  
(800 µl)  
 
15.  Difco LB BROTH Medium 
- Difco LB Broth Medium 16 gm 
- Add distilled water up to 400 ml 
- Before use: add Ampicillin 1:1,000 (400 µl) 
 
16. Human ES cell culture medium 
- Knock out DMEM 160 ml 
- Knock out serum replacement 40 ml 
- 2 ml L-Glutamine/-mercaptoethanol solution 
- 2 ml 100X non-essential amino acid solution 
- 400 µl of 2 μg/ml bFGF stock 
- Filter and store at 4C and use within two weeks 
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17. Human basic FGF 
- 0.1%BSA in PBS (without Ca+, Mg++) 5 ml 
- Human bFGF 10 µg 
- Aliquot into 400 µl lots and stored at -20C 
 
18. Collagenase IV solution 
- Collagenase Type IV 50 mg 
- DMEM/F12 50 ml 
- Sterile with a 0.2 micron acetate filter and store at 4C  
- Use within two weeks 
 
19. Cryopreservation Medium 
- Defined FBS 6 ml 
- hES cell culture medium 2 ml 
- Filter sterile with a 50 ml filter unit and then add 
- DMSO 2 ml 
- Make the medium fresh and keep it on ice. 
 
20.  KSR medium 
- K/O DMEM 87 ml 
- K/O Serum Replacement 10 ml 
- L-glutamine (200 mM) 1 ml 
- Non-essential amino acid 1 ml 
- Β-mercaptoethanol (50 mM) 100 µl 
- Penicillin/Streptomycin 1 ml 
 
21. N2B27 with RA 
- Advanced DMEM/F12 60 ml 
- Neurobasal medium 30 ml 
- N2 (1:150) 600 µl 
- B27 with RA (1:150) 600 µl 
 
22. N2B27 without RA 
- Advanced DMEM/F12 60 ml 
- Neurobasal medium 30 ml 
- N2 (1:150) 600 µl 
- B27 with RA (1:150) 600 µl 
 
23.  Human fifroblast medium 
- MEM α medium+Glutamax 160 ml 
- FBS 40 ml 
- Non-essential amino acid 2 ml 
- Penicillin/Streptomycin 2 ml 
- Filter and store at 4˚C up to 1 month. 
 
24. Tris non saline (TNS) Buffer 
- TRIS 6.0 g. 
- Distilled water 1 litre 
- Adjust to pH 7.4 with HCl 
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25. Pre-wash (0.1 M PBS) 
- Di- Sodium hydrogen phosphate (dehydrate) 18 g. 
- Sodium chloride 9 g. 
- Make up to 1 litre with distilled water 
 
26. 1.5% Paraformaldehyde solution (PFA) 
- Paraformaldehyde (granulated) 15 g. 
- Make up to 1 litre with Pre-wash 1 litre 
(Dissolve with heat on the stirring (50-60°C) for 3 hours, then turn off the 
heat and leave stirring overnight at room temperature. Check the pH and 
adjust to pH 7.3 with either sodium hydroxide or orthophosphoric acid.) 
 
27. 4.0% Paraformaldehyde solution (PFA) 
- Paraformaldehyde (granulated) 200 g. 
- Di- Sodium hydrogen phosphate (dehydrate) 90 g. 
- Sodium chloride 45 g. 
- Make up to 5 litre with distilled water 
- (Dissolve with heat on the stirring (50-60°C) for 3 hours, then turn off the 
heat and leave stirring overnight at room temperature. Check the pH and 
adjust to pH 7.3 with either sodium hydroxide or orthophosphoric acid.) 
 
28. Sucrose 25% 
- Sucrose 250 g. 
- Make up to 1 litre with Pre-wash, mix well and adjust pH to 7.3 if necessary. 
 
29. DAB stock solution 
- DAB 1 g. 
- Mix with TNS 100 ml. 
- Dissolve and divide into 2 ml aliquots in small bijou pots. Freeze the 
aliquots as quickly as possible after dissolving the DAB. 
 
30. DAB solution 
- DAB 20 mg. 
- Buffer solution 40 ml. 
- 30% Hydrogen peroxide 12 µl 
- This solution can be diluted 2-5 times in TNS before use. This slows the 
reaction down without affecting the quality of the reaction. 
 
31. Antifreeze Solution 
- Di-sodium hydrogen orthophosphate 5.45 g. 
- Sodium di-hydrogen orthophosphate 1.57 g. 
- Distilled water 400 ml. 
- Dissolve fully, adjust pH to 7.3-7.4 then add: 
- Ethylene Glycol 300 ml. 
- Glycerol 300 ml. 
- Store solution in the fridge 
 
 
 
